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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14748. G protein-coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion chan-
nels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools,
alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2019,
and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union
of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug
targets, where appropriate.
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Overview: G protein-coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although
there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular
N-terminus, an intracellular C-terminus and seven hydrophobic transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). About
800 GPCRs have been identiﬁed in man, of which about half have sensory functions, mediating olfaction (˜400), taste (33), light perception (10) and pheromone signalling (5) [1479]. The remaining 350
non-sensory GPCRs mediate signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage [1642, 1772], although
only a minority of these receptors are exploited therapeutically. The ﬁrst classiﬁcation scheme to be proposed for GPCRs [1129] divided them, on the basic of sequence homology, into six classes. These
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classes and their prototype members were as follows: Class A (rhodopsin-like), Class B (secretin receptor family), Class C (metabotropic glutamate), Class D (fungal mating pheromone receptors), Class
E (cyclic AMP receptors) and Class F (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classiﬁcation scheme "GRAFS" [1890] divides vertebrate GPCRs into ﬁve
classes, overlapping with the A-F nomenclature, viz:
Glutamate family (class C), which includes metabotropic glutamate receptors, a calcium-sensing receptor and GABAB receptors, as well as three taste type 1 receptors and a family of pheromone
receptors (V2 receptors) that are abundant in rodents but absent in man [1479].
Rhodopsin family (class A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2
receptors and ﬁve pheromone receptors (V1 receptors).
Adhesion family GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N-termini that are autoproteolytically cleaved from their 7TM domains
at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (320 residue) "GPCR autoproteolysis-inducing" (GAIN) domain, an evolutionary ancient moﬁf also found in polycystic kidney
disease 1 (PKD1)-like proteins, which has been suggested to be both required and sufﬁcient for autoproteolysis [1743].
Frizzled family consists of 10 Frizzled proteins (FZD(1-10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the
Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).
Secretin family, encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27-141 amino acid residues; nine of the mammalian receptors respond to ligands
that are structurally related to one another (glucagon, glucagon-like peptides (GLP-1, GLP-2), glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary
adenylate cyclase-activating polypeptide (PACAP) and growth-hormone-releasing hormone (GHRH)) [811].
GPCR families
Family Class A Class B (Secretin) Class C (Glutamate) Adhesion Frizzled
Receptors with known ligands 197 15 12 0 11
Orphans 87 (54)a - 8 (1)a 26 (6)a 0
Sensory (olfaction) 390b,c - - - -
Sensory (vision) 10d opsins - - - -
Sensory (taste) 30c taste 2 - 3c taste 1 - -
Sensory (pheromone) 5c vomeronasal 1 - - - -
Total 719 15 22 33 11
aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [455]; b[1634]; c[1479]; d[2109].
Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the β2 adrenoceptor, the latter culminating in the
award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [1121, 1244].
Pseudogenes
Below is a curated list of pseudogenes that in humans are non-coding for receptor protein. In some cases these have a shared ancestry with genes that encode functional receptors in rats and mice.
ADGRE4P, GNRHR2, GPR79, HTR5BP, NPY6R, TAAR3P, TAAR4P, TAAR7P, TAS2R12P, TAS2R15P, TAS2R18P, TAS2R2P, TAS2R62P, TAS2R63P, TAS2R64P, TAS2R67P, TAS2R68P, TAS2R6P. A more detailed
listing containg further information can be viewed here.
Olfactory receptors
Olfactory receptors are also seven-transmembrane spanning G protein-coupled receptors, responsible for the detection of odorants. These are not currently included as they are not yet associated with
extensive pharmacological data but are curated in the following databases: The gene list of olfactory receptors at HGNC, and curated by HORDE and ORDB.
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Further reading on G protein-coupled receptors
Kenakin T. (2018) Is the Quest for Signaling Bias Worth the Effort? Mol. Pharmacol. 93: 266-269
[PMID:29348268]
Michel MC et al. (2018) Biased Agonism in Drug Discovery-Is It Too Soon to Choose a Path? Mol.
Pharmacol. 93: 259-265 [PMID:29326242]
Roth BL et al. (2017) Discovery of new GPCR ligands to illuminate new biology. Nat. Chem. Biol. 13:
1143-1151 [PMID:29045379]
Sriram K et al. (2018) G Protein-Coupled Receptors as Targets for Approved Drugs: HowMany Targets
and How Many Drugs? Mol. Pharmacol. 93: 251-258 [PMID:29298813]
Family structure
Orphan and other 7TM receptors
G protein-coupled receptors → Orphan and other 7TM receptors
Overview: This set contains ’orphan’ G protein coupled receptors where the endogenous ligand(s) is not known, and other 7TM receptors.
Searchable database: http://www.guidetopharmacology.org/index.jsp Orphan and other 7TM receptors S23
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S23 Orphan and other 7TM receptors
S24 Class A Orphans
– Class B Orphans
S33 Class C Orphans
– Opsin receptors
S33 Taste 1 receptors
S34 Taste 2 receptors
S35 Other 7TM proteins
S36 5-Hydroxytryptamine receptors
S39 Acetylcholine receptors (muscarinic)
S41 Adenosine receptors
S42 Adhesion Class GPCRs
S45 Adrenoceptors
S48 Angiotensin receptors
S50 Apelin receptor
S51 Bile acid receptor
S51 Bombesin receptors
S53 Bradykinin receptors
S54 Calcitonin receptors
S56 Calcium-sensing receptor
S57 Cannabinoid receptors
S58 Chemerin receptors
S59 Chemokine receptors
S63 Cholecystokinin receptors
S64 Class Frizzled GPCRs
S67 Complement peptide receptors
S68 Corticotropin-releasing factor receptors
S69 Dopamine receptors
S71 Endothelin receptors
S72 G protein-coupled estrogen receptor
S73 Formylpeptide receptors
S74 Free fatty acid receptors
S76 GABAB receptors
S78 Galanin receptors
S79 Ghrelin receptor
S80 Glucagon receptor family
S81 Glycoprotein hormone receptors
S82 Gonadotrophin-releasing hormone receptors
S83 GPR18, GPR55 and GPR119
S84 Histamine receptors
S86 Hydroxycarboxylic acid receptors
S87 Kisspeptin receptor
S88 Leukotriene receptors
S89 Lysophospholipid (LPA) receptors
S90 Lysophospholipid (S1P) receptors
S92 Melanin-concentrating hormone receptors
S93 Melanocortin receptors
S94 Melatonin receptors
S95 Metabotropic glutamate receptors
S97 Motilin receptor
S98 Neuromedin U receptors
S99 Neuropeptide FF/neuropeptide AF receptors
S100 Neuropeptide S receptor
S101 Neuropeptide W/neuropeptide B receptors
S102 Neuropeptide Y receptors
S103 Neurotensin receptors
S104 Opioid receptors
S106 Orexin receptors
S107 Oxoglutarate receptor
S108 P2Y receptors
S110 Parathyroid hormone receptors
S111 Platelet-activating factor receptor
S112 Prokineticin receptors
S113 Prolactin-releasing peptide receptor
S114 Prostanoid receptors
S116 Proteinase-activated receptors
S117 QRFP receptor
S118 Relaxin family peptide receptors
S120 Somatostatin receptors
S121 Succinate receptor
S122 Tachykinin receptors
S123 Thyrotropin-releasing hormone receptors
S124 Trace amine receptor
S125 Urotensin receptor
S126 Vasopressin and oxytocin receptors
S127 VIP and PACAP receptors
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Class A Orphans
G protein-coupled receptors → Orphan and other 7TM receptors → Class A Orphans
Overview: Table 1 lists a number of putative GPCRs identiﬁed by NC-IUPHAR [612], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential
link to a disease, or disorder. These GPCRs have recently been reviewed in detail [455]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative
GPCRs with as-yet unidentiﬁed endogenous ligands.
Table 1: Class A orphan GPCRs with putative endogenous ligands
GPR3 GPR4 GPR6 GPR12 GPR15 GPR17 GPR20
GPR22 GPR26 GPR31 GPR34 GPR35 GPR37 GPR39
GPR50 GPR63 GRP65 GPR68 GPR75 GPR84 GPR87
GPR88 GPR132 GPR149 GPR161 GPR183 LGR4 LGR5
LGR6 MAS1 MRGPRD MRGPRX1 MRGPRX2 P2RY10 TAAR2
In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together
(GPR18, GPR55 and GPR119).
Nomenclature GPR3 GPR4 GPR6
HGNC, UniProt GPR3, P46089 GPR4, P46093 GPR6, P46095
Agonists diphenyleneiodonium chloride [2388] – –
Endogenous ligands – Protons –
Comments Sphingosine 1-phosphate was reported to be an
endogenous agonist [2168], but this ﬁnding was not
replicated in subsequent studies [2389]. Reported to
activate adenylyl cyclase constitutively through Gs [545].
Gene disruption results in premature ovarian ageing
[1234], reduced β-amyloid deposition [2112] and
hypersensitivity to thermal pain [1837] in mice. First
small molecule inverse agonist [993] and agonists
identiﬁed [2386]
An initial report suggesting activation by
lysophosphatidylcholine and
sphingosylphosphorylcholine [2440] has been retracted
[1597]. GPR4, GPR65, GPR68 and GPR132 are now
thought to function as proton-sensing receptors
detecting acidic pH [455, 1932]. Gene disruption is
associated with increased perinatal mortality and
impaired vascular proliferation [2377]. Negative allosteric
modulators of GPR4 have been reported [2137].
An initial report that sphingosine 1-phosphate (S1P) was
a high-afﬁnity ligand (EC50 value of 39nM) [941, 2168]
was not repeated in arrestin-based assays [2015, 2389].
Reported to activate adenylyl cyclase constitutively
through Gs and to be located intracellularly [1644].
GPR6-deﬁcient mice showed reduced striatal cyclic AMP
production in vitro and selected alterations in
instrumental conditioning in vivo. [1309].
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Nomenclature GPR12 GPR15 GPR17
HGNC, UniProt GPR12, P47775 GPR15, P49685 GPR17, Q13304
Endogenous agonists – – UDP-glucose [143, 395], LTC4 [395], UDP-galactose [143, 395], uridine diphosphate [143, 395], LTD4 [395]
Comments Reports that
sphingosine 1-phosphate is a ligand
of GPR12 [940, 2168] have not
been replicated in arrestin-based
assays [2015, 2389]. Gene
disruption results in dyslipidemia
and obesity [170].
Reported to act as a co-receptor for
HIV [541]. In an infection-induced
colitis model, Gpr15 knockout mice
were more prone to tissue damage
and inﬂammatory cytokine
expression [1089].
Reported to be a dual leukotriene and uridine diphosphate receptor [395]. Another group instead proposed
that GPR17 functions as a negative regulator of the CysLT1 receptor response to leukotriene D4 (LTD4). For
further discussion, see [455]. Reported to antagonize CysLT1 receptor signalling in vivo and in vitro [1350]. See
reviews [280] and [455].
Nomenclature GPR19 GPR20 GPR21 GPR22 GPR25 GPR26 GPR27
HGNC, UniProt GPR19, Q15760 GPR20, Q99678 GPR21, Q99679 GPR22, Q99680 GPR25, O00155 GPR26, Q8NDV2 GPR27, Q9NS67
Agonists adropin (ENHO,
Q6UWT2) [1770]
– – – – – –
Comments – Reported to inhibit
adenylyl cyclase
constitutively through Gi/o
[817]. GPR20 deﬁcient
mice exhibit hyperactivity
characterised by increased
total distance travelled in
an open ﬁeld test [230].
Gpr21 knockout mice were
resistant to diet-induced
obesity, exhibiting an
increase in glucose
tolerance and insulin
sensitivity, as well as a
modest lean phenotype
[1639].
Gene disruption results in
increased severity of
functional
decompensation following
aortic banding [10].
Identiﬁed as a
susceptibility locus for
osteoarthritis [574, 1072,
2187].
– Has been reported to
activate adenylyl cyclase
constitutively through Gs
[1016]. Gpr26 knockout
mice show increased levels
of anxiety and
depression-like behaviours
[2421].
Knockdown of Gpr27
reduces endogenous
mouse insulin promotor
activity and
glucose-stimulated insulin
secretion [1160].
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Nomenclature GPR31 GPR32 GPR33 GPR34
HGNC, UniProt GPR31, O00270 GPR32, O75388 GPR33, Q49SQ1 GPR34, Q9UPC5
Potency order of endogenous ligands – resolvin D1 > LXA4 – –
Endogenous agonists 12S-HETE [769] – Mouse resolvin D1 [1153], LXA4 [1153] – lysophosphatidylserine [1107, 2054]
Labelled ligands – [3H]resolvin D1 (Agonist) [1153] – –
Comments See [455] for discussion of pairing. Resolvin D1 has been demonstrated to
activate GPR32 in two publications
[366, 1153]. The pairing was not
replicated in a recent study based on
arrestin recruitment [2015]. GPR32 is a
pseudogene in mice and rats. See
reviews [280] and [455].
GPR33 is a pseudogene in most
individuals, containing a premature stop
codon within the coding sequence of
the second intracellular loop [1845].
Lysophosphatidylserine has been
reported to be a ligand of GPR34 in
several publications, but the pairing was
not replicated in a recent study based
on arrestin recruitment [2015]. Fails to
respond to a variety of lipid-derived
agents [2389]. Gene disruption results
in an enhanced immune response
[1277]. Characterization of agonists at
this receptor is discussed in [945] and
[455].
Nomenclature GPR35 GPR37
HGNC, UniProt GPR35, Q9HC97 GPR37, O15354
Endogenous agonists 2-oleoyl-LPA [1626], kynurenic acid [2015, 2253] –
Agonists – neuropeptide head activator [1795]
Comments Several studies have shown that kynurenic acid is an agonist of GPR35 but it remains
controversial whether the proposed endogenous ligand reaches sufﬁcient tissue
concentrations to activate the receptor [1162]. 2-oleoyl-LPA has also been proposed as an
endogenous ligand [1626] but these results were not replicated in an arrestin assay [2015].
The phosphodiesterase inhibitor zaprinast [2105] has become widely used as a surrogate
agonist to investigate GPR35 pharmacology and signalling [2105]. GPR35 is also activated
by the pharmaceutical adjunct pamoic acid [2432]. See reviews [455] and [502].
Reported to associate and regulate the dopamine transporter [1382] and to be a substrate
for parkin [1380]. Gene disruption results in altered striatal signalling [1381]. The peptides
prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1
[1438].
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Nomenclature GPR37L1 GPR39 GPR45 GPR50
HGNC, UniProt GPR37L1, O60883 GPR39, O43194 GPR45, Q9Y5Y3 GPR50, Q13585
Endogenous agonists – Zn2+ [898] – –
Comments The peptides prosaptide and prosaposin are proposed
as endogenous ligands for GPR37 and GPR37L1
[1438].
Zn2+ has been reported to be a potent and efﬁcacious
agonist of human, mouse and rat GPR39 [2383].
Obestatin (GHRL, Q9UBU3), a fragment from the
ghrelin precursor, was reported initially as an
endogenous ligand, but subsequent studies failed to
reproduce these ﬁndings. GPR39 has been reported to
be down-regulated in adipose tissue in obesity-related
diabetes [315]. Gene disruption results in obesity and
altered adipocyte metabolism [1696]. Reviewed in
[455].
– GPR50 is structurally related to MT1 and MT2
melatonin receptors, with which it heterodimerises
constitutively and speciﬁcally [1265]. Gpr50 knockout
mice display abnormal thermoregulation and are much
more likely than wild-type mice to enter
fasting-induced torpor [126].
Nomenclature GPR52 GPR61 GPR62 GPR63
HGNC, UniProt GPR52, Q9Y2T5 GPR61, Q9BZJ8 GPR62, Q9BZJ7 GPR63, Q9BZJ6
Comments First small molecule agonist reported [1931]. GPR61 deﬁcient mice exhibit obesity associated
with hyperphagia [1545]. Although no
endogenous ligands have been identiﬁed,
5-(nonyloxy)tryptamine has been reported to be
a low afﬁnity inverse agonist [2092].
– Sphingosine 1-phosphate and
dioleoylphosphatidic acid have been reported to
be low afﬁnity agonists for GPR63 [1584] but this
ﬁnding was not replicated in an arrestin-based
assay [2389].
Nomenclature GPR65 GPR68
HGNC, UniProt GPR65, Q8IYL9 GPR68, Q15743
Endogenous ligands Protons Protons
Allosteric modulators – ogerin (Positive) (pKB 5) [925], lorazepam (Positive) [925]
Comments GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton-sensing receptors
detecting acidic pH [455, 1932]. Reported to activate adenylyl cyclase; gene disruption leads
to reduced eosinophilia in models of allergic airway disease [1145].
GPR68 was previously identiﬁed as a receptor for sphingosylphosphorylcholine (SPC) [2358],
but the original publication has been retracted [2357]. GPR4, GPR65, GPR68 and GPR132
are now thought to function as proton-sensing receptors detecting acidic pH [455, 1932]. A
family of 3,5-disubstituted isoxazoles were identiﬁed as agonists of GPR68 [1839].
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Nomenclature GPR75 GPR78 GPR79 GPR82
HGNC, UniProt GPR75, O95800 GPR78, Q96P69 GPR79, – GPR82, Q96P67
Comments CCL5 (CCL5, P13501) was reported to be an agonist of
GPR75 [942], but the pairing could not be repeated in an
arrestin assay [2015].
GPR78 has been reported to be constitutively active,
coupled to elevated cAMP production [1016].
– Mice with Gpr82 knockout have a lower body weight and
body fat content associated with reduced food intake,
decreased serum triglyceride levels, as well as higher
insulin sensitivity and glucose tolerance [558].
Nomenclature GPR83 GPR84 GPR85 GPR87 GPR88 GPR101
HGNC, UniProt GPR83, Q9NYM4 GPR84, Q9NQS5 GPR85, P60893 GPR87, Q9BY21 GPR88, Q9GZN0 GPR101, Q96P66
Endogenous agonists – – – LPA [1523, 2076] – –
Agonists PEN {Mouse} [719] –
Mouse, Zn2+ [1531] –
Mouse
decanoic acid [2015, 2254],
undecanoic acid [2254],
lauric acid [2254]
– – – –
Comments One isoform has been
implicated in the induction
of CD4(+) CD25(+)
regulatory T cells (Tregs)
during inﬂammatory
immune responses [803].
The extracellular N-terminal
domain is reported as an
intramolecular inverse
agonist [1532].
Medium chain free fatty
acids with carbon chain
lengths of 9-14 activate
GPR84 [2064, 2254]. A
surrogate ligand for GPR84,
6-n-octylaminouracil has
also been proposed [2064].
See review [455] for
discussion of classiﬁcation.
Mutational analysis and
molecular modelling of
GPR84 has been reported
[1588].
Proposed to regulate
hippocampal neurogenesis
in the adult, as well as
neurogenesis-dependent
learning and memory [352].
– Gene disruption results in
altered striatal signalling
[1312]. Small molecule
agonists have been reported
[163].
Mutations in GPR101 have
been linked to gigantism
and acromegaly [2154].
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Nomenclature GPR132 GPR135 GPR139 GPR141 GPR142 GPR146
HGNC, UniProt GPR132, Q9UNW8 GPR135,
Q8IZ08
GPR139, Q6DWJ6 GPR141,
Q7Z602
GPR142, Q7Z601 GPR146, Q96CH1
Endogenous ligands Protons – – – – –
Comments GPR4, GPR65, GPR68 and GPR132
are now thought to function as
proton-sensing receptors
detecting acidic pH [455, 1932].
Reported to respond to
lysophosphatidylcholine [1027],
but later retracted [2321].
– Peptide agonists have been
reported [953].
– Small molecule agonists have
been reported [2138, 2407].
Yosten et al. demonstrated
inhibition of proinsulin C-peptide
(INS, P01308)-induced stimulation
of cFos expression folllowing
knockdown of GPR146 in KATO III
cells, suggesting proinsulin
C-peptide as an endogenous
ligand of the receptor [2404].
Nomenclature GPR148 GPR149 GPR150 GPR151 GPR152 GPR153 GPR160
HGNC, UniProt GPR148, Q8TDV2 GPR149, Q86SP6 GPR150, Q8NGU9 GPR151, Q8TDV0 GPR152, Q8TDT2 GPR153, Q6NV75 GPR160, Q9UJ42
Comments – Gpr149 knockout mice
displayed increased
fertility and enhanced
ovulation, with
increased levels of FSH
receptor and cyclin D2
mRNA levels [542].
– GPR151 responded to
galanin with an EC50
value of 2 μM,
suggesting that the
endogenous ligand
shares structural features
with galanin (GAL,
P22466) [939].
– – –
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Nomenclature GPR161 GPR162 GPR171 GPR173
HGNC, UniProt GPR161, Q8N6U8 GPR162, Q16538 GPR171, O14626 GPR173, Q9NS66
Comments A C-terminal truncation (deletion) mutation in
Gpr161 causes congenital cataracts and neural
tube defects in the vacuolated lens (vl) mouse
mutant [1403]. The mutated receptor is
associated with cataract, spina biﬁda and white
belly spot phenotypes in mice [1140]. Gene
disruption is associated with a failure of
asymmetric embryonic development in zebraﬁsh
[1261].
– GPR171 has been shown to be activated by the
endogenous peptide BigLEN {Mouse}. This
receptor-peptide interaction is believed to be
involved in regulating feeding and metabolism
responses [718].
–
Nomenclature GPR174 GPR176 GPR182 GPR183
HGNC, UniProt GPR174, Q9BXC1 GPR176, Q14439 GPR182, O15218 GPR183, P32249
Endogenous agonists lysophosphatidylserine [949] – – 7α,25-dihydroxycholesterol [799, 1301],
7α,27-dihydroxycholesterol [1301],
7β, 25-dihydroxycholesterol [1301],
7β, 27-dihydroxycholesterol [1301]
Comments See [945] which discusses
characterization of agonists at this
receptor.
– Rat GPR182 was ﬁrst proposed as the
adrenomedullin receptor [1041].
However, it was later reported that rat
and human GPR182 did not respond to
adrenomedullin [1070] and GPR182 is
not currently considered to be a genuine
adrenomedullin receptor [831].
Two independent publications have
shown that 7α,25-dihydroxycholesterol
is an agonist of GPR183 and have
demonstrated by mass spectrometry
that this oxysterol is present
endogenously in tissues [799, 1301].
Gpr183-deﬁcient mice show a reduction
in the early antibody response to a
T-dependent antigen. GPR183-deﬁcient
B cells fail to migrate to the outer follicle
and instead stay in the follicle centre
[1062, 1685].
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Nomenclature LGR4 LGR5 LGR6
HGNC, UniProt LGR4, Q9BXB1 LGR5, O75473 LGR6, Q9HBX8
Endogenous agonists R-spondin-2 (RSPO2, Q6UXX9) [305], R-spondin-1 (RSPO1,
Q2MKA7) [305], R-spondin-3 (RSPO3, Q9BXY4) [305],
R-spondin-4 (RSPO4, Q2I0M5) [305]
R-spondin-2 (RSPO2, Q6UXX9) [305], R-spondin-1 (RSPO1,
Q2MKA7) [305], R-spondin-3 (RSPO3, Q9BXY4) [305],
R-spondin-4 (RSPO4, Q2I0M5) [305]
R-spondin-1 (RSPO1, Q2MKA7) [305, 467], R-spondin-2
(RSPO2, Q6UXX9) [305, 467], R-spondin-3 (RSPO3, Q9BXY4)
[305, 467], R-spondin-4 (RSPO4, Q2I0M5) [305, 467]
Comments LGR4 does not couple to heterotrimeric G proteins or recruit
arrestins when stimulated by the R-spondins, indicating a
unique mechanism of action. R-spondins bind to LGR4,
which speciﬁcally associates with Frizzled and LDL
receptor-related proteins (LRPs) that are activated by the
extracellular Wnt molecules and then trigger canonical Wnt
signalling to increase gene expression [305, 467, 1834].
Gene disruption leads to multiple developmental disorders
[1002, 1329, 2011, 2284].
The four R-spondins can bind to LGR4, LGR5, and LGR6,
which speciﬁcally associate with Frizzled and LDL
receptor-related proteins (LRPs), proteins that are activated
by extracellular Wnt molecules and which then trigger
canonical Wnt signalling to increase gene expression [305,
467].
–
Nomenclature MAS1 MAS1L
HGNC, UniProt MAS1, P04201 MAS1L, P35410
Agonists angiotensin-(1-7) (AGT, P01019) [707] – Mouse –
Nomenclature MRGPRD MRGPRE MRGPRF MRGPRG
HGNC, UniProt MRGPRD, Q8TDS7 MRGPRE, Q86SM8 MRGPRF, Q96AM1 MRGPRG, Q86SM5
Endogenous agonists β-alanine [1958, 2015] – – –
Comments An endogenous peptide with a high degree of
sequence similarity to angiotensin-(1-7) (AGT,
P01019), alamandine (AGT), was shown to
promote NO release in MRGPRD-transfected
cells. The binding of alamandine to MRGPRD
to was shown to be blocked by
D-Pro7-angiotensin-(1-7), β-alanine and
PD123319 [1208]. Genetic ablation of
MRGPRD+ neurons of adult mice decreased
behavioural sensitivity to mechanical stimuli
but not to thermal stimuli [322]. See reviews
[455] and [2009].
See reviews [455] and [2009]. MRGPRF has been reported to respond to
stimulation by angiotensin metabolites [678].
See reviews [455] and [2009].
See reviews [455] and [2009].
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Nomenclature MRGPRX1 MRGPRX2 MRGPRX3 MRGPRX4 P2RY8 P2RY10
HGNC, UniProt MRGPRX1, Q96LB2 MRGPRX2, Q96LB1 MRGPRX3, Q96LB0 MRGPRX4, Q96LA9 P2RY8, Q86VZ1 P2RY10, O00398
Endogenous agonists bovine adrenal medulla peptide 8-22
(PENK, P01210) [347, 1253, 2015]
PAMP-20 (ADM, P35318) [1035] – – – sphingosine 1-phosphate [1523],
LPA [1523]
Agonists – cortistatin-14 {Mouse, Rat}
[1035, 1202, 1815, 2015]
– – – –
Selective agonists – PAMP-12 (human) [1035] – – – –
Comments Reported to mediate the sensation of itch
[1305, 1969]. Reports that
bovine adrenal medulla peptide 8-22
(PENK, P01210) was the most potent of a
series of proenkephalin A-derived peptides
as an agonist of MRGPRX1 in assays of
calcium mobilisation and radioligand
binding [1253] were replicated in an
independent study using an arrestin
recruitment assay [2015]. See reviews
[455] and [2009].
A diverse range of substances has
been reported to be agonists of
MRGPRX2, with cortistatin 14
the highest potency agonist in
assays of calcium mobilisation
[1815], also conﬁrmed in an
independent study using an
arrestin recruitment assay [2015].
See reviews [455] and [2009].
– See reviews [455] and [2009]. – –
Nomenclature TAAR2 TAAR3 TAAR4P TAAR5 TAAR6 TAAR8 TAAR9
HGNC, UniProt TAAR2, Q9P1P5 TAAR3P, Q9P1P4 TAAR4P, – TAAR5, O14804 TAAR6, Q96RI8 TAAR8, Q969N4 TAAR9, Q96RI9
Potency order of
endogenous ligands
β-phenylethylamine >
tryptamine [205]
– – – – – –
Comments Probable pseudogene in
10–15% of Asians due
to a polymorphism
(rs8192646) producing
a premature stop codon
at amino acid 168 [455].
TAAR3 is thought to be a
pseudogene in man
though functional in
rodents [455].
Pseudogene in man but
functional in rodents
[455].
Trimethylamine is
reported as an agonist
[2242] and
3-iodothyronamine an
inverse agonist [499].
– – TAAR9 appears to be
functional in most
individuals but has a
polymorphic premature
stop codon at amino
acid 61 (rs2842899)
with an allele frequency
of 10–30% in different
populations [2202].
Further reading on Class A Orphans
McNeil BD et al. (2015) Identiﬁcation of a mast-cell-speciﬁc receptor crucial for pseudo-allergic drug
reactions. Nature 519: 237-41 [PMID:25517090]
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Class C Orphans
G protein-coupled receptors → Orphan and other 7TM receptors → Class C Orphans
Overview: This set contains class C ’orphan’ G protein coupled receptors where the endogenous ligand(s) is not known.
Nomenclature GPR156 GPR158 GPR179 GPRC5A GPRC5B GPRC5C GPRC5D GPRC6 receptor
HGNC, UniProt GPR156,
Q8NFN8
GPR158,
Q5T848
GPR179,
Q6PRD1
GPRC5A,
Q8NFJ5
GPRC5B,
Q9NZH0
GPRC5C,
Q9NQ84
GPRC5D,
Q9NZD1
GPRC6A, Q5T6X5
Comments – – – – – – – GPRC6 is a Gq-coupled receptor which responds to basic amino acids [2282].
Further reading on Class C Orphans
Harpse K et al. (2017) Structural insight to mutation effects uncover a common allosteric site in class
C GPCRs. Bioinformatics 33: 1116-1120 [PMID:28011766]
Taste 1 receptors
G protein-coupled receptors → Orphan and other 7TM receptors → Taste 1 receptors
Overview: Whilst the taste of acid and salty foods appear to
be sensed by regulation of ion channel activity, bitter, sweet and
umami tastes are sensed by specialised GPCR. Two classes of taste
GPCR have been identiﬁed, T1R and T2R, which are similar in se-
quence and structure to Class C and Class A GPCR, respectively.
Activation of taste receptors appears to involve gustducin- (Gαt3)
and Gα14-mediated signalling, although the precise mechanisms
remain obscure. Gene disruption studies suggest the involvement
of PLCβ2 [2429], TRPM5 [2429] and IP3 [883] receptors in post-
receptor signalling of taste receptors. Although predominantly
associated with the oral cavity, taste receptors are also located else-
where, including further down the gastrointestinal system, in the
lungs and in the brain.
Sweet/Umami: T1R3 acts as an obligate partner in T1R1/T1R3
and T1R2/T1R3 heterodimers, which sense umami or sweet, re-
spectively. T1R1/T1R3 heterodimers respond to L-glutamic acid
and may be positively allosterically modulated by 5’-nucleoside
monophosphates, such as 5’-GMP [1272]. T1R2/T1R3 het-
erodimers respond to sugars, such as sucrose, and artiﬁcial sweet-
eners, such as saccharin [1564].
Nomenclature TAS1R1 TAS1R2 TAS1R3
HGNC, UniProt TAS1R1, Q7RTX1 TAS1R2, Q8TE23 TAS1R3, Q7RTX0
Comments: Positive allosteric modulators of T1R2/T1R3 have been reported [2363]. Such compounds enhance the sweet taste of sucrose mediated by these receptors, but are tasteless on their own.
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Further reading on Taste 1 receptors
Palmer RK. (2019) A Pharmacological Perspective on the Study of Taste. Pharmacol. Rev. 71: 20-48
[PMID:30559245]
Taste 2 receptors
G protein-coupled receptors → Orphan and other 7TM receptors → Taste 2 receptors
Overview: The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand speciﬁcity or much broader
responsiveness. For example, T2R5 responded to cycloheximide, but not 10 other bitter compounds [334], while T2R14 responded to at least eight different bitter tastants, including (-)-α-thujone and
picrotoxinin [133].
Specialist database BitterDB contains additional information on bitter compounds and receptors [2306].
Nomenclature TAS2R1 TAS2R3 TAS2R4 TAS2R5 TAS2R7 TAS2R8 TAS2R9
HGNC, UniProt TAS2R1, Q9NYW7 TAS2R3, Q9NYW6 TAS2R4, Q9NYW5 TAS2R5, Q9NYW4 TAS2R7, Q9NYW3 TAS2R8, Q9NYW2 TAS2R9, Q9NYW1
Nomenclature TAS2R10 TAS2R13 TAS2R14 TAS2R16 TAS2R19 TAS2R20 TAS2R30
HGNC, UniProt TAS2R10, Q9NYW0 TAS2R13, Q9NYV9 TAS2R14, Q9NYV8 TAS2R16, Q9NYV7 TAS2R19, P59542 TAS2R20, P59543 TAS2R30, P59541
Nomenclature TAS2R31 TAS2R38 TAS2R39 TAS2R40
HGNC, UniProt TAS2R31, P59538 TAS2R38, P59533 TAS2R39, P59534 TAS2R40, P59535
Antagonists 6-methoxysakuranetin (pIC50 5.6) [1098],
GIV3727 (pIC50 5.1–5.2) [1984]
– – –
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Nomenclature TAS2R41 TAS2R42 TAS2R43 TAS2R45 TAS2R46 TAS2R50 TAS2R60
HGNC, UniProt TAS2R41, P59536 TAS2R42, Q7RTR8 TAS2R43, P59537 TAS2R45, P59539 TAS2R46, P59540 TAS2R50, P59544 TAS2R60, P59551
Further reading on Taste 2 receptors
Palmer RK. (2019) A Pharmacological Perspective on the Study of Taste. Pharmacol. Rev. 71: 20-48
[PMID:30559245]
Other 7TM proteins
G protein-coupled receptors → Orphan and other 7TM receptors → Other 7TM proteins
Nomenclature GPR107 GPR137 TPRA1 GPR143 GPR157
HGNC, UniProt GPR107, Q5VW38 GPR137, Q96N19 TPRA1, Q86W33 GPR143, P51810 GPR157, Q5UAW9
Endogenous agonists – – – levodopa [1316] –
Comments GPR107 is a member of the LUSTR
family of proteins found in both plants
and animals, having similar topology to
G protein-coupled receptors [540]
– TPRA1 shows no homology to known G
protein-coupled receptors.
Loss-of-function mutations underlie
ocular albinism type 1 [117].
GPR157 has ambiguous sequence
similarities to several different GPCR
families (class A, class B and the slime
mould cyclic AMP receptor). Because of
its distant relationship to other GPCRs, it
cannot be readily classiﬁed.
Further reading on Orphan and other 7TM receptors
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G
protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharma-
col. Rev. 65: 967-86 [PMID:23686350]
Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther. 159:
56-65 [PMID:26808164]
Insel PA et al. (2015) G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel"
endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol. Pharmacol. 88: 181-7
[PMID:25737495]
Khan MZ et al. (2017) Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin
(class A) family of G protein-coupled receptors. Psychopharmacology (Berl.) 234: 1181-1207
[PMID:28289782]
Mackenzie AE et al. (2017) The emerging pharmacology and function of GPR35 in the nervous sys-
tem. Neuropharmacology 113: 661-671 [PMID:26232640]
Ngo T et al. (2016) Identifying ligands at orphan GPCRs: current status using structure-based ap-
proaches. Br. J. Pharmacol. 173: 2934-51 [PMID:26837045]
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5-Hydroxytryptamine receptors
G protein-coupled receptors → 5-Hydroxytryptamine receptors
Overview: 5-HT receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on 5-HT receptors [914] and
subsequently revised [816]) are, with the exception of the
ionotropic 5-HT3 class, GPCRs where the endogenous agonist is
5-hydroxytryptamine. The diversity of metabotropic 5-HT recep-
tors is increased by alternative splicing that produces isoforms of
the 5-HT2A (non-functional), 5-HT2C (non-functional), 5-HT4, 5-
HT6 (non-functional) and 5-HT7 receptors. Unique amongst the
GPCRs, RNA editing produces 5-HT2C receptor isoforms that dif-
fer in function, such as efﬁciency and speciﬁcity of coupling to
Gq/11 and also pharmacology [181, 2291]. Most 5-HT receptors
(except 5-ht1e and 5-ht5b) play speciﬁc roles mediating functional
responses in different tissues (reviewed by [1765, 2219]).
Nomenclature 5-HT1A receptor 5-HT1B receptor
HGNC, UniProt HTR1A, P08908 HTR1B, P28222
Agonists U92016A [1416], vilazodone (Partial agonist) [463], vortioxetine (Partial agonist) [105] L-694,247 [738], naratriptan (Partial agonist) [1548], eletriptan [1548], frovatriptan [2359],
zolmitriptan (Partial agonist) [1548], vortioxetine (Partial agonist) [105], rizatriptan (Partial
agonist) [1548]
Selective agonists 8-OH-DPAT [473, 791, 1032, 1251, 1452, 1575, 1577, 1578], NLX-101 [1576] CP94253 [1122]
Antagonists (S)-UH 301 (pKi 7.9) [1575] –
Selective antagonists WAY-100635 (pKi 7.9–9.2) [1575, 1577], robalzotan (pKi 9.2) [1007] SB 224289 (Inverse agonist) (pKi 8.2–8.6) [670, 1573, 1924], SB236057 (Inverse agonist)
(pKi 8.2) [1445], GR-55562 (pKB 7.4) [915]
Labelled ligands [3H]robalzotan (Antagonist) (pKd 9.8) [994], [
3H]WAY100635 (Antagonist) (pKd 9.5)
[1075], [3H]8-OH-DPAT (Agonist) [174, 1032, 1574, 1577], [3H]NLX-112 (Agonist) [864],
[11C]WAY100635 (Antagonist) [2161], p-[18F]MPPF (Antagonist) [418]
[3H]N-methyl-AZ10419369 (Agonist, Partial agonist) [1356], [3H]GR 125,743 (Selective
Antagonist) (pKd 8.6–9.2) [738, 2350], [
3H]alniditan (Agonist) [1260], [125I]GTI (Agonist)
[213, 256] – Rat, [3H]eletriptan (Agonist, Partial agonist) [1548], [3H]sumatriptan (Agonist,
Partial agonist) [1548], [11C]AZ10419369 (Agonist, Partial agonist) [2207]
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Nomenclature 5-HT1D receptor 5-ht1e receptor 5-HT1F receptor
HGNC, UniProt HTR1D, P28221 HTR1E, P28566 HTR1F, P30939
Agonists dihydroergotamine [790, 1260, 1267], ergotamine [711],
L-694,247 [2340], naratriptan [506, 1548, 1794],
zolmitriptan [1548], frovatriptan [2359], rizatriptan [1548]
BRL-54443 [250] BRL-54443 [250], eletriptan [1548], sumatriptan [12, 13,
1548, 2236]
Selective agonists PNU109291 [564] – Gorilla, eletriptan [1548] – lasmiditan [1563], LY334370 [2236], 5-BODMT [1113],
LY344864 [1702]
Selective antagonists SB 714786 (pKi 9.1) [2264] – –
Labelled ligands [3H]eletriptan (Agonist) [1548], [3H]alniditan (Agonist)
[1260], [125I]GTI (Selective Agonist) [213, 256] – Rat,
[3H]GR 125,743 (Selective Antagonist) (pKd 8.6) [2350],
[3H]sumatriptan (Agonist) [1548]
[3H]5-HT (Agonist) [1413, 1657] [3H]LY334370 (Agonist) [2236], [125I]LSD (Agonist) [48] –
Mouse
Nomenclature 5-HT2A receptor 5-HT2B receptor 5-HT2C receptor
HGNC, UniProt HTR2A, P28223 HTR2B, P41595 HTR2C, P28335
Agonists DOI [227, 1562, 1986] methysergide (Partial agonist) [1117, 1827, 2237], DOI
[1179, 1562, 1883]
DOI [544, 1562, 1883], Ro 60-0175 [1097, 1117]
Selective agonists – BW723C86 [124, 1117, 1883], Ro 60-0175 [1117] WAY-163909 [533], lorcaserin [2125]
Antagonists risperidone (Inverse agonist) (pKi 9.3–10) [1131, 1156,
1901], mianserin (pKi 7.7–9.6) [1117, 1146, 1452],
ziprasidone (pKi 8.8–9.5) [1131, 1156, 1901, 1939],
volinanserin (pIC50 6.5–9.3) [1117, 1317, 1782], blonanserin
(pKi 9.1) [1611], clozapine (Inverse agonist) (pKi 7.6–9)
[1117, 1156, 1449, 1901, 2201], H05 (pIC50 7.2) [2356]
mianserin (pKi 7.9–8.8) [200, 1117, 2237] mianserin (Inverse agonist) (pKi 8.3–9.2) [607, 1117, 1452],
methysergide (pKi 8.6–9.1) [544, 1117], ziprasidone (Inverse
agonist) (pKi 7.9–9) [858, 1156, 1939], olanzapine (Inverse
agonist) (pKi 8.1–8.4) [858, 1156, 1939], loxapine (Inverse
agonist) (pKi 7.8–8) [858, 1156]
Selective antagonists compound 3b (pKi 10.6) [603], ketanserin (pKi 8.1–9.7)
[261, 1117, 1771], pimavanserin (Inverse agonist) (pKi 9.3)
[659, 2201]
BF-1 (pKi 10.1) [1895], RS-127445 (pKi 9–9.5) [200, 1117],
EGIS-7625 (pKi 9) [1146]
FR260010 (pKi 9) [807], SB 242084 (pKi 8.2–9) [1071,
1117], RS-102221 (pKi 8.3–8.4) [201, 1117]
Labelled ligands [3H]fananserin (Antagonist) (pKd 9.9) [1362] – Rat,
[3H]ketanserin (Antagonist) (pKd 8.6–9.7) [1117, 1771],
[11C]volinanserin (Antagonist) [784], [18F]altanserin
(Antagonist) [1823]
[3H]LSD (Agonist) [1771], [3H]5-HT (Agonist) [2235] – Rat,
[3H]mesulergine (Antagonist, Inverse agonist) (pKd 7.9)
[1117], [125I]DOI (Agonist)
[3H]mesulergine (Antagonist, Inverse agonist) (pKd 8.7–9.3)
[607, 1771], [125I]DOI (Agonist) [607], [3H]LSD (Agonist)
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Nomenclature 5-HT4 receptor 5-HT5A receptor 5-ht5b receptor
HGNC, UniProt HTR4, Q13639 HTR5A, P47898 HTR5BP, –
Agonists cisapride (Partial agonist) [89, 141, 690, 1440, 1441, 2190]
Selective agonists TD-8954 [1427], ML 10302 (Partial agonist) [152, 178, 1440,
1441, 1442], RS67506 [842] – Rat, relenopride (Partial
agonist) [702], velusetrag [1314, 1994], BIMU 8 [398]
– –
Selective antagonists RS 100235 (pKi 8.7–12.2) [398, 1809], SB 204070 (pKi
9.8–10.4) [141, 1440, 1441, 2192], GR 113808 (pKi
9.3–10.3) [89, 141, 178, 398, 1401, 1809, 2190]
SB 699551 (pKi 8.2) [416] –
Labelled ligands [ H]GR 1138083 (Antagonist) (pKd 9.7–10.3) [89, 141, 1442,
2190], [123I]SB 207710 (Antagonist) (pKd 10.1) [251] – Pig,
[3H]RS 57639 (Selective Antagonist) (pKd 9.7) [199] – Guinea
pig, [ C]SB20714511 (Antagonist) (pKd 8.6) [1344]
[125I]LSD (Agonist) [737], [3H]5-CT (Agonist) [737] [125I]LSD (Agonist) [1404] – Mouse, [ H]5-CT3 (Agonist)
[2233] – Mouse
Nomenclature 5-HT6 receptor 5-HT7 receptor
HGNC, UniProt HTR6, P50406 HTR7, P34969
Selective agonists WAY-181187 [1887], E6801 (Partial agonist) [893], WAY-208466 [151], EMD-386088 [1405] LP-12 [1257], LP-44 [1257], LP-211 [1258] – Rat, AS-19 [1091], E55888 [229]
Antagonists – lurasidone (pKi 9.3) [954], pimozide (pKi 9.3) [1826] – Rat, vortioxetine (pKi 6.3) [105]
Selective antagonists SB399885 (pKi 9) [882], SB 271046 (pKi 8.9) [247], cerlapirdine (pKi 8.9) [407], SB357134
(pKi 8.5) [248], Ro 63-0563 (pKi 7.9–8.4) [184, 1985]
SB269970 (pKi 8.6–8.9) [2119], SB656104 (pKi 8.7) [613], DR-4004 (pKi 8.7) [710, 1082],
JNJ-18038683 (pKi 8.2) [197], SB 258719 (Inverse agonist) (pKi 7.5) [2120]
Labelled ligands [11C]GSK215083 (Antagonist) (pKi 9.8) [1656], [
125I]SB258585 (Selective Antagonist) (pKd
9) [882], [3H]LSD (Agonist) [183], [3H]Ro 63-0563 (Antagonist) (pKd 8.3) [184], [
3H]5-CT
(Agonist)
[3H]5-CT (Agonist) [2119], [3H]5-HT (Agonist) [107, 2026], [3H]SB269970 (Selective
Antagonist) (pKd 8.9) [2119], [
3H]LSD (Agonist) [2026]
Comments: Tabulated pKi and KD values refer to binding to hu-
man 5-HT receptors unless indicated otherwise. The nomencla-
ture of 5-HT1B/5-HT1D receptors has been revised [816]. Only the
non-rodent form of the receptor was previously called 5-HT1D:
the human 5-HT1B receptor (tabulated) displays a different phar-
macology to the rodent forms of the receptor due to Thr335 of
the human sequence being replaced by Asn in rodent receptors
[800]. Wang et al. (2013) report X-ray structures which reveal the
binding modality of ergotamine and dihydroergotamine (DHE) to
the 5-HT1B receptor in comparison with the structure of the 5-
HT2B receptor [2249]; some of these drugs adopt rather different
conformations depending on the target receptor [1681]. Various
5-HT receptors have multiple partners in addition to G proteins,
which may affect function and pharmacology [1384]. NAS181 is
a selective antagonist of the rodent 5-HT1B receptor. Fananserin
(LSD) and ketanserin bind with high afﬁnity to dopamine D4 and
histamine H1 receptors respectively, and ketanserin is a potent
α1 adrenoceptor antagonist, in addition to blocking 5-HT2A re-
ceptors. Lysergic acid (LSD) and ergotamine show a strong pref-
erence for arrestin recruitment over G protein coupling at the
5-HT2B receptor, with no such preference evident at 5-HT1B re-
ceptors, and they also antagonise 5-HT7A receptors [2231]. DHE
(dihydroergocryptine), pergolide and cabergoline also show sig-
niﬁcant preference for arrestin recruitment over G protein cou-
pling at 5-HT2B receptors [2231]. The 5-HT2B (and other 5-HT)
receptors interact with immunocompetent cells [1645]. The sero-
tonin antagonist mesulergine was key to the discovery of the 5-
HT2C receptor [1672], initially known as 5-HT1C [83]. The human
5-HT5A receptor may couple to several signal transduction path-
ways when stably expressed in C6 glioma cells [1599] and rodent
prefrontal cortex (layer V pyramidal neurons) [724]. The human
orthologue of the mouse 5-ht5b receptor is non-functional (stop
codons); the 5-ht1e receptor has not been cloned from mouse, or
rat, impeding deﬁnition of its function [800]. In addition to ac-
cepted receptors, an ’orphan’ receptor, unofﬁcially termed 5-HT1P,
has been described [695].
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Further reading on 5-Hydroxytryptamine receptors
Bockaert J et al. (2011) 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11: 87-93
[PMID:21342787]
Hayes DJ et al. (2011) 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev
35: 1419-49 [PMID:21402098]
Hoyer D et al. (1994) International Union of Pharmacology classiﬁcation of receptors for 5-
hydroxytryptamine (Serotonin). Pharmacol. Rev. 46: 157-203 [PMID:7938165]
LeopoldoM et al. (2011) Serotonin 5-HT7 receptor agents: Structure-activity relationships and poten-
tial therapeutic applications in central nervous system disorders. Pharmacol. Ther. 129: 120-48
[PMID:20923682]
Meltzer HY et al. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs.
Curr Opin Pharmacol 11: 59-67 [PMID:21420906]
Roberts AJ et al. (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22: 762-71
[PMID:21484935]
Acetylcholine receptors (muscarinic)
G protein-coupled receptors → Acetylcholine receptors (muscarinic)
Overview: Muscarinic acetylcholine receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on Mus-
carinic Acetylcholine Receptors [318]) are GPCRs of the
Class A, rhodopsin-like family where the endogenous agonist
is acetylcholine. In addition to the agents listed in the ta-
ble, AC-42, its structural analogues AC-260584 and 77-LH-28-1,
N-desmethylclozapine, TBPB and LuAE51090 have been described
as functionally selective agonists of the M1 receptor subtype via
binding in amode distinct from that utilized by non-selective ago-
nists [82, 1014, 1198, 1199, 1408, 1859, 2018, 2019, 2061]. There
are two pharmacologically characterised allosteric sites on mus-
carinic receptors, one deﬁned by it binding gallamine, strychnine
and brucine, and the other deﬁned by the binding of KT 5720,
WIN 62,577, WIN 51,708 and staurosporine [1215, 1216].
Nomenclature M1 receptor M2 receptor
HGNC, UniProt CHRM1, P11229 CHRM2, P08172
Agonists carbachol [385, 976, 2326], pilocarpine (Partial agonist) [976], bethanechol [976] carbachol [358, 976, 1147], bethanechol [976]
Selective agonists SPP1 [242] –
Antagonists glycopyrrolate (pIC50 9.9) [2037], AE9C90CB (pKi 9.7) [1979], atropine (pKi 8.5–9.6) [385,
636, 878, 923, 1683, 1993], tiotropium (pKi 9.6) [501], 4-DAMP (pKi 9.2) [537]
tiotropium (pKi 9.9) [501], glycopyrrolate (pIC50 9.3) [2037], atropine (pKi 7.8–9.2) [265,
358, 878, 923, 1147, 1561, 1683], AE9C90CB (pKi 8.6) [1979], tolterodine (Inverse agonist)
(pKi 8.4–8.6) [704, 1561, 1979]
Selective antagonists biperiden (pKd 9.3) [190], VU0255035 (pKi 7.8) [1943], guanylpirenzepine (pKi 7.3–7.6)
[25, 2234] – Rat
tripitramine (pKi 9.6) [1351]
Allosteric modulators muscarinic toxin 7 (Negative) (pKi 11–11.1) [1606], benzoquinazolinone 12 (Positive) (pKB
6.6) [4], KT 5720 (Positive) (pKd 6.4) [1215], brucine (Positive) (pKd 4.5–5.8) [976, 1214],
BQCA (Positive) (pKB 4–4.8) [4, 5, 296, 1336], VU0029767 (Positive) [1385], VU0090157
(Positive) [1385]
W-84 (Negative) (pKd 6–7.5) [1470, 2155], C7/3-phth (Negative) (pKd 7.1) [386],
alcuronium (Negative) (pKd 6.1–6.9) [976, 2155], gallamine (Negative) (pKd 5.9–6.3) [399,
1212], LY2119620 (Positive) (pKd 5.7) [437, 1158], LY2033298 (Positive) (pKd 4.4) [2185]
Labelled ligands [3H]QNB (Antagonist) (pKd 10.6–10.8) [387, 1683], Cy3B-telenzepine (Antagonist) (pKd
10.5) [856], [3H]N-methyl scopolamine (Antagonist) (pKd 9.4–10.3) [324, 385, 387, 878,
976, 977, 1011, 1074, 1212], [3H](+)telenzepine (Antagonist) (pKi 9.4) [580] – Rat,
Alexa-488-telenzepine (Antagonist) (pKd 9.3) [856], [
3H]pirenzepine (Antagonist) (pKd 7.9)
[2273]
[3H]QNB (Antagonist) (pKd 10.1–10.6) [1683], Cy3B-telenzepine (Antagonist) (pKi 10.4)
[1568], [3H]tiotropium (Antagonist) (pKd 10.3) [1856], [
3H]N-methyl scopolamine
(Antagonist) (pKd 9.3–9.9) [324, 358, 878, 976, 977, 1011, 1074, 1212, 2261],
Alexa-488-telenzepine (Antagonist) (pKi 8.8) [1568], [
3H]acetylcholine (Agonist) [1213],
[3H]oxotremorine-M (Agonist) [153], [3H]dimethyl-W84 (Allosteric modulator, Positive)
(pKd 8.5) [2154], [
18F]FP-TZTP (Agonist) [975] – Mouse
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Nomenclature M3 receptor M4 receptor M5 receptor
HGNC, UniProt CHRM3, P20309 CHRM4, P08173 CHRM5, P08912
Agonists pilocarpine (Partial agonist) [976], carbachol [358, 976,
2326], bethanechol [976]
pilocarpine (Partial agonist) [976], carbachol [976, 2326],
bethanechol [976]
pilocarpine (Partial agonist) [740], carbachol [2326]
Antagonists tiotropium (pKi 9.5–11.1) [501, 519], AE9C90CB (pKi
9.9) [1979], atropine (pKi 8.9–9.8) [265, 519, 878, 923,
1683, 1993], ipratropium (pKi 9.3–9.8) [519, 878],
aclidinium (pIC50 9.8) [1733]
glycopyrrolate (pIC50 9.8) [2037], AE9C90CB (pKi 9.5)
[1979], 4-DAMP (pKi 8.9) [537], oxybutynin (pKi 8.7)
[1979], biperiden (pKd 8.6) [190], UH-AH 37 (pKi
8.3–8.4) [704, 2292]
glycopyrrolate (pIC50 9.7) [2037], AE9C90CB (pKi 9.5)
[1979], 4-DAMP (pKi 9) [537], tolterodine (pKi 8.5–8.8)
[704, 1979], darifenacin (pKi 7.9–8.6) [704, 841, 878,
1979]
Selective antagonists – – ML381 (pKi 6.3) [684]
Allosteric modulators WIN 62,577 (Positive) (pKd 5.1) [1216],
N-chloromethyl-brucine (Positive) (pKd 3.3) [1214]
muscarinic toxin 3 (Negative) (pKi 8.7) [1011, 1635],
VU0152100 (Positive) (pEC50 6.4) [224] – Rat,
VU0152099 (Positive) (pEC50 6.4) [224] – Rat, LY2119620
(Positive) (pKd 5.7) [437], thiochrome (Positive) (pKd 4)
[1213], LY2033298 (Positive) [333]
ML380 (Positive) (pEC50 6.7) [149, 686]
Selective allosteric modulators – – ML375 (Negative) (pIC50 6.5) [685]
Labelled ligands [3H]tiotropium (Antagonist) (pKd 10.7) [1856], [
3H]QNB
(Antagonist) (pKd 10.4) [1683],
[3H]N-methyl scopolamine (Antagonist) (pKd 9.7–10.2)
[324, 358, 878, 923, 976, 1011, 1074, 1212],
[3H]darifenacin (Antagonist) (pKd 9.5) [1993]
[3H]QNB (Antagonist) (pKd 9.7–10.5) [387, 1683],
[3H]N-methyl scopolamine (Antagonist) (pKd 9.9–10.2)
[324, 358, 387, 878, 976, 1011, 1074, 1212, 1635,
2261], [3H]acetylcholine (Agonist) [1213]
[3H]QNB (Antagonist) (pKd 10.2–10.7),
[3H]N-methyl scopolamine (Antagonist) (pKd 9.3–9.7)
[324, 358, 878, 1011, 1074, 2261]
Comments: The crystal structures of the M1-M4 receptor sub-
types have been reported [777, 2111, 2382]. Direct activation
via an allosteric site has been reported for M1 receptors (BQCA,
PF-06767832) and M4 receptors (LY2033298) [462, 1225, 1227,
1336, 1550, 1551]. The allosteric site for gallamine and strychnine
on M2 receptors can be labelled by [3H]dimethyl-W84 [2155].
McN-A-343 is a functionally selective partial agonist that appears
to interact in a bitopic mode with both the orthosteric and an al-
losteric site on the M2 muscarinic receptor [2186]. THRX160209,
hybrid 1 and hybrid 2, are multivalent (bitopic) ligands that also
achieve selectivity for M2 receptors by binding both to the orthos-
teric and a nearby allosteric site [59, 2028].
Although numerous ligands for muscarinic acetylcholine recep-
tors have been described, relatively few selective antagonists have
been described, so it is common to assess the rank order of afﬁn-
ity of a number of antagonists of limited selectivity (e.g. 4-DAMP,
darifenacin, pirenzepine) in order to identify the involvement of
particular subtypes. It should be noted that the measured afﬁni-
ties of antagonists (and agonists) in radioligand binding studies
are sensitive to ionic strength and can increase over 10-fold at
low ionic strength compared to their values at physiological ionic
strengths [167].
Further reading on Acetylcholine receptors (muscarinic)
Burger WAC et al. (2018) Toward an understanding of the structural basis of allostery in muscarinic
acetylcholine receptors. J Gen Physiol 150: 1360-1372 [PMID:30190312]
Caulﬁeld MP et al. (1998) International Union of Pharmacology. XVII. Classiﬁcation of muscarinic
acetylcholine receptors. Pharmacol Rev 50: 279-290 [PMID:9647869]
Eglen RM. (2012) Overview of muscarinic receptor subtypes. Handb Exp Pharmacol 3-28
[PMID:22222692]
Kruse AC et al. (2014)Muscarinic acetylcholine receptors: novel opportunities for drug development.
Nat Rev Drug Discov 13: 549-60 [PMID:24903776]
Leach K et al. (2012) Structure-function studies of muscarinic acetylcholine receptors. Handb Exp
Pharmacol 29-48 [PMID:22222693]
Valant C et al. (2012) The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-
coupled receptors. Annu Rev Pharmacol Toxicol 52: 153-78 [PMID:21910627]
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Adenosine receptors
G protein-coupled receptors → Adenosine receptors
Overview: Adenosine receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Adenosine Receptors
[624]) are activated by the endogenous ligand adenosine (po-
tentially inosine also at A3 receptors). Crystal structures for the
antagonist-bound [410, 964, 1307, 1922], agonist-bound [1232,
1233, 2354] and G protein-bound A2A adenosine receptors [307]
have been described. The structures of an antagonist-bound A1
receptor [712] and an adenosine-bound A1 receptor-Gi complex
[521] have been resolved by cryo-electronmicroscopy. Another
structure of an antagonist-bound A1 receptor obtained with X-ray
crystallography has also been reported [361].
Nomenclature A1 receptor A2A receptor A2B receptor A3 receptor
HGNC, UniProt ADORA1, P30542 ADORA2A, P29274 ADORA2B, P29275 ADORA3, P0DMS8
Endogenous agonists adenosine [2369] adenosine [2369] adenosine [2369] adenosine [2369]
Agonists NECA [658, 1005, 1813, 2151, 2369] NECA [209, 500, 658, 1088, 1173, 2369] NECA [160, 209, 995, 1289, 2033, 2203,
2369]
NECA [209, 658, 971, 1858, 2204, 2369]
Selective agonists cyclopentyladenosine [442, 469, 658, 848,
968, 1005, 1813], 5-Cl-5-deoxy-(±)-ENBA
[620], TCPA [162], CCPA [968, 1609],
MRS7469 [2148]
apadenoson [1674], UK-432,097 [768,
2354], AZD4635 [410], CGS 21680 [209,
500, 658, 968, 1088, 1115, 1173, 1609],
regadenoson [968]
BAY 60-6583 [539] piclidenoson [592, 647, 1115, 2204],
Cl-IB-MECA [225, 971, 1085], MRS5698
[2147]
Antagonists CGS 15943 (pKi 8.5) [1636],
xanthine amine congener (pKd 7.5) [620]
CGS 15943 (pKi 7.7–9.4) [500, 1088, 1115,
1636], xanthine amine congener (pKi 8.4–9)
[500, 1115]
xanthine amine congener (pKi 6.9–8.8)
[160, 995, 996, 1115, 1289, 2033],
CGS 15943 (pKi 6–8.1) [76, 995, 996, 1115,
1636, 2033]
CGS 15943 (pKi 7–7.9) [1093, 1115, 1636,
2204], xanthine amine congener (pKi 7–7.4)
[1115, 1858, 2204]
Selective antagonists PSB36 (pKi 9.9) [6] – Rat, DPCPX (pKi
7.4–9.2) [469, 950, 1609, 1813, 2295],
derenofylline (pKi 9) [1033], WRC-0571 (pKi
8.8) [1387], DU172 (pKi 7.4) [712]
SCH442416 (pKi 8.4–10.3) [1957, 2139],
ZM-241385 (pKi 8.8–9.1) [1636]
PSB-0788 (pKi 9.4) [208], PSB603 (pKi 9.3)
[208], MRS1754 (pKi 8.8) [995, 1092],
PSB1115 (pKi 7.3) [832]
MRS1220 (pKi 8.2–9.2) [971, 1093, 2055,
2384], VUF5574 (pKi 8.4) [2193], MRS1523
(pKi 7.7) [1268], MRS1191 (pKi 7.5) [971,
998, 1273]
Allosteric modulators PD81723 (Positive) [258] – – LUF6000 (Positive) [772], LUF6096 (Positive)
[847]
Labelled ligands [3H]CCPA (Agonist) [1115, 1813],
[3H]DPCPX (Antagonist) (pKd 8.4–9.2) [442,
592, 1115, 1636, 1813, 2151]
[3H]ZM 241385 (Antagonist) (pKd 8.7–9.1)
[39, 656], [3H]CGS 21680 (Agonist) [983,
2246]
[3H]MRS1754 (Antagonist) (pKd 9.8) [995] [
125I]AB-MECA (Agonist) [1636, 2204]
Comments: Adenosine inhibits many intracellular ATP-utilising
enzymes, including adenylyl cyclase (P-site). A pseudogene exists
for the A2B adenosine receptor (ADORA2BP1) with 79% identity
to the A2B adenosine receptor cDNA coding sequence, but which
is unable to encode a functional receptor [972]. DPCPX also ex-
hibits antagonism at A2B receptors (pKi ca. 7,[37, 1115]). An-
tagonists at A3 receptors exhibit marked species differences, such
that only MRS1523 and MRS1191 are selective at the rat A3 re-
ceptor. In the absence of other adenosine receptors, [3H]DPCPX
and [3H]ZM 241385 can also be used to label A2B receptors (KD
ca. 30 and 60 nM respectively). [125I]AB-MECA also binds to A1
receptors [1115]. [3H]CGS 21680 is relatively selective for A2A re-
ceptors, but may also bind to other sites in cerebral cortex [438,
1006]. [3H]NECA binds to other non-receptor elements, which
also recognise adenosine [1318]. XAC-BY630 has been described
as a ﬂuorescent antagonist for labelling A1 adenosine receptors in
living cells, although activity at other adenosine receptors was not
examined [234].
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Further reading on Adenosine receptors
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Adhesion Class GPCRs
G protein-coupled receptors → Adhesion Class GPCRs
Overview: Adhesion GPCRs are structurally identiﬁed on the ba-
sis of a large extracellular region, similar to the Class B GPCR, but
which is linked to the 7TM region by a GPCR autoproteolysis-
inducing (GAIN) domain [60] containing a GPCR proteolytic
site. The N-terminus often shares structural homology with
adhesive domains (e.g. cadherins, immunolobulin, lectins) fa-
cilitating inter- and matricellular interactions and leading to
the term adhesion GPCR [626, 2397]. Several receptors have
been suggested to function as mechanosensors [219, 1697, 1900,
2310]. The nomenclature of these receptors was re-
vised in 2015 as recommended by NC-IUPHAR and the
Adhesion GPCR Consortium [788].
Nomenclature ADGRA1 ADGRA2 ADGRA3 ADGRB1 ADGRB2 ADGRB3
HGNC, UniProt ADGRA1, Q86SQ6 ADGRA2, Q96PE1 ADGRA3, Q8IWK6 ADGRB1, O14514 ADGRB2, O60241 ADGRB3, O60242
Endogenous agonists – – – phosphatidylserine
[1655]
– –
Comments – Required to assemble
higher-order
Reck/Gpr124/Frizzled/
Lrp5/6 complexes [573,
1726, 2188, 2200, 2436].
– Reported to mediate
phagocytosis through
binding of
phosphatidylserine
[1655] and
lipopolysaccharide [447].
– Reported to bind C1q-like molecules [194].
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Nomenclature CELSR1 CELSR2 CELSR3 ADGRD1 ADGRD2
HGNC, UniProt CELSR1, Q9NYQ6 CELSR2, Q9HCU4 CELSR3, Q9NYQ7 ADGRD1, Q6QNK2 ADGRD2, Q7Z7M1
Comments – Mutated in Joubert syndrome
patients [2218].
High-conﬁdence risk gene for
Tourette syndrome [2260].
Is a Gs protein-coupled receptor
[186, 1278] and highly expressed in
glioblastoma [122].
–
Nomenclature ADGRE1 ADGRE2 ADGRE3 ADGRE4P ADGRE5
HGNC, UniProt ADGRE1, Q14246 ADGRE2, Q9UHX3 ADGRE3, Q9BY15 ADGRE4P, Q86SQ3 ADGRE5, P48960
Comments – –A mutation destabilizing the GAIN
domain sensitizes mast cells to
IgE-independent vibration-induced
degranulation [219]. Reported to bind
chondroitin sulfate B [2024].
– Reported to bind CD55 [789],
chondroitin sulfate B [2024], α β5 1 and
αγβ3 integrins [2262], and CD90
[2248].
Nomenclature ADGRF1 ADGRF2 ADGRF3 ADGRF4 ADGRF5
HGNC, UniProt ADGRF1, Q5T601 ADGRF2, Q8IZF7 ADGRF3, Q8IZF5 ADGRF4, Q8IZF3 ADGRF5, Q8IZF2
Comments Synaptamide is an agonist at
ADGRF1 supporting neurogenesis
[1240] and couples to Gs and Gq
pathways [482, 2041].
ADGRF2 is highly expressed in
squamous epithelia and gene
deﬁciency did not result in
detectable defects [1744].
ADGRF3 is highly expressed in
gastrointestinal neuroendocrine
tumors [308, 308].
ADGRF4 couples to Gq/11 proteins
[482], is highly expressed in
squamous epithelia and gene
deﬁciency did not result in
detectable defects [1744].
ADGRF5 controls alveolar surfactant
secretion via Gq/11 pathway [253].
Nomenclature ADGRG1 ADGRG2 ADGRG3 ADGRG4 ADGRG5 ADGRG6 ADGRG7
HGNC, UniProt ADGRG1, Q9Y653 ADGRG2, Q8IZP9 ADGRG3, Q86Y34 ADGRG4, Q8IZF6 ADGRG5, Q8IZF4 ADGRG6, Q86SQ4 ADGRG7, Q96K78
Comments Reported to bind tissue
transglutaminase 2
[2355] and collagen,
which activates the
G12/13 pathway [1330].
ADGRG2 is coupled to Gq
and Gs pathways [481]
and gene deﬁciency
causes congenital
obstructive azoospermia
[1663].
ADGRG3 is expressed in
immune cells [1947,
2255] and couples to Go
proteins [770].
ADGRG4 is highly
expressed in
enterochromafﬁn cells
and gastrointestinal
neuroendocrine tumors
[1250].
ADGRG5 is a
constitutively active Gs
protein-coupled receptor
[770, 2310], highly
expressed in eosinophils
and NK cells [1682].
ADGRG6 is a key
regulator of Schwann
cell-mediated myelination
[1481], and couples to Gs
and Gi/o pathways
[1468].
ADGRG7 is expressed in
interstine and involved in
interstine contractility
regulation [1580].
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Nomenclature ADGRL1 ADGRL2 ADGRL3 ADGRL4 ADGRV1
HGNC, UniProt ADGRL1, O94910 ADGRL2, O95490 ADGRL3, Q9HAR2 ADGRL4, Q9HBW9 ADGRV1, Q8WXG9
Comments Couples to Gs and Gq pathways
[1252, 1533].
– A LPHN3 gene variant in humans is
associated with
attention-deﬁcit-hyperactivity
disorder [62, 2313].
– Loss-of-function mutations are
associated with Usher syndrome, a
sensory deﬁcit disorder [973].
Further reading on Adhesion Class GPCRs
Hamann J et al. (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G
protein-coupled receptors. Pharmacol Rev 67: 338-67 [PMID:25713288]
Langenhan T et al. (2013) Sticky signaling–adhesion class G protein-coupled receptors take the stage.
Sci Signal 6: re3 [PMID:23695165]
Liebscher I et al. (2016) Tethered Agonism: A Common Activation Mechanism of Adhesion GPCRs.
Handb Exp Pharmacol 234: 111-125 [PMID:27832486]
Monk KR et al. (2015) Adhesion G Protein-Coupled Receptors: From In Vitro Pharmacology to In
Vivo Mechanisms. Mol Pharmacol 88: 617-23 [PMID:25956432]
Purcell RH et al. (2018) Adhesion G Protein-Coupled Receptors as Drug Targets. Annu Rev Pharmacol
Toxicol 58: 429-449 [PMID:28968187]
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Adrenoceptors
G protein-coupled receptors → Adrenoceptors
Overview: The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [277], see also [869].
Adrenoceptors, α1
α1-Adrenoceptors are activated by the endogenous ago-
nists (-)-adrenaline and (-)-noradrenaline. Phenylephrine,
methoxamine and cirazoline are agonists and prazosin and
cirazoline antagonists considered selective for α1- relative to
α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are
relatively selective radioligands. S(+)-niguldipine also has high
afﬁnity for L-type Ca2+ channels. Fluorescent derivatives of
prazosin (Bodipy PLprazosin- QAPB) are used to examine cellu-
lar localisation of α1-adrenoceptors. Selective α1-adrenoceptor
agonists are used as nasal decongestants; antagonists to treat hy-
pertension (doxazosin, prazosin) and benign prostatic hyperplasia
(alfuzosin, tamsulosin). The α1- and β2-adrenoceptor antagonist
carvedilol is used to treat congestive heart failure, although the
contribution of α1-adrenoceptor blockade to the therapeutic ef-
fect is unclear. Several anti-depressants and anti-psychotic drugs
are α1-adrenoceptor antagonists contributing to side effects such
as orthostatic hypotension and extrapyramidal effects.
Nomenclature α1A-adrenoceptor α1B-adrenoceptor α1D-adrenoceptor
HGNC, UniProt ADRA1A, P35348 ADRA1B, P35368 ADRA1D, P25100
Endogenous agonists (-)-adrenaline [904, 1948], (-)-noradrenaline [904, 1948,
2104]
– (-)-noradrenaline [904, 1948], (-)-adrenaline [904, 1948]
Agonists oxymetazoline [904, 1610, 1948, 2104], phenylephrine
[2104], methoxamine [1948, 2104]
phenylephrine [614, 1459] –
Selective agonists A61603 [614, 1116], dabuzalgron [179] – –
Antagonists prazosin (Inverse agonist) (pKi 9–9.9) [335, 443, 614, 1948,
2312], doxazosin (pKi 9.3) [795], terazosin (pKi 8.7) [1436],
phentolamine (pKi 8.6) [1948], alfuzosin (pKi 8.1) [867]
prazosin (Inverse agonist) (pKi 9.6–9.9) [614, 1948, 2312],
tamsulosin (Inverse agonist) (pKi 9.5–9.7) [614, 1948,
2312], doxazosin (pKi 9.1) [795], alfuzosin (pKi 8.6) [868],
terazosin (pKi 8.6) [1436], phentolamine (pKi 7.5) [1948]
prazosin (Inverse agonist) (pKi 9.5–10.2) [614, 1948, 2312],
tamsulosin (pKi 9.8–10.2) [614, 1948, 2312], doxazosin (pKi
9.1) [795], terazosin (pKi 9.1) [1436], alfuzosin (pKi 8.4)
[867], dapiprazole (pKi 8.4) [79], phentolamine (Inverse
agonist) (pKi 8.2) [1948], RS-100329 (pKi 7.9) [2312],
labetalol (pKi 6.6) [79]
Selective antagonists tamsulosin (pKi 10–10.7) [335, 443, 614, 1948, 2312],
silodosin (pKi 10.4) [1948], S(+)-niguldipine (pKi 9.1–10)
[614, 1948], RS-100329 (pKi 9.6) [2312], SNAP5089 (pKi
8.8–9.4) [867, 1256, 2294], ρ-Da1a (pKi 9.2–9.3) [1412,
1755], RS-17053 (pKi 9.2–9.3) [335, 443, 611, 614]
Rec 15/2615 (pKi 9.5) [2110], L-765314 (pKi 7.7) [1662],
AH 11110 (pKi 7.5) [1875]
BMY-7378 (pKi 8.7–9.1) [310, 2403]
Comments: The α1C-adrenoceptor corresponds to the pharma-
cologically deﬁned α1A-adrenoceptor [869]. Some tissues pos-
sess α1A-adrenoceptors (α1L-adrenoceptors [614, 1501]) that dis-
play relatively low afﬁnity in functional and binding assays for
prazosin indicative of different receptor states or locations. α1A-
adrenoceptor C-terminal splice variants form homo- and het-
erodimers, but fail to generate a functional α1L-adrenoceptor
[1768]. α1D-Adrenoceptors form heterodimers with α1B- or
β2-adrenoceptors that show increased cell-surface expression
[2164]. Recombinant α1D-adrenoceptors have been shown in
some heterologous systems to be mainly located intracellularly
but cell-surface localization is encouraged by truncation of the N-
terminus, or by co-expression of α1B- or β2-adrenoceptors [779,
2164]. In blood vessels all three α1-adrenoceptor subtypes are lo-
cated on the surface and intracellularly [1433, 1434]. Signalling is
predominantly via Gq/11 but α1-adrenoceptors also couple toGi/o,
Gs and G12/13. Several α1A-adrenoceptor agonists display ligand
directed signalling bias relative to noradrenaline [575]. There are
also differences between subtypes in coupling efﬁciency to differ-
ent pathways. In vascular smooth muscle, the potency of agonists
is related to the predominant subtype, α1D- conveying greater ag-
onist sensitivity than α1A-adrenoceptors [609].
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Adrenoceptors, α2
α2-Adrenoceptors are activated by (-)-adrenaline and with lower
potency by (-)-noradrenaline. Brimonidine and talipexole are
agonists and rauwolscine and yohimbine antagonists selec-
tive for α2- relative to α1-adrenoceptors. [3H]rauwolscine,
[3H]brimonidine and [3H]RX821002 are relatively selective ra-
dioligands. There is species variation in the pharmacology of
the α2A-adrenoceptor. Multiple mutations of α2-adrenoceptors
have been described, some associated with alterations in func-
tion. Presynaptic α2-adrenoceptors regulate many functions in
the nervous system. The α2-adrenoceptor agonists clonidine,
guanabenz and brimonidine affect central baroreﬂex control (hy-
potension and bradycardia), induce hypnotic effects and anal-
gesia, and modulate seizure activity and platelet aggregation.
Clonidine is an anti-hypertensive and counteracts opioid with-
drawal. Dexmedetomidine (also xylazine) is used as a sedative
and analgesic in human and veterinary medicine with sympa-
tholytic and anxiolytic properties. The α2-adrenoceptor antago-
nist yohimbine has been used to treat erectile dysfunction and
mirtazapine as an anti-depressant. The α2B subtype appears to be
involved in neurotransmission in the spinal cord and α2C in reg-
ulating catecholamine release from adrenal chromafﬁn cells.
Nomenclature α2A-adrenoceptor α2B-adrenoceptor α2C-adrenoceptor
HGNC, UniProt ADRA2A, P08913 ADRA2B, P18089 ADRA2C, P18825
Endogenous agonists (-)-adrenaline [985, 1704], (-)-noradrenaline [985, 1704] (-)-noradrenaline (Partial agonist) [985, 1704], (-)-adrenaline
[985]
(-)-noradrenaline [985, 1704], (-)-adrenaline [985]
Agonists dexmedetomidine (Partial agonist) [985, 1339, 1678, 1704],
clonidine (Partial agonist) [985, 1678, 1704], brimonidine
[985, 1339, 1678, 1704], apraclonidine [1519], guanabenz
[79], guanfacine (Partial agonist) [985, 1342]
dexmedetomidine [985, 1339, 1678, 1704], clonidine
(Partial agonist) [985, 1678, 1704], brimonidine (Partial
agonist) [985, 1678, 1704], guanabenz [79], guanfacine
[985]
dexmedetomidine [985, 1678, 1704], brimonidine (Partial
agonist) [985, 1339, 1678, 1704], apraclonidine [1519],
guanfacine (Partial agonist) [985], guanabenz [79]
Selective agonists oxymetazoline (Partial agonist) [985, 1339, 2169] – –
Antagonists yohimbine (pKi 8.4–9.2) [276, 487, 2169] yohimbine (pKi 7.9–8.9) [276, 487, 2169],
phenoxybenzamine (pKi 8.5) [2280], tolazoline (pKi 5.5)
[985]
yohimbine (pKi 8.5–9.5) [276, 487, 2169], WB 4101 (pKi
8.4–9.4) [276, 487, 2169], spiroxatrine (pKi 9) [2169],
mirtazapine (pKi 7.7) [593], tolazoline (pKi 5.4) [985]
Selective antagonists BRL 44408 (pKi 8.2–8.8) [2169, 2405] imiloxan (pKi 7.3) [1443] – Rat JP1302 (pKB 7.8) [1855]
Labelled ligands – – [3H]MK-912 (Antagonist) (pKd 10.1) [2169]
Comments: ARC-239 and prazosin show selectivity for α2B- and
α2C-adrenoceptors over α2A-adrenoceptors.Oxymetazoline is a re-
duced efﬁcacy imidazoline agonist but also binds to non-GPCR
binding sites for imidazolines, classiﬁed as I1, I2 and I3 sites [444];
catecholamines have a low afﬁnity, while rilmenidine and mox-
onidine are selective ligands evoking hypotensive effects in vivo.
I1-imidazoline receptors cause central inhibition of sympathetic
tone, I2-imidazoline receptors are an allosteric binding site on
monoamine oxidase B, and I3-imidazoline receptors regulate in-
sulin secretion from pancreatic β-cells. α2A-adrenoceptor stimu-
lation reduces insulin secretion from β-islets [2375], with a poly-
morphism in the 5’-UTR of the ADRA2A gene being associated
with increased receptor expression in β-islets and heightened sus-
ceptibility to diabetes [1821]. α2A- and α2C-adrenoceptors form
homodimers [1990]. Heterodimers between α2A- and either the
α2c-adrenoceptor or μ opioid peptide receptor exhibit altered sig-
nalling and trafﬁcking properties compared to the individual re-
ceptors [1990, 2099, 2217]. Signalling by α2-adrenoceptors is pri-
marily via Gi/o, although the α2A-adrenoceptor also couples to Gs
[538]. Imidazoline compounds display bias relative to each other
at the α2A-adrenoceptor [1670]. The noradrenaline reuptake in-
hibitor desipramine acts directly on the α2A-adrenoceptor to pro-
mote internalisation via recruitment of arrestin [421].
Adrenoceptors, β
β-Adrenoceptors are activated by the endogenous agonists
(-)-adrenaline and (-)-noradrenaline. Isoprenaline is selec-
tive for β-adrenoceptors relative to α1- and α2-adrenoceptors,
while propranolol (pKi 8.2-9.2) and cyanopindolol (pKi 10.0-
11.0) are relatively β1 and β2 adrenoceptor-selective antagonists.
(-)-noradrenaline, xamoterol and (-)-Ro 363 show selectivity for
β1- relative to β2-adrenoceptors. Pharmacological differences ex-
ist between human and mouse β3-adrenoceptors, and the ’rodent
selective’ agonists BRL 37344 and CL316243 have low efﬁcacy at
the human β3-adrenoceptor whereas CGP 12177 and L 755507
activate human β3-adrenoceptors [88]. β3-Adrenoceptors are
resistant to blockade by propranolol, but can be blocked by
high concentrations of bupranolol. SR59230A has reason-
ably high afﬁnity at β3-adrenoceptors, but does not discrimi-
nate well between the three β- subtypes whereas L 755507 is
more selective. [125I]-cyanopindolol, [125I]-hydroxy benzylpin-
dolol and [3H]-alprenolol are high afﬁnity radioligands that la-
bel β1- and β2- adrenoceptors and β3-adrenoceptors can be la-
belled with higher concentrations (nM) of [125I]-cyanopindolol
together with β1- and β2-adrenoceptor antagonists. [3H]-L-
748337 is a β3-selective radioligand [2197]. Fluorescent lig-
ands such as BODIPY-TMR-CGP12177 can be used to track β-
adrenoceptors at the cellular level [8]. Somewhat selective β1-
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adrenoceptor agonists (denopamine, dobutamine) are used short
term to treat cardiogenic shock but, chronically, reduce survival.
β1-Adrenoceptor-preferring antagonists are used to treat hyperten-
sion (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol),
cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac
failure (metoprolol, nebivolol). Cardiac failure is also treated
with carvedilol that blocks β1- and β2-adrenoceptors, as well
as α1-adrenoceptors. Short (salbutamol, terbutaline) and long
(formoterol, salmeterol) acting β2-adrenoceptor-selective agonists
are powerful bronchodilators used to treat respiratory disorders.
Many ﬁrst generation β-adrenoceptor antagonists (propranolol)
block both β1- and β2-adrenoceptors and there are no β2-
adrenoceptor-selective antagonists used therapeutically. The β3-
adrenoceptor agonist mirabegron is used to control overactive
bladder syndrome.
Nomenclature β1-adrenoceptor β2-adrenoceptor β3-adrenoceptor
HGNC, UniProt ADRB1, P08588 ADRB2, P07550 ADRB3, P13945
Potency order of endogenous ligands (-)-noradrenaline > (-)-adrenaline (-)-adrenaline > (-)-noradrenaline (-)-noradrenaline = (-)-adrenaline
Endogenous agonists (-)-adrenaline [633, 891], (-)-noradrenaline [633, 891],
noradrenaline [633]
(-)-adrenaline [633, 891, 982], (-)-noradrenaline [633,
891]
(-)-noradrenaline [891, 1720, 2044], (-)-adrenaline
[891]
Agonists pindolol (Partial agonist) [1159], isoprenaline [633,
1874], dobutamine (Partial agonist) [956]
pindolol (Partial agonist) [1159], arformoterol [40],
isoprenaline [1874], ephedrine (Partial agonist) [982]
carazolol [1431]
Selective agonists (-)-Ro 363 [1472], xamoterol (Partial agonist) [956],
denopamine (Partial agonist) [956, 2066]
formoterol [94], salmeterol [94], zinterol [94], vilanterol
[1737], procaterol [94], indacaterol [123], fenoterol
[65], salbutamol (Partial agonist) [96, 956], terbutaline
(Partial agonist) [96], orciprenaline [2014]
L 755507 [94], L742791 [2277], mirabegron [2089],
CGP 12177 (Partial agonist) [177, 1319, 1431, 1472],
SB251023 [936] – Mouse, BRL 37344 [177, 505, 891,
1431], CL316243 [2372]
Antagonists carvedilol (pKi 9.5) [297], bupranolol (pKi 7.3–9) [297,
1319], SR59230A (pKi 8.6) [297], levobunolol (pKi 8.4)
[79], labetalol (pKi 8.2) [79], metoprolol (pKi 7–7.6)
[96, 297, 891, 1319], esmolol (pKi 6.9) [79], nadolol
(pKi 6.9) [297], practolol (pKi 6.1–6.8) [96, 1319],
propafenone (pKi 6.7) [79], sotalol (pKi 6.1) [79]
carvedilol (pKi 9.4–9.9) [96, 297], timolol (pKi 9.7)
[96], propranolol (pKi 9.1–9.5) [96, 99, 956, 1319],
SR59230A (pKi 9.3) [297], levobunolol (pKi 9.3) [79],
bupranolol (pKi 8.3–9.1) [297, 1319], alprenolol (pKi
9) [96], nadolol (pKi 7–8.6) [96, 297], labetalol (pKi 8)
[79], propafenone (pKi 7.4) [79], sotalol (pKi 6.5) [79]
SR59230A (pKi 6.9–8.4) [297, 471, 891], bupranolol
(pKi 6.8–7.3) [177, 297, 1319, 1431], propranolol (pKi
6.3–7.2) [1319, 1720], levobunolol (pKi 6.8) [1720]
Selective antagonists CGP 20712A (pKi 8.5–9.2) [96, 297, 1319],
levobetaxolol (pKi 9.1) [1942], betaxolol (pKi 8.8)
[1319], nebivolol (pIC50 8.1–8.7) [1669] – Rabbit,
atenolol (pKi 6.7–7.6) [96, 1021, 1319], acebutolol
(pKi 6.4) [79]
ICI 118551 (Inverse agonist) (pKi 9.2–9.5) [96, 99,
1319]
L-748337 (pKi 8.4) [297], L748328 (pKi 8.4) [297]
Labelled ligands [125I]ICYP (Antagonist) (pKd 10.4–11.3) [956, 1319,
1874]
[125I]ICYP (Antagonist) (pKd 11.1) [1319, 1874] [
125I]ICYP (Agonist, Partial agonist) [1319, 1472, 1720,
1874, 2044]
Comments The agonists indicated have less than two orders of
magnitude selectivity [94].
– Agonist SB251023 has a pEC50 of 6.9 for the splice
variant of the mouse β3 receptor, β3b [936].
Comments: [125I]ICYP can be used to deﬁne β1- or β2-
adrenoceptors when conducted in the presence of a β1- or β2-
adrenoceptor-selective antagonist. A ﬂuorescent analogue of
CGP 12177 can be used to study β2-adrenoceptors in living cells
[97]. [125I]ICYP at higher (nM) concentrations can be used to label
β3-adrenoceptors in systems with few if any other β-adrenoceptor
subtypes. The β3-adrenoceptor has an intron in the coding re-
gion, but splice variants have only been described for the mouse
[576], where the isoforms display different signalling characteris-
tics [936]. There are 3 β-adrenoceptors in turkey (termed the tβ,
tβ3c and tβ4c) that have a pharmacology that differs from the hu-
man β-adrenoceptors [95]. Numerous polymorphisms have been
described for the β-adrenoceptors; some are associated with sig-
nalling and trafﬁcking, altered susceptibility to disease and/or al-
tered responses to pharmacotherapy [1279]. All β-adrenoceptors
couple to Gs (activating adenylyl cyclase and elevating cAMP
levels), but also activate Gi and β-arrestin-mediated signalling.
Many β1- and β2-adrenoceptor antagonists are agonists at β3-
adrenoceptors (CL316243, CGP 12177 and carazolol). Many ‘an-
tagonists’ of cAMP accumulation, for example carvedilol and
bucindolol, weakly activate MAP kinase pathways [98, 577, 644,
645, 1872, 1873] and thus display ’protean agonism’. Bupranolol
acts as a neutral antagonist in most systems so far examined. Ag-
onists also display biased signalling at the β2-adrenoceptor via Gs
or arrestins [520]. X-ray crystal structures have been described of
the agonist bound [2265] and antagonist bound forms of the β1-
[2266], agonist-bound [363] and antagonist-bound forms of the
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β2-adrenoceptor [1773, 1820], as well as a fully active agonist-
bound, Gs protein-coupled β2-adrenoceptor [1774]. Carvedilol
and bucindolol bind to a site on the β1-adrenoceptor involving
contacts in TM2, 3, and 7 and extracellular loop 2 that may facili-
tate coupling to arrestins [2266]. Compounds displaying arrestin-
biased signalling at the β2-adrenoceptor have a greater effect on
the conformation of TM7, whereas full agonists for Gs coupling
promote movement of TM5 and TM6 [1302]. Recent studies using
NMR spectroscopy demonstrate signiﬁcant conformational ﬂex-
ibility in the β2-adrenoceptor that is stabilized by both agonist
and G proteins highlighting the dynamic nature of interactions
with both ligand and downstream signalling partners [1090, 1372,
1605]. Such ﬂexibility likely has consequences for our understand-
ing of biased agonism, and for the future therapeutic exploitation
of this phenomenon.
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Angiotensin receptors
G protein-coupled receptors → Angiotensin receptors
Overview: The actions of angiotensin II (AGT, P01019) (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors
[465, 1045]), which have around 30% sequence similarity. The decapeptide angiotensin I (AGT, P01019), the octapeptide angiotensin II (AGT, P01019) and the heptapeptide angiotensin III (AGT,
P01019) are endogenous ligands. Losartan, candesartan, telmisartan, etc. are clinically used AT1 receptor blockers.
Nomenclature AT1 receptor AT2 receptor
HGNC, UniProt AGTR1, P30556 AGTR2, P50052
Endogenous agonists angiotensin II (AGT, P01019) [466, 2199], angiotensin III (AGT, P01019) [466],
angiotensin IV (AGT, P01019) (Partial agonist) [1222]
angiotensin III (AGT, P01019) [432, 466, 2298], angiotensin II (AGT, P01019) [466, 2000,
2298], angiotensin-(1-7) (AGT, P01019) [210]
Agonists [Sar1,Cha4]Ang-II [896, 1464] – Rat –
Selective agonists L-162,313 [1687], L-163,101 [2175] CGP42112 [210], [p-aminoPhe6]ang II [466, 2021] – Rat, compound 21 [2214]
Antagonists saprisartan (pKi 9.1) [870] – Rat, 5-oxo-1-2-4-oxadiazol biphenyl (pIC50 8.8) [1583] – Rat,
5-butyl-methyl immidazole carboxylate 30 (pIC50 8.5) [16], LY303336 (pIC50 8.3) [2198],
TRV120027 (pKd 7.7) [2220]
saralasin (pIC50 9) [371] – Rat
Selective antagonists candesartan (pIC50 9.5–9.7) [2199], eprosartan (pIC50 8.4–8.8) [543], losartan (pIC50
7.4–8.7) [466, 2135], telmisartan (pIC50 8.4) [1417], olmesartan (pIC50 8.1) [1127]
PD123177 (pIC50 8.5–9.5) [337, 371, 529] – Rat, EMA401 (pIC50 8.5–9.3) [599, 1800,
1998], PD123319 (pKd 8.7–9.2) [466, 528, 2308]
Labelled ligands [3H]candesartan (Antagonist) (pKd 10.3) [594], [
125I][Sar1]Ang-II (Agonist) [591] – Rat,
[125I][Sar1,Ile8]Ang-II (Agonist, Partial agonist) [591] – Rat, [3H]eprosartan (Antagonist)
(pKd 9.1) [24] – Rat, [
3H]losartan (Antagonist) (pKd 8.2) [341] – Rat
[125I]CGP42112 (Agonist) [466, 2298, 2299], [125I][Sar1,Ile8]Ang-II (Agonist) [2097] – Rat
Comments Telmisartan and candesartan are also reported to be agonists of PPARγ [2040]. –
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Comments: AT1 receptors are predominantly coupled to Gq/11,
however they are also linked to arrestin recruitment and stimulate
G protein-independent arrestin signalling [1332]. Most species ex-
press a single AGTR1 gene, but two related agtr1a and agtr1b recep-
tor genes are expressed in rodents. The AT2 receptor counteracts
several of the growth responses initiated by the AT1 receptors. The
AT2 receptor is much less abundant than the AT1 receptor in adult
tissues and is upregulated in pathological conditions. AT1 receptor
antagonists bearing substituted 4-phenylquinoline moieties have
been synthesized, which bind to AT1 receptors with nanomolar
afﬁnity and are slightly more potent than losartan in functional
studies [300]. The antagonist activity of CGP42112 at the AT2 re-
ceptor has also been reported [1596]. The AT1 and bradykinin B2
receptors have been proposed to form a heterodimeric complex
[3]. β-Arrestin1 prevents AT1-B2 receptor heteromerization[1756].
There is also evidence for an AT4 receptor that speciﬁcally binds
angiotensin IV (AGT, P01019) and is located in the brain and kid-
ney. An additional putative endogenous ligand for the AT4 recep-
tor has been described (LVV-hemorphin (HBB, P68871), a globin
decapeptide) [1467].
Further reading on Angiotensin receptors
Asada H et al. (2018) Crystal structure of the human angiotensin II type 2 receptor bound to an
angiotensin II analog. Nat. Struct. Mol. Biol. 25: 570-576 [PMID:29967536]
Karnik SS et al. (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin
Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol.
Rev. 67: 754-819 [PMID:26315714]
Singh KD et al. (2019) Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Ac-
tivated State of AT_1R Initiated by van der Waals Attraction. J Chem Inf Model 59: 373-385
[PMID:30608150]
Wingler LM et al. (2019) Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Con-
formations. Cell 176: 468-478.e11 [PMID:30639099]
Wingler LM et al. (2019) Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a
Synthetic Nanobody. Cell 176: 479-490.e12 [PMID:30639100]
Zhang H et al. (2015) Structure of the Angiotensin receptor revealed by serial femtosecond crystal-
lography. Cell 161: 833-44 [PMID:25913193]
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Apelin receptor
G protein-coupled receptors → Apelin receptor
Overview: The apelin receptor (nomenclature as agreed by
the NC-IUPHAR Subcommittee on the apelin receptor
[1713]) responds to apelin, a 36 amino-acid peptide derived ini-
tially from bovine stomach. Apelin-36 (APLN, Q9ULZ1), apelin-13
(APLN, Q9ULZ1) and [Pyr1]apelin-13 (APLN, Q9ULZ1) are the
predominant endogenous ligands which are cleaved from a 77
amino-acid precursor peptide (APLN, Q9ULZ1) by a so far uniden-
tiﬁed enzymatic pathway [2106]. A second family of peptides dis-
covered independently and named Elabela [372] or Toddler, that
has little sequence similarity to apelin, is present, and functional
at the apelin receptor in the adult cardiovascular system [1668,
2379]. Structure-activity relationship Elabela analogues have been
described [1528].
Nomenclature apelin receptor
HGNC, UniProt APLNR, P35414
Potency order of endogenous ligands [Pyr1]apelin-13 (APLN, Q9ULZ1) ≥ apelin-13 (APLN, Q9ULZ1) > apelin-36 (APLN, Q9ULZ1) [584, 2106]
Endogenous agonists apelin-13 (APLN, Q9ULZ1) [584, 909, 1428], apelin receptor early endogenous ligand (APELA, P0DMC3) [483], apelin-17 (APLN, Q9ULZ1)
[547, 1428], [Pyr ]apelin-131 (APLN, Q9ULZ1) [1056, 1428], Elabela/Toddler-21 (APELA, P0DMC3) [2378], Elabela/Toddler-32 (APELA,
P0DMC3) [2378], apelin-36 (APLN, Q9ULZ1) [584, 909, 1056, 1428], Elabela/Toddler-11 (APELA, P0DMC3) [2378]
Selective agonists CMF-019 (Biased agonist) [1781], MM07 (Biased agonist) [226]
Antagonists MM54 (pKi 8.2) [1338]
Labelled ligands [125I][Nle75,Tyr77]apelin-36 (human) (Agonist) [1056], [125I][Glp65Nle75,Tyr77]apelin-13 (Agonist) [909], [125I](Pyr1)apelin-13 (Agonist)
[1050], [125I]apelin-13 (Agonist) [584], [3H](Pyr1)[Met(0)11]-apelin-13 (Agonist) [1428]
Comments: Potency order determined for heterologously ex-
pressed human apelin receptor (pD2 values range from 9.5 to 8.6).
The apelin receptor may also act as a co-receptor with CD4 for iso-
lates of human immunodeﬁciency virus, with apelin blocking this
function [323]. Amodiﬁed apelin-13 peptide, apelin-13(F13A) was
reported to block the hypotensive response to apelin in rat in vivo
[1238], however, this peptide exhibits agonist activity in HEK293
cells stably expressing the recombinant apelin receptor [584]. The
apelin receptor antagonist, MM54, was reported to suppress tu-
mour growth and increase survival in an intracranial xenograft
mouse model of glioblastoma [809].
Further reading on Apelin receptor
Cheng B et al. (2012) Neuroprotection of apelin and its signaling pathway. Peptides 37: 171-3
[PMID:22820556]
Langelaan DN et al. (2009) Structural insight into G-protein coupled receptor binding by apelin.
Biochemistry 48: 537-48 [PMID:19123778]
Mughal A et al. (2018) Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol.
Ther. 190: 139-147 [PMID:29807055]
O’Carroll AM et al. (2013) The apelin receptor APJ: journey from an orphan to a multifaceted regu-
lator of homeostasis. J. Endocrinol. 219: R13-35 [PMID:23943882]
Pitkin SL et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIV. Apelin re-
ceptor nomenclature, distribution, pharmacology, and function. Pharmacol. Rev. 62: 331-42
[PMID:20605969]
Yang P et al. (2015) Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the
cardiovascular system. Trends Pharmacol. Sci. 36: 560-7 [PMID:26143239]
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Bile acid receptor
G protein-coupled receptors → Bile acid receptor
Overview: The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such
as type II diabetes, obesity and atherosclerosis.
Nomenclature GPBA receptor
HGNC, UniProt GPBAR1, Q8TDU6
Potency order of endogenous ligands lithocholic acid > deoxycholic acid > chenodeoxycholic acid, cholic acid [1055, 1392]
Selective agonists S-EMCA [1676] – Mouse, betulinic acid [680], oleanolic acid [1871]
Comments: The triterpenoid natural product betulinic acid has also been reported to inhibit inﬂammatory signalling through the NFκB pathway [2081]. Disruption of GPBA expression is reported to
protect from cholesterol gallstone formation [2209]. A new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides have been reported as highly potent agonists [1313].
Further reading on Bile acid receptor
Duboc H et al. (2014) The bile acid TGR5 membrane receptor: from basic research to clinical appli-
cation. Dig Liver Dis 46: 302-12 [PMID:24411485]
Lefebvre P et al. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev.
89: 147-91 [PMID:19126757]
Lieu T et al. (2014) GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of
digestion and sensation. Br. J. Pharmacol. 171: 1156-66 [PMID:24111923]
van Nierop FS et al. (2017) Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet
Diabetes Endocrinol 5: 224-233 [PMID:27639537]
Bombesin receptors
G protein-coupled receptors → Bombesin receptors
Overview: Mammalian bombesin (Bn) receptors comprise 3
subtypes: BB1, BB2, BB3 (nomenclature recommended by
the NC-IUPHAR Subcommittee on bombesin receptors,
[990]). BB1 and BB2 are activated by the endogenous ligands
gastrin-releasing peptide (GRP, P07492) (GRP), neuromedin B
(NMB, P08949) (NMB) and GRP-(18-27) (GRP, P07492). Bombesin
is a tetradecapeptide, originally derived from amphibians. The
three Bn receptor subtypes couple primarily to the Gq/11 and
G12/13 family of G proteins [990]. Each of these receptors is widely
distributed in the CNS and peripheral tissues [723, 990, 1721,
1766, 1866, 2420]. Activation of BB1 and BB2 receptors causes a
wide range of physiological/pathophysiogical actions, including
the stimulation of normal and neoplastic tissue growth, smooth-
muscle contraction, feeding behavior, secretion and many central
nervous system effects including regulation of circadian rhythm
and mediation of pruritus [990, 991, 992, 1359, 1489, 1766]. A
physiological role for the BB3 receptor has yet to be fully deﬁned
although recently studies suggest an important role in glucose and
insulin regulation, metabolic homeostasis, feeding, regulation of
body temperature, obesity, diabetes mellitus and growth of nor-
mal/neoplastic tissues [723, 1360, 1619, 2345].
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Nomenclature BB1 receptor BB2 receptor BB3 receptor
HGNC, UniProt NMBR, P28336 GRPR, P30550 BRS3, P32247
Endogenous agonists neuromedin B (NMB, P08949) [990, 1766, 2166] neuromedin C [2166],
gastrin releasing peptide(14-27) (human) [2166]
–
Selective agonists – – compound 9g [1398], MK-7725 [373], MK-5046 [1494,
1915], [D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14)
[1376], compound 17c [1397], bag-1 [759], compound 22e
[836]
Antagonists D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (pIC50 6.2–6.6)
[722]
– –
Selective antagonists PD 176252 (pIC50 9.3–9.8) [722], PD 168368 (pIC50
9.3–9.6) [722], dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH2
[D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (pKi 9.8)
[722], JMV641 (pIC50 9.3) [2140] – Mouse,
[(3-Ph-Pr6), His7,D-Ala11,D-Pro13,ψ13-14),Phe14]bombesin-(6-14)
(pIC50 9.2) [722, 1231], JMV594 (pIC50 8.9) [1308, 2140] –
Mouse, [D-Tpi6, Leu13 ψ(CH2NH)-Leu14]bombesin-(6-14)
(pIC50 8.9) [722]
bantag-1 (pIC50 8.6–8.7) [759, 1494], ML-18 (pIC50 5.3)
[1488]
Labelled ligands [125I]BH-NMB (human, mouse, rat) (Agonist),
[125I][Tyr4]bombesin (Agonist)
[125I][D-Tyr6]bombesin-(6-13)-methyl ester (Selective
Antagonist) (pKd 9.3) [1375] – Mouse, [
125I][Tyr4]bombesin
(Agonist) [144], [125I]GRP (human) (Agonist)
[3H]bag-2 (Agonist) [759] – Mouse,
[125I][D-Tyr6,β-Ala11,Phe13,Nle14]bombesin-(6-14)
(Agonist) [1377, 1494]
Comments: All three human subtypes may be activated by [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) [1377]. [D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14) has more than 200-fold selectivity for
BB3 receptors over BB1 and BB2 [1376, 1377, 1766, 1767].
Further reading on Bombesin receptors
González N et al. (2015) Bombesin receptor subtype 3 as a potential target for obesity and diabetes.
Expert Opin. Ther. Targets 19: 1153-70 [PMID:26066663]
Jensen RT et al. (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin recep-
tors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease
states. Pharmacol. Rev. 60: 1-42 [PMID:18055507]
Maina T et al. (2017) Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists
in Oncology. PET Clin 12: 297-309 [PMID:28576168]
Moreno P et al. (2016) Bombesin related peptides/receptors and their promising therapeutic
roles in cancer imaging, targeting and treatment. Expert Opin. Ther. Targets 20: 1055-73
[PMID:26981612]
Qu X et al. (2018) Recent insights into biological functions of mammalian bombesin-like peptides
and their receptors. Curr Opin Endocrinol Diabetes Obes 25: 36-41 [PMID:29120926]
Ramos-Álvarez I et al. (2015) Insights into bombesin receptors and ligands: Highlighting recent
advances. Peptides 72: 128-44 [PMID:25976083]
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Bradykinin receptors
G protein-coupled receptors → Bradykinin receptors
Overview: Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [1243]) are activated by the endogenous peptides
bradykinin (KNG1, P01042) (BK), [des-Arg9]bradykinin (KNG1, P01042), Lys-BK (kallidin (KNG1, P01042)), [des-Arg10]kallidin (KNG1, P01042), [Phospho-Ser6]-Bradykinin, T-kinin (KNG1, P01042) (Ile-Ser-
BK), [Hyp3]bradykinin (KNG1, P01042) and Lys-[Hyp3]-bradykinin (KNG1, P01042). Variation in pharmacology and activity of B1 and B2 receptor antagonists at species orthologs has been documented.
Icatibant (Hoe140, Firazir) is approved in North America and Europe for the treatment of acute attacks of hereditary angioedema.
Nomenclature B1 receptor B2 receptor
HGNC, UniProt BDKRB1, P46663 BDKRB2, P30411
Potency order of endogenous ligands [des-Arg10]kallidin (KNG1, P01042) > [des-Arg9]bradykinin (KNG1, P01042) =
kallidin (KNG1, P01042) > bradykinin (KNG1, P01042)
kallidin (KNG1, P01042) > bradykinin (KNG1, P01042)  [des-Arg9]bradykinin
(KNG1, P01042), [des-Arg10]kallidin (KNG1, P01042)
Endogenous agonists [des-Arg10]kallidin (KNG1, P01042) [80, 118, 714, 1012] bradykinin (KNG1, P01042)
Selective agonists NG29 [1879], [Sar,D-Phe8,des-Arg9]bradykinin [1012] NG291 [282, 1880], [Hyp3,Tyr(Me)8]BK, [Phe8,ψ(CH2-NH)Arg9]BK, labradimil
[282, 1880]
Selective antagonists B-9958 (pKi 9.2–10.3) [689, 1784], [Leu
9,des-Arg10]kallidin (pKi 9.1–9.3) [80,
118], SSR240612 (pKi 9.1–9.2) [732], R-954 (pA2 8.6) [715], R-715 (pA2 8.5) [713]
icatibant (pKi 10.2) [43], FR173657 (pA2 8.2) [1814], anatibant (pKi 8.2) [1742]
Labelled ligands [125I]Hpp-desArg10HOE140 (pKd 10), [
3H]Lys-[des-Arg9]BK (Agonist),
[3H]Lys-[Leu8][des-Arg9]BK (Antagonist)
[3H]BK (human, mouse, rat) (Agonist) [2318] – Mouse, [3H]NPC17731 (Antagonist)
(pKd 9.1–9.4) [2423, 2424], [
125I][Tyr8]bradykinin (Agonist)
Further reading on Bradykinin receptors
Campos MM et al. (2006) Non-peptide antagonists for kinin B1 receptors: new insights into their
therapeutic potential for the management of inﬂammation and pain. Trends Pharmacol. Sci. 27:
646-51 [PMID:17056130]
Duchene J et al. (2009) The kinin B(1) receptor and inﬂammation: new therapeutic target for cardio-
vascular disease. Curr Opin Pharmacol 9: 125-31 [PMID:19124274]
Marceau F et al. (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3:
845-52 [PMID:15459675]
Paquet JL et al. (1999) Pharmacological characterization of the bradykinin B2 receptor: inter-species
variability and dissociation between binding and functional responses. Br. J. Pharmacol. 126:
1083-90 [PMID:10204994]
Thornton E et al. (2010) Kinin receptor antagonists as potential neuroprotective agents in central
nervous system injury. Molecules 15: 6598-618 [PMID:20877247]
Whalley ET et al. (2012) Discovery and therapeutic potential of kinin receptor antagonists. Expert
Opin Drug Discov 7: 1129-48 [PMID:23095011]
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Calcitonin receptors
G protein-coupled receptors → Calcitonin receptors
Overview: This receptor family comprises a group of recep-
tors for the calcitonin/CGRP family of peptides. The calcitonin
(CT), amylin (AMY), calcitonin gene-related peptide (CGRP) and
adrenomedullin (AM) receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on CGRP, AM, AMY, and
CT receptors [830, 1732]) are generated by the genes CALCR
(which codes for the CT receptor) and CALCRL (which codes for
the calcitonin receptor-like receptor, CLR, previously known as
CRLR). Their function and pharmacology are altered in the pres-
ence of RAMPs (receptor activity-modifying proteins), which are
single TM domain proteins of ca. 130 amino acids, identiﬁed as a
family of three members; RAMP1, RAMP2 and RAMP3. There are
splice variants of the CT receptor; these in turn produce variants of
the AMY receptor [1732], some of which can be potently activated
by CGRP. The endogenous agonists are the peptides calcitonin
(CALCA, P01258), α-CGRP (CALCA, P06881) (formerly known as
CGRP-I), β-CGRP (CALCB, P10092) (formerly known as CGRP-II),
amylin (IAPP, P10997) (occasionally called islet-amyloid polypep-
tide, diabetes-associated polypeptide), adrenomedullin (ADM,
P35318) and adrenomedullin 2/intermedin (ADM2, Q7Z4H4).
There are species differences in peptide sequences, particularly for
the CTs. CTR-stimulating peptide {Pig} (CRSP) is another mem-
ber of the family with selectivity for the CT receptor but it is
not expressed in humans [1047]. Olcegepant (also known as
BIBN4096BS, pKi10.5) and telcagepant (also known as MK0974,
pKi9) are the most selective antagonists available, showing selec-
tivity for CGRP receptors, with a particular preference for those
of primate origin. CLR (calcitonin receptor-like receptor) by itself
binds no known endogenous ligand, but in the presence of RAMPs
it gives receptors for CGRP, adrenomedullin and adrenomedullin
2/intermedin.
Nomenclature CT receptor AMY1 receptor AMY2 receptor AMY3 receptor
HGNC, UniProt CALCR, P30988 – – –
Subunits – RAMP1 (Accessory protein), CT receptor CT receptor, RAMP2 (Accessory protein) CT receptor, RAMP3 (Accessory protein)
Potency order of endogenous ligands calcitonin (salmon) ≥ calcitonin (CALCA,
P01258) ≥ amylin (IAPP, P10997),
α-CGRP (CALCA, P06881), β-CGRP
(CALCB, P10092) > adrenomedullin
(ADM, P35318),
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4)
calcitonin (salmon) ≥ amylin (IAPP,
P10997) ≥ α-CGRP (CALCA, P06881),
β-CGRP (CALCB, P10092) >
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) ≥ calcitonin (CALCA, P01258)
> adrenomedullin (ADM, P35318)
Poorly deﬁned calcitonin (salmon) ≥ amylin (IAPP,
P10997) > α-CGRP (CALCA,
P06881),β-CGRP (CALCB, P10092) ≥
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) ≥ calcitonin (CALCA, P01258)
> adrenomedullin (ADM, P35318)
Endogenous agonists calcitonin (CALCA, P01258) [35, 68,
827, 1183, 1263, 1517]
α-CGRP (CALCA, P06881) [827, 1182,
1183, 1263, 2241], amylin (IAPP,
P10997) [705], β-CGRP (CALCB,
P10092)
amylin (IAPP, P10997) [705] amylin (IAPP, P10997) [705]
Sub/family-selective agonists pramlintide [705] pramlintide [705] – pramlintide [705]
Sub/family-selective antagonists CT-(8-32) (salmon) (pKd 9) [874],
AC187 (pKi 7.2) [827]
AC187 (pKi 8) [827],
CT-(8-32) (salmon) (pKi 7.8) [827],
olcegepant (pKd 7.2) [2241]
– CT-(8-32) (salmon) (pKi 7.9) [827],
AC187 (pKi 7.7) [827]
Labelled ligands [125I]CT (human) (Agonist),
[125I]CT (salmon) (Agonist)
[125I]αCGRP (human) (Agonist),
[125I]BH-AMY (rat, mouse) (Agonist)
[125I]BH-AMY (rat, mouse) (Agonist) [125I]BH-AMY (rat, mouse) (Agonist)
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Nomenclature calcitonin receptor-like receptor CGRP receptor AM1 receptor AM2 receptor
HGNC, UniProt CALCRL, Q16602 – – –
Subunits – calcitonin receptor-like receptor, RAMP1
(Accessory protein)
calcitonin receptor-like receptor, RAMP2
(Accessory protein)
calcitonin receptor-like receptor, RAMP3
(Accessory protein)
Potency order of endogenous ligands – α-CGRP (CALCA, P06881), β-CGRP
(CALCB, P10092) > adrenomedullin
(ADM, P35318) ≥
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) > amylin (IAPP, P10997) ≥
calcitonin (salmon)
adrenomedullin (ADM, P35318) >
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) > α-CGRP (CALCA, P06881),
β-CGRP (CALCB, P10092), amylin (IAPP,
P10997) > calcitonin (salmon)
adrenomedullin (ADM, P35318) ≥
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) ≥ α-CGRP (CALCA, P06881),
β-CGRP (CALCB, P10092) > amylin
(IAPP, P10997) > calcitonin (salmon)
Endogenous agonists – β-CGRP (CALCB, P10092) [23, 1426],
α-CGRP (CALCA, P06881) [23, 1426]
adrenomedullin (ADM, P35318) [23,
1426]
adrenomedullin (ADM, P35318) [23,
623]
Antagonists – olcegepant (pKi 10.7–11) [512, 828,
829, 1022, 1368], telcagepant (pKi 9.1)
[1857]
– –
Selective antagonists – – AM-(22-52) (human) (pKi 7–7.8) [829] AM-(22-52) (human)
Labelled ligands – [125I]αCGRP (human) (Agonist),
[125I]αCGRP (mouse, rat) (Agonist)
[125I]AM (rat) (Agonist) [125I]AM (rat) (Agonist)
Comments: It is important to note that a complication with the
interpretation of pharmacological studies with AMY receptors in
transfected cells is that most of this work has likely used a mixed
population of receptors, encompassing RAMP-coupled CTR as well
as CTR alone. This means that although in binding assays human
calcitonin (CALCA, P01258) has low afﬁnity for 125I-AMY binding
sites, cells transfected with CTR and RAMPs can display potent
CT functional responses. Transfection of human CTR with any
RAMP can generate receptors with a high afﬁnity for both salmon
CT and AMY and varying afﬁnity for different antagonists [388,
827, 828]. The major human CTR splice variant (hCT(a), which
does not contain an insert) with RAMP1 (i.e. the AMY1(a) recep-
tor) has a high afﬁnity for CGRP [2241], unlike hCT(a)-RAMP3 (i.e.
AMY3(a) receptor) [388, 827]. However, the AMY receptor pheno-
type is RAMP-type, splice variant and cell-line-dependent [1495,
1750, 2134]. Emerging data suggests that AMY1 could be a second
CGRP receptor [826].
The ligands described have limited selectivity. Adrenomedullin
has appreciable afﬁnity for CGRP receptors. CGRP can show
signiﬁcant cross-reactivity at AMY receptors and AM2 receptors.
Adrenomedullin 2/intermedin also has high afﬁnity for the AM2
receptor [903]. CGRP-(8-37) acts as an antagonist of CGRP (pKi 8)
and inhibits some AM and AMY responses (pKi 6-7). It is weak at
CT receptors. HumanAM-(22-52) has some selectivity towards AM
receptors, but with modest potency (pKi 7), limiting its use [829].
Olcegepant shows the greatest selectivity between receptors but
still has signiﬁcant afﬁnity for AMY1 receptors [2241].
Gs is a prominent route for effector coupling for CLR and CTR but
other pathways (e.g. Ca2+, ERK, Akt), and G proteins can be acti-
vated [2240]. There is evidence that CGRP-RCP (a 148 amino-acid
hydrophilic protein, ASL (P04424) is important for the coupling
of CLR to adenylyl cyclase [578].
[125I]-Salmon CT is the most common radioligand for CT recep-
tors but it has high afﬁnity for AMY receptors and is also poorly
reversible.
Further reading on Calcitonin receptors
Hay DL et al. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR
Review 25. Br. J. Pharmacol. 175: 3-17 [PMID:29059473]
Hay DL et al. (2016) Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles. Annu.
Rev. Pharmacol. Toxicol. 56: 469-87 [PMID:26514202]
Kato J et al. (2015) Bench-to-bedside pharmacology of adrenomedullin. Eur. J. Pharmacol. 764: 140-8
[PMID:26144371]
Russell FA et al. (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol.
Rev. 94: 1099-142 [PMID:25287861]
Russo AF. (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu. Rev.
Pharmacol. Toxicol. 55: 533-52 [PMID:25340934]
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Calcium-sensing receptor
G protein-coupled receptors → Calcium-sensing receptor
Overview: The calcium-sensing receptor (CaS, provisional
nomenclature as recommended by NC-IUPHAR [612])
responds to multiple endogenous ligands, including extracel-
lular calcium and other divalent/trivalent cations, polyamines
and polycationic peptides, L-amino acids (particularly L-Trp
and L-Phe), glutathione and various peptide analogues, ionic
strength and extracellular pH (reviewed in [1228]). While diva-
lent/trivalent cations, polyamines and polycations are CaS recep-
tor agonists [252, 1754], L-amino acids, glutamyl peptides, ionic
strength and pH are allosteric modulators of agonist function
[411, 612, 885, 1752, 1753]. Indeed, L-amino acids have been
identiﬁed as "co-agonists", with both concomitant calcium and
L-amino acid binding required for full receptor activation [682,
2416]. The sensitivity of the CaS receptor to primary agonists is
increased by elevated extracellular pH [295] or decreased extracel-
lular ionic strength [1753]. This receptor bears no sequence or
structural relation to the plant calcium receptor, also called CaS.
Nomenclature CaS receptor
HGNC, UniProt CASR, P41180
Amino-acid rank order of potency L-phenylalanine, L-tryptophan, L-histidine > L-alanine > L-serine, L-proline, L-glutamic acid > L-aspartic acid (not L-lysine, L-arginine, L-leucine and
L-isoleucine) [411]
Cation rank order of potency Gd3+ > Ca2+ > Mg2+ [252]
Glutamyl peptide rank order of potency S-methylglutathione ≈ γGlu-Val-Gly > glutathione > γGlu-Cys [243, 1621, 2256]
Polyamine rank order of potency spermine > spermidine > putrescine [1754]
Allosteric modulators ATF 936 (Negative) (pIC50 8.9) [2302], encaleret (Negative) (pIC50 7.9) [1956], SB-423562 (Negative) (pIC50 7.1) [1176], ronacaleret (Negative) (pIC50
6.5–6.8) [101], NPS 2143 (Negative) (pKB 6.2–6.7) [459, 1226, 1229], cinacalcet (Positive) (pKB 5.9–6.6) [414, 459, 1226, 1229], tecalcet (Positive) (pKB
6.2–6.6) [414, 459], AC265347 (Positive) (pKB 6.3–6.4) [414, 1226], calhex 231 (Negative) (pIC50 6.4) [1699], calindol (Positive) (pKB 6.3) [414]
Comments: The CaS receptor has a number of physiological
functions, but it is best known for its central role in parathy-
roid and renal regulation of extracellular calcium homeostasis
[798]. This is seen most clearly in patients with loss-of-function
CaS receptor mutations who develop familial hypocalciuric hy-
percalcaemia (heterozygous mutations) or neonatal severe hyper-
parathyroidism (heterozygous, compound heterozygous or ho-
mozygous mutations) [798] and in Casr null mice [339, 885],
which exhibit similar increases in PTH secretion and blood cal-
cium levels. Gain-of-function CaS mutations are associated with
autosomal dominant hypocalcaemia and Bartter syndrome type V
[798].
The CaS receptor primarily couples to Gq/11, G12/13 and Gi/o [459,
693, 922, 2124], but in some cell types can couple to Gs [1370].
However, the CaS receptor can form heteromers with Class C
GABAB [340, 362] and mGlu1/5 receptors [651], which may in-
troduce further complexity in its signalling capabilities.
Multiple other small molecule chemotypes are positive and neg-
ative allosteric modulators of the CaS receptor [1078, 1565]. Fur-
ther, etelcalcetide is a novel peptide positive allosteric modula-
tor of the receptor [2243]. Agonists and positive allosteric modu-
lators of the CaS receptor are termed Type I and II calcimimet-
ics, respectively, and can suppress parathyroid hormone (PTH
(PTH, P01270)) secretion [1567]. Negative allosteric modulators
are called calcilytics and can act to increase PTH (PTH, P01270)
secretion [1566].
Where functional pKB values are provided for allosteric modu-
lators, this refers to ligand afﬁnity determined in an assay that
measures a functional readout of receptor activity (i.e. a receptor
signalling assay), as opposed to afﬁnity determined in a radioli-
gand binding assay. The functional pKB may differ depending
on the signalling pathway studied. Consult the ’More detailed
page’ for the assay description, as well as other functional
readouts.
Further reading on Calcium-sensing receptor
Brown EM. (2013) Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best
Pract. Res. Clin. Endocrinol. Metab. 27: 333-43 [PMID:23856263]
Conigrave AD et al. (2013) Calcium-sensing receptor (CaSR): pharmacological properties and signal-
ing pathways. Best Pract. Res. Clin. Endocrinol. Metab. 27: 315-31 [PMID:23856262]
Hannan FM et al. (2018) The calcium-sensing receptor in physiology and in calcitropic and noncal-
citropic diseases. Nat Rev Endocrinol 15: 33-51 [PMID:30443043]
Nemeth EF et al. (2018) Discovery and Development of Calcimimetic and Calcilytic Compounds.
Prog Med Chem 57: 1-86 [PMID:29680147]
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Cannabinoid receptors
G protein-coupled receptors → Cannabinoid receptors
Overview: Cannabinoid receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on
Cannabinoid Receptors [1692]) are activated by en-
dogenous ligands that include N-arachidonoylethanolamine
(anandamide), N-homo-γ-linolenoylethanolamine,
N-docosatetra-7,10,13,16-enoylethanolamine and
2-arachidonoylglycerol. Potency determinations of endogenous
agonists at these receptors are complicated by the possibility of
differential susceptibility of endogenous ligands to enzymatic
conversion [38].
There are currently three licenced cannabinoid medicines each of
which contains a compound that can activate CB1 and CB2 re-
ceptors [1690]. Two of these medicines were developed to sup-
press nausea and vomiting produced by chemotherapy. These
are nabilone (Cesamet®), a synthetic CB1/CB2 receptor ago-
nist, and synthetic 9-tetrahydrocannabinol (Marinol®; dron-
abinol), which can also be used as an appetite stimulant. The third
medicine, Sativex®, contains mainly 9-tetrahydrocannabinol
and cannabidiol, both extracted from cannabis, and is used to
treat multiple sclerosis and cancer pain.
Nomenclature CB1 receptor CB2 receptor
HGNC, UniProt CNR1, P21554 CNR2, P34972
Agonists HU-210 [590, 1960], CP55940 [590, 1824, 1960], WIN55212-2 [590, 1959, 1960],
9-tetrahydrocannabinol (Partial agonist) [590, 1960], cannabinol (Partial agonist) [590,
1960]
HU-210 [590, 1796, 1960], WIN55212-2 [590, 1959, 1960], CP55940 [590, 1824, 1960],
9-tetrahydrocannabinol (Partial agonist) [121, 590, 1796, 1960]
Selective agonists arachidonyl-2-chloroethylamide [872] – Rat, arachidonylcyclopropylamide [872] – Rat,
O-1812 [489] – Rat, R-(+)-methanandamide [1073] – Rat
JWH-133 [930, 1691], L-759,633 [663, 1824], AM1241 [2381], L-759,656 [663, 1824],
HU-308 [806]
Selective antagonists rimonabant (pKi 7.9–8.7) [589, 590, 1804, 1835, 1960], AM6545 (pKi 8.5) [217], AM251
(pKi 8.1) [1196] – Rat, AM281 (pKi 7.9) [1195] – Rat, LY320135 (pKi 6.9) [589]
SR144528 (pKi 8.3–9.2) [1805, 1824], AM-630 (pKi 7.5) [1824]
Allosteric modulators GAT100 (Negative) (pEC50 7.7) [1172], ZCZ011 (Positive) (pEC50 6.3) [943] – Mouse,
GAT211 (Positive) [1205], cannabidiol (Negative) [1204]
pepcan-12 (Positive) (pKi ∼7.3) [1701], compound C2 (Positive) [643]
Labelled ligands [3H]rimonabant (Antagonist) (pKd 8.9–10) [228, 880, 1025, 1698, 1806, 1972, 2118] – Rat –
Comments: Both CB1 and CB2 receptors may be labelled with
[3H]CP55940 (0.5 nM; [1960]) and [3H]WIN55212-2 (2–2.4 nM;
[1987, 2013]). Anandamide is also an agonist at vanilloid recep-
tors (TRPV1) and PPARs [1608, 2444]. There is evidence for an
allosteric site on the CB1 receptor [1735]. All of the compounds
listed as antagonists behave as inverse agonists in some bioassay
systems [1692]. For some cannabinoid receptor ligands, additional
pharmacological targets that include GPR55 and GPR119 have
been identiﬁed [1692]. Moreover, GPR18, GPR55 and GPR119,
although showing little structural similarity to CB1 and
CB2 receptors, respond to endogenous agents that are structurally
similar to the endogenous cannabinoid ligands [1692].
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Further reading on Cannabinoid receptors
Howlett AC et al. (2002) International Union of Pharmacology. XXVII. Classiﬁcation of cannabinoid
receptors. Pharmacol. Rev. 54: 161-202 [PMID:12037135]
Pertwee RG. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and
antagonists. Curr. Med. Chem. 17: 1360-81 [PMID:20166927]
Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabi-
noid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev. 62: 588-631
[PMID:21079038]
Chemerin receptors
G protein-coupled receptors → Chemerin receptors
Overview: Nomenclature for the chemerin receptors is presented
as recommended by NC-IUPHAR [455, 1065]). The chemoat-
tractant protein and adipokine, chemerin (RARRES2, Q99969),
has been shown to be the endogenous ligand for both chemerin
family receptors. Chemerin1 was the founding family member,
and when GPR1 was de-orphanised it was re-named Chermerin2
[1065]. Chemerin1 is also activated by the lipid-derived, anti-
inﬂammatory ligand resolvin E1 (RvE1), which is formed via the
sequential metabolism of EPA by aspirin-modiﬁed cyclooxygenase
and lipoxygenase [66, 67]. In addition, two GPCRs for resolvin D1
(RvD1) have been identiﬁed: FPR2/ALX, the lipoxin A4 receptor,
and GPR32, an orphan receptor [1153].
Nomenclature chemerin receptor 1 chemerin receptor 2
Common abbreviation Chemerin1 Chemerin2
HGNC, UniProt CMKLR1, Q99788 GPR1, P46091
Potency order of endogenous ligands resolvin E1 > chemerin C-terminal peptide > 18R-HEPE > EPA [66] –
Endogenous agonists – chemerin (RARRES2, Q99969) [109]
Selective agonists resolvin E1 –
Labelled ligands [3H]resolvin E1 (Agonist) [66, 67] –
Comments – Reported to act as a co-receptor for HIV [1952]. See review [455] for discussion of
pairing with chemerin.
Comments: CCX832 (structure not disclosed) is a selective antagonist, pKi=9.2 [1066].
Further reading on Chemerin receptors
Kennedy AJ et al. (2018) International Union of Basic and Clinical Pharmacology CIII: Chemerin Re-
ceptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Func-
tion. Pharmacol. Rev. 70: 174-196 [PMID:29279348]
Shin WJ et al. (2018) Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Thera-
peutic Intervention. Front Immunol 9: 2772 [PMID:30555465]
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Chemokine receptors
G protein-coupled receptors → Chemokine receptors
Overview: Chemokine receptors (nomenclature as agreed
by the NC-IUPHAR Subcommittee on Chemokine Recep-
tors [90, 1524, 1525]) comprise a large subfamily of 7TM pro-
teins that bind one or more chemokines, a large family of small
cytokines typically possessing chemotactic activity for leukocytes.
Additional hematopoietic and non-hematopoietic roles have been
identiﬁed for many chemokines in the areas of embryonic de-
velopment, immune cell proliferation, activation and death, vi-
ral infection, and as antibiotics, among others. Chemokine
receptors can be divided by function into two main groups:
G protein-coupled chemokine receptors, which mediate leuko-
cyte trafﬁcking, and "Atypical chemokine receptors", which may
signal through non-G protein-coupled mechanisms and act as
chemokine scavengers to downregulate inﬂammation or shape
chemokine gradients [90].
Chemokines in turn can be divided by structure into four sub-
classes by the number and arrangement of conserved cysteines.
CC (also known as β-chemokines; n= 28), CXC (also known as
α-chemokines; n= 17) and CX3C (n= 1) chemokines all have four
conserved cysteines, with zero, one and three amino acids separat-
ing the ﬁrst two cysteines respectively. C chemokines (n= 2) have
only the second and fourth cysteines found in other chemokines.
Chemokines can also be classiﬁed by function into homeostatic
and inﬂammatory subgroups. Most chemokine receptors are able
to bind multiple high-afﬁnity chemokine ligands, but the ligands
for a given receptor are almost always restricted to the same struc-
tural subclass. Most chemokines bind to more than one recep-
tor subtype. Receptors for inﬂammatory chemokines are typically
highly promiscuous with regard to ligand speciﬁcity, andmay lack
a selective endogenous ligand. G protein-coupled chemokine re-
ceptors are named acccording to the class of chemokines bound,
whereas ACKR is the root acronym for atypical chemokine recep-
tors [91]. There can be substantial cross-species differences in the
sequences of both chemokines and chemokine receptors, and in
the pharmacology and biology of chemokine receptors. Endoge-
nous and microbial non-chemokine ligands have also been iden-
tiﬁed for chemokine receptors. Many chemokine receptors func-
tion as HIV co-receptors, but CCR5 is the only one demonstrated
to play an essential role in HIV/AIDS pathogenesis. The tables in-
clude both standard chemokine receptor names [2401] and aliases.
Nomenclature CCR1 CCR2 CCR3
HGNC, UniProt CCR1, P32246 CCR2, P41597 CCR3, P51677
Endogenous agonists CCL3 (CCL3, P10147) [375, 406, 862, 2443], CCL23
(CCL23, P55773) [375], CCL5 (CCL5, P13501) [406, 862],
CCL7 (CCL7, P80098) [375, 775], CCL15 (CCL15, Q16663)
[423], CCL14 (CCL14, Q16627) [375], CCL13 (CCL13,
Q99616), CCL8 (CCL8, P80075)
CCL2 (CCL2, P13500) [423, 1335, 1461, 1658, 2167],
CCL13 (CCL13, Q99616) [1335, 2167], CCL7 (CCL7,
P80098) [423, 1335, 2167], CCL11 (CCL11, P51671)
(Partial agonist) [1335, 1658], CCL16 (CCL16, O15467)
CCL13 (CCL13, Q99616) [1505, 2167], CCL24 (CCL24,
O00175) [1505, 1658], CCL5 (CCL5, P13501) [449], CCL7
(CCL7, P80098) [449], CCL11 (CCL11, P51671) [531, 1108,
1505, 1849, 2167], CCL26 (CCL26, Q9Y258) [1108, 1505,
1658], CCL15 (CCL15, Q16663) [423], CCL28 (CCL28,
Q9NRJ3), CCL8 (CCL8, P80075)
Agonists – – CCL11 {Mouse} [449]
Endogenous antagonists CCL4 (CCL4, P13236) (pKi 7.1–7.8) [375, 406] CCL26 (CCL26, Q9Y258) (pIC50 8.5) [1658] CXCL10 (CXCL10, P02778), CXCL11 (CXCL11, O14625),
CXCL9 (CXCL9, Q07325)
Selective antagonists BX 471 (pKi 8.2–9) [1274], compound 2b-1 (pIC50 8.7)
[1552], UCB35625 (pIC50 8) [1849], CP-481,715 (pKd 8)
[708]
GSK Compound 34 (pKi 7.6) banyu (I) (Inverse agonist) (pKi 8.5) [2247], SB328437 (pKi
8.4), BMS compound 87b (pKi 8.1) [2232]
Labelled ligands [125I]CCL7 (human) (Agonist) [140], [125I]CCL3 (human)
(Agonist) [140, 720, 1870], [125I]CCL5 (human) (Agonist)
[1870]
[125I]CCL2 (human) (Agonist), [125I]CCL7 (human)
(Agonist)
[125I]CCL11 (human) (Antagonist) (pKd 8.3) [2247],
[125I]CCL5 (human) (Agonist), [125I]CCL7 (human)
(Agonist)
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Nomenclature CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CCR10
HGNC, UniProt CCR4, P51679 CCR5, P51681 CCR6, P51684 CCR7, P32248 CCR8, P51685 CCR9, P51686 CCR10, P46092
Endogenous agonists CCL22 (CCL22,
O00626) [947], CCL17
(CCL17, Q92583) [947]
CCL5 (CCL5, P13501)
[87, 1547, 1833], CCL4
(CCL4, P13236) [1547,
1833], CCL8 (CCL8,
P80075) [1833], CCL3
(CCL3, P10147) [1547,
1833, 2443], CCL11
(CCL11, P51671) [175],
CCL2 (CCL2, P13500)
[1547], CCL14 (CCL14,
Q16627) [1547], CCL16
(CCL16, O15467)
CCL20 (CCL20, P78556)
[22, 86, 1730],
beta-defensin 4A
(DEFB4A DEFB4B,
O15263) [2373]
CCL21 (CCL21,
O00585) [2399], CCL19
(CCL19, Q99731)
[1640, 2398, 2399]
CCL1 (CCL1, P22362)
[441, 819, 948], CCL8
{Mouse}
CCL25 (CCL25,
O15444)
CCL27 (CCL27,
Q9Y4X3) [901], CCL28
(CCL28, Q9NRJ3)
Agonists vMIP-III R5-HIV-1 gp120 – – vMIP-I [441, 948] – –
Endogenous antagonists – CCL7 (CCL7, P80098)
(pKi 7.5) [1547]
– – – – –
Antagonists – vicriviroc (pKi 9.1)
[2043], ancriviroc (pKi
7.8–8.7) [1348, 1647,
2043]
– – – – –
Selective antagonists compound 8ic (pIC50
7.7) [2396]
E913 (pIC50 8.7) [1349],
aplaviroc (pKi 8.5)
[1348], maraviroc
(pIC50 8.1) [1547],
TAK-779 (pKi 7.5)
[1348], MRK-1 [1175] –
Rat
– – vMCC-I (pIC50 9.4)
[441]
– –
Selective allosteric
modulators
– – – – – vercirnon (Antagonist)
(pIC50 8.2) [2244]
–
Antibodies mogamulizumab
(Inhibition) [58, 1962]
– – – – – –
Labelled ligands [125I]CCL17 (human)
(Agonist),
[125I]CCL27 (human)
(Agonist)
[125I]CCL4 (human)
(Agonist) [1547],
[125I]CCL3 (human)
(Agonist),
[125I]CCL5 (human)
(Agonist),
[125I]CCL8 (human)
(Agonist)
[125I]CCL20 (human)
(Agonist) [742]
[125I]CCL19 (human)
(Agonist),
[125I]CCL21 (human)
(Agonist) [989]
[125I]CCL1 (human)
(Agonist) [948, 1819]
[125I]CCL25 (human)
(Agonist)
–
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Nomenclature CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CX3CR1
HGNC, UniProt CXCR1, P25024 CXCR2, P25025 CXCR3, P49682 CXCR4, P61073 CXCR5, P32302 CXCR6, O00574 CX3CR1, P49238
Endogenous agonists CXCL8 (CXCL8, P10145)
[157, 783, 1239, 2316,
2336], CXCL6 (CXCL6,
P80162) [2341]
CXCL1 (CXCL1, P09341)
[783, 1239, 2336],
CXCL8 (CXCL8, P10145)
[157, 783, 1239, 2316,
2336], CXCL7 (PPBP,
P02775) [20], CXCL3
(CXCL3, P19876) [20],
CXCL2 (CXCL2, P19875)
[20], CXCL5 (CXCL5,
P42830) [20], CXCL6
(CXCL6, P80162) [2341]
CXCL11 (CXCL11,
O14625) [845], CXCL10
(CXCL10, P02778) [845,
2285], CXCL9 (CXCL9,
Q07325) [845, 2285]
CXCL12α (CXCL12,
P48061) [861, 1311],
CXCL12β (CXCL12,
P48061) [861]
CXCL13 (CXCL13,
O43927) [111]
CXCL16 (CXCL16,
Q9H2A7) [2309]
CX3CL1 (CX3CL1,
P78423) [664]
Agonists vCXCL1 [1334],
HIV-1 matrix protein p17
[698]
vCXCL1 [1334],
HIV-1 matrix protein p17
[698]
– – – – –
Selective agonists – – – ALX40-4C (Partial
agonist) [2426],
X4-HIV-1 gp120
– – –
Endogenous antagonists – – CCL11 (CCL11, P51671)
(pKi 7.2) [2285], CCL7
(CCL7, P80098) (pKi
6.6) [2285]
– – – –
Antagonists – – – plerixafor (pKi 7) [2426] – – –
Selective antagonists – navarixin (pIC50 10.3)
[90, 535], danirixin
(pIC50 7.9) [1457],
SB 225002 (pIC50 7.7)
[2296], elubirixin (pIC50
7.7) [90], SX-517 (pIC50
7.2) [1347]
– T134 (pIC50 8.4)
[2096], mavorixafor
(pIC50 7.9) [1980],
HIV-Tat
– – –
Allosteric modulators reparixin (Negative)
(pIC50 9) [157]
reparixin (Negative)
(pIC50 6.4) [157]
– – – – –
Labelled ligands [125I]CXCL8 (human)
(Agonist) [783, 1802]
[125I]CXCL8 (human)
(Agonist) [783, 1802],
[125I]CXCL1 (human)
(Agonist),
[125I]CXCL5 (human)
(Agonist),
[125I]CXCL7 (human)
(Agonist)
[125I]CXCL10 (human)
(Agonist),
[125I]CXCL11 (human)
(Agonist)
[125I]CXCL12α (human)
(Agonist) [491, 861]
[125I]CXCL13 (mouse)
(Agonist) [245] – Mouse
[125I]CXCL16 (human)
(Agonist)
[125I]CX3CL1 (human)
(Agonist)
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Nomenclature XCR1 ACKR1 ACKR2 ACKR3 ACKR4 CCRL2
HGNC, UniProt XCR1, P46094 ACKR1, Q16570 ACKR2, O00590 ACKR3, P25106 ACKR4, Q9NPB9 CCRL2, O00421
Endogenous ligands – CXCL5 (CXCL5, P42830),
CXCL6 (CXCL6, P80162),
CXCL8 (CXCL8, P10145),
CXCL11 (CXCL11, O14625),
CCL2 (CCL2, P13500),
CCL5 (CCL5, P13501),
CCL7 (CCL7, P80098),
CCL11 (CCL11, P51671),
CCL14 (CCL14, Q16627),
CCL17 (CCL17, Q92583)
– – –
chemerin C-terminal peptide,
CCL19 (CCL19, Q99731)
[109]
Endogenous agonists XCL1 (XCL1, P47992) [619],
XCL2 (XCL2, Q9UBD3)
[619]
– CCL2 (CCL2, P13500),
CCL3 (CCL3, P10147),
CCL4 (CCL4, P13236),
CCL5 (CCL5, P13501),
CCL7 (CCL7, P80098),
CCL8 (CCL8, P80075),
CCL11 (CCL11, P51671),
CCL13 (CCL13, Q99616),
CCL14 (CCL14, Q16627),
CCL17 (CCL17, Q92583),
CCL22 (CCL22, O00626)
CXCL12α (CXCL12,
P48061) [741, 2015],
CXCL11 (CXCL11, O14625)
CCL19 (CCL19, Q99731)
[2276], CCL25 (CCL25,
O15444) [2276], CCL21
(CCL21, O00585) [2276]
–
Comments XCL1 cannot be iodinated,
but a secreted alkaline
phophatase (SEAP)-XCL1
fusion peptide can be used
as a probe at XCR1.
ACKR1 is used by
Plasmodium vivax and
Plasmodium knowlsei for
entering erythrocytes.
– Several lines of evidence
have suggested that CGRP
and adrenomedullin could
be ligands for ACKR3;
however, classical direct
binding to the receptor has
not yet been convincingly
demonstrated [2074].
– –
Comments: Speciﬁc chemokine receptors facilitate cell entry
by microbes, such as ACKR1 for Plasmodium vivax, and CCR5
and CXCR4 for HIV-1. Virally encoded chemokine receptors
are known (e.g. US28, a homologue of CCR1 from human cy-
tomegalovirus and ORF74, which encodes a homolog of CXCR2
in Herpesvirus saimiri and gamma-Herpesvirus-68), but their role
in viral life cycles is not established. Viruses can exploit or subvert
the chemokine system by producing chemokine antagonists and
scavengers. Three chemokine receptor antagonists have now been
approved by the FDA: 1) the CCR5 antagonist maraviroc (Pﬁzer)
for treatment of HIV/AIDS in patients with CCR5-using strains;
and 2) the CXCR4 antagonist plerixafor (Sanoﬁ) for hematopoi-
etic stem cell mobilization with G-CSF (CSF3, P09919) in patients
undergoing transplantation in the context of chemotherapy for
Hodgkins’ Disease andmultiple myeloma; and 3) the CCR4 block-
ing antibody Poteligeo (mogamulizumab-kpkc, Kyowa Kirin, Inc.)
for mycosis fungoides or Sezary syndrome.
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Further reading on Chemokine receptors
Bachelerie F et al. (2015) An atypical addition to the chemokine receptor nomenclature: IUPHAR
Review 15. Br. J. Pharmacol. 172: 3945-9 [PMID:25958743]
Koelink PJ et al. (2012) Targeting chemokine receptors in chronic inﬂammatory diseases: an exten-
sive review. Pharmacol. Ther. 133: 1-18 [PMID:21839114]
Murphy PM. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor
nomenclature. Pharmacol. Rev. 54: 227-9 [PMID:12037138]
Murphy PM et al. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine
receptors. Pharmacol. Rev. 52: 145-176 [PMID:10699158]
Scholten DJ et al. (2012) Pharmacological modulation of chemokine receptor function. Br. J. Phar-
macol. 165: 1617-43 [PMID:21699506]
Cholecystokinin receptors
G protein-coupled receptors → Cholecystokinin receptors
Overview: Cholecystokinin receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on CCK
receptors [1598) are activated by the endogenous pep-
tides cholecystokinin-8 (CCK-8 (CCK, P06307)), CCK-33 (CCK,
P06307), CCK-58 (CCK, P06307) and gastrin (gastrin-17 (GAST,
P01350)). There are only two distinct subtypes of CCK recep-
tors, CCK1 and CCK2 receptors [1139, 2263], with some alter-
natively spliced forms most often identiﬁed in neoplastic cells.
The CCK receptor subtypes are distinguished by their peptide se-
lectivity, with the CCK1 receptor requiring the carboxyl-terminal
heptapeptide-amide that includes a sulfated tyrosine for high
afﬁnity and potency, while the CCK2 receptor requires only the
carboxyl-terminal tetrapeptide shared by each CCK and gastrin
peptides. These receptors have characteristic and distinct distribu-
tions, with both present in both the central nervous system and
peripheral tissues.
Nomenclature CCK1 receptor CCK2 receptor
HGNC, UniProt CCKAR, P32238 CCKBR, P32239
Potency order of
endogenous ligands
CCK-8 (CCK, P06307), CCK-58 (CCK, P06307), CCK-39 (CCK), CCK-33 (CCK, P06307) 
gastrin-17 (GAST, P01350), desulfated cholecystokinin-8 > CCK-4 (CCK, P06307)
CCK-8 (CCK, P06307), CCK-39 (CCK), CCK-33 (CCK, P06307), CCK-58 (CCK, P06307) ≥
gastrin-17 (GAST, P01350), desulfated cholecystokinin-8, CCK-4 (CCK, P06307)
Endogenous agonists CCK-33 (CCK, P06307), CCK-39 (CCK), CCK-58 (CCK, P06307), CCK-8 (CCK, P06307) desulfated cholecystokinin-8 [1242], gastrin-17 (GAST, P01350) [931] – Mouse, CCK-4 (CCK,
P06307) [957], desulfated gastrin-14 (GAST, P01350), desulfated gastrin-17 (GAST,
P01350), desulfated gastrin-34 (GAST, P01350), desulfated gastrin-71 (GAST, P01350),
gastrin-14 (GAST, P01350), gastrin-34 (GAST, P01350), gastrin-71 (GAST, P01350)
Selective agonists A-71623 [74] – Rat, JMV180 [1068], GW-5823 [851] RB-400 [138] – Rat, PBC-264 [974] – Rat
Antagonists lintitript (pIC50 8.3) [733] –
Selective antagonists devazepide (pIC50 9.7) [931] – Rat, T-0632 (pIC50 9.6) [2103] – Rat, PD-140548 (pIC50 8.6)
[1977] – Rat, lorglumide (pIC50 6.7–8.2) [931, 963] – Rat
YF-476 (pIC50 9.7) [218, 2094], GV150013 (pIC50 9.4) [2180], L-740093 (pIC50 9.2)
[1590], YM-022 (pIC50 9.2) [1590], JNJ-26070109 (pIC50 8.5) [1510], L-365260 (pIC50 8.4)
[1242], RP73870 (pIC50 8) [1291] – Rat, LY262691 (pIC50 7.5) [1773] – Rat
Labelled ligands [3H]devazepide (Antagonist) (pKd 9.7) [338], [
125I]DTyr-Gly-[(Nle28,31)CCK-26-33
(Agonist) [1731]
[3H]PD140376 (Antagonist) (pKi 9.7–10) [935] – Guinea pig, [
125I]PD142308 (Antagonist)
(pKd 9.6) [905] – Guinea pig, [
125I]DTyr-Gly-[(Nle28,31)CCK-26-33 (Agonist) [1731],
[125I]gastrin (Agonist), [3H]gastrin (Agonist), [3H]L365260 (Antagonist) (pKd 8.2–8.5)
[1590], [125I]-BDZ2 (Antagonist) (pKi 8.4) [27]
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Comments: While a cancer-speciﬁc CCK receptor has been pos-
tulated to exist, which also might be responsive to incompletely
processed forms of CCK (Gly-extended forms), this has never been
isolated. An alternatively spliced form of the CCK2 receptor in
which intron 4 is retained, adding 69 amino acids to the intracel-
lular loop 3 (ICL3) region, has been described to be present par-
ticularly in certain neoplasms where mRNA mis-splicing has been
commonly observed [1995], but it is not clear that this receptor
splice form plays a special role in carcinogenesis. Another alter-
native splicing event for the CCK2 receptor was reported [2012],
with alternative donor sites in exon 4 resulting in long (452 amino
acids) and short (447 amino acids) forms of the receptor differing
by ﬁve residues in ICL3, however, no clear functional differences
have been observed.
Further reading on Cholecystokinin receptors
Ballaz S. (2017) The unappreciated roles of the cholecystokinin receptor CCK(1) in brain functioning.
Rev Neurosci 28: 573-585 [PMID:28343167]
Cawston EE et al. (2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin
receptor. Br. J. Pharmacol. 159: 1009-21 [PMID:19922535]
Dockray GJ. (2009) Cholecystokinin and gut-brain signalling. Regul. Pept. 155: 6-10
[PMID:19345244]
Dufresne M et al. (2006) Cholecystokinin and gastrin receptors. Physiol. Rev. 86: 805-47
[PMID:16816139]
Class Frizzled GPCRs
G protein-coupled receptors → Class Frizzled GPCRs
Overview: Receptors of the Class Frizzled (FZD, nomencla-
ture as agreed by the NC-IUPHAR subcommittee on the
Class Frizzled GPCRs [1902]), are GPCRs originally identiﬁed
in Drosophila [332], which are highly conserved across species.
While SMO shows structural resemblance to the 10 FZDs, it is
functionally separated as it mediates effects in the Hedgehog sig-
naling pathway [1902]. FZDs are activated by WNTs, which are
cysteine-rich lipoglycoproteins with fundamental functions in on-
togeny and tissue homeostasis. FZD signalling was initially di-
vided into two pathways, being either dependent on the accumu-
lation of the transcription regulator β-catenin (CTNNB1, P35222)
or being β-catenin-independent (often referred to as canonical vs.
non-canonical WNT/FZD signalling, respectively). WNT stimula-
tion of FZDs can, in cooperation with the low density lipoprotein
receptors LRP5 (O75197) and LRP6 (O75581), lead to the inhibi-
tion of a constitutively active destruction complex, which results
in the accumulation of β-catenin and subsequently its translo-
cation to the nucleus. β-Catenin, in turn, modiﬁes gene tran-
scription by interacting with TCF/LEF transcription factors. β-
Catenin-independent FZD signalling is far more complex with re-
gard to the diversity of the activated pathways. WNT/FZD sig-
nalling can lead to the activation of heterotrimeric G proteins
[496, 1694, 1903], the elevation of intracellular calcium [1989],
activation of cGMP-speciﬁc PDE6 [21] and elevation of cAMP as
well as RAC-1, JNK, Rho and Rho kinase signalling [802]. Novel
resonance energy transfer-based tools have allowed the study of
the GPCR-like nature of FZDs in greater detail. Upon ligand stim-
ulation, FZDs undergo conformational changes and signal via
heterotrimeric G proteins [2332, 2333]. Furthermore, the phos-
phoprotein Dishevelled constitutes a key player in WNT/FZD sig-
nalling. Importantly, FZDs exist in at least two distinct confor-
mational states that regulate the pathway selection [2333]. As
with other GPCRs, members of the Frizzled family are functionally
dependent on the arrestin scaffolding protein for internalization
[354], as well as for β-catenin-dependent [262] and -independent
[263, 1084] signalling. The pattern of cell signalling is compli-
cated by the presence of additional ligands, which can enhance
or inhibit FZD signalling (secreted Frizzled-related proteins (sFRP),
Wnt-inhibitory factor (WIF1, Q9Y5W5) (WIF), sclerostin (SOST,
Q9BQB4) or Dickkopf (DKK)), as well as modulatory (co)-receptors
with Ryk, ROR1, ROR2 and Kremen, which may also function as
independent signalling proteins.
Searchable database: http://www.guidetopharmacology.org/index.jsp Class Frizzled GPCRs S64
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
Nomenclature FZD1 FZD2 FZD3 FZD4 FZD5
HGNC, UniProt FZD1, Q9UP38 FZD2, Q14332 FZD3, Q9NPG1 FZD4, Q9ULV1 FZD5, Q13467
Allosteric modulators – – – FzM1.8 (Negative) (pIC50 5.5–7.8)
[679], FzM1.8 (Positive) (pEC50 6.4)
[1799], FzM1 (Negative) (pIC50 6.2)
[679, 1799]
–
Antibodies vantictumab (Antagonist) (pIC50 ∼9.1)
[771]
vantictumab (Antagonist) (pIC50 ∼9)
[771]
– – vantictumab (Antagonist) (pIC50 ∼9)
[771]
Comments – – – – IgG-2919 and IgG-2921 are FZD5
antibodies that have exhibited
antitumour activities in vitro and in vivo
(inhibiting the growth of RNF43-mutant
pancreatic ductal adenocarcinoma
cells/xenograft tumours), by blocking
autocrine Wnt-β-catenin signalling in
these mutant, FZD5-dependent cells
[2029].
Nomenclature FZD6 FZD7 FZD8 FZD9 FZD10
HGNC, UniProt FZD6, O60353 FZD7, O75084 FZD8, Q9H461 FZD9, O00144 FZD10, Q9ULW2
Selective antagonists – Fz7-21 (pIC50 7) [1589] – – –
Antibodies – vantictumab (Antagonist) (pIC50 ∼9) [771] vantictumab (Antagonist) (pIC50 ∼8) [771] – –
Comments – – FZD8-Fc/OMP-54F28 is a FZD8 antagonist [477]. – Radio-labelled murine monoclonal antibody MAb
92-13 has been used to demonstrate the
therapeutic potential of targeting FZD10-positive
tumours [639].
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Nomenclature SMO
HGNC, UniProt SMO, Q99835
Agonists SMO agonist (SAG) [350] – Mouse, purmorphamine [1978]
Antagonists MRT-92 (pKd 9.5) [890], SANT-1 (pKi 7.7) [350] – Mouse, cyclopamine-KAAD (pIC50 7.7) [2080] – Mouse, cyclopamine (pIC50 ∼7) [2162] – Mouse
Selective antagonists vismodegib (pKi 7.8) [2252]
Allosteric modulators GSA-10 (Positive) (pEC50 5.9) [726]
Comments SANT-3 and SANT-4 are SMO antagonists [350].
Comments: There is limited knowledge about WNT/FZD speci-
ﬁcity and which molecular entities determine the signalling
outcome of a speciﬁc WNT/FZD pair. Understanding of theFZD
and SMO coupling to G proteins is incomplete, but progress have
been made [72, 496, 1083, 1374, 1808, 1945, 2229, 2332]. There
is also a scarcity of information on basic pharmacological char-
acteristics of FZDs, such as binding constants, ligand speciﬁcity
or concentration-response relationships [1081]. Development of
pharmacological tools for SMO has been faciliated by successful
crystalization of several SMO structures [278, 924, 2250, 2251,
2279, 2427]. The recently solved FZD4 in apo state has provided
ﬁrst insight into FZD transmembranous organization [2380].
Ligands associated with FZD signalling
WNTs: Wnt-1 (WNT1, P04628), Wnt-2 (WNT2, P09544) (also
known as Int-1-related protein), Wnt-2b (WNT2B, Q93097)
(also known as WNT-13), Wnt-3 (WNT3, P56703) , Wnt-3a
(WNT3A, P56704), Wnt-4 (WNT4, P56705), Wnt-5a (WNT5A,
P41221) (pEC50 7.7-8.9 [2332]), Wnt-5b (WNT5B, Q9H1J7),
Wnt-6 (WNT6, Q9Y6F9), Wnt-7a (WNT7A, O00755), Wnt-7b
(WNT7B, P56706), Wnt-8a (WNT8A, Q9H1J5), Wnt-8b (WNT8B,
Q93098), Wnt-9a (WNT9A, O14904) (also known as WNT-14),
Wnt-9b (WNT9B, O14905) (also known as WNT-15 or WNT-
14b), Wnt-10a (WNT10A, Q9GZT5), Wnt-10b (WNT10B, O00744)
(also known as WNT-12), Wnt-11 (WNT11, O96014) and Wnt-16
(WNT16, Q9UBV4).
Extracellular proteins that interact with FZDs: norrin
(NDP, Q00604), R-spondin-4 (RSPO4, Q2I0M5), sFRP-1 (SFRP1,
Q8N474), sFRP-2 (SFRP2, Q96HF1), sFRP-3 (FRZB, Q92765), sFRP-4
(SFRP4, Q6FHJ7), sFRP-5 (SFRP5, Q6FHJ7).
Extracellular proteins that interact with WNTs or
LRPs: Dickkopf 1 (DKK1, O94907), WIF1 (Q9Y5W5), sclerostin
(SOST, Q9BQB4), kremen 1 (KREMEN1, Q96MU8) and kremen 2
(KREMEN2, Q8NCW0)
Small exogenous ligands: Foxy-5 [2075], Box-5 [988], UM206
[1189], and XWnt8 (P28026) also known as mini-Wnt8.
Ligands associated with SMO signalling: cholesterol, oxys-
terols [278, 1325, 1761].
Further reading on Class Frizzled GPCRs
Angers S et al. (2009) Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 10:
468-77 [PMID:19536106]
Schulte G. (2015) Frizzleds andWNT/β-catenin signaling–The black box of ligand-receptor selectivity,
complex stoichiometry and activation kinetics. Eur. J. Pharmacol. 763: 191-5 [PMID:26003275]
Schulte G et al. (2018) Frizzleds as GPCRs - More Conventional ThanWe Thought! Trends Pharmacol.
Sci. 39: 828-842 [PMID:30049420]
van Amerongen R. (2012) Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol 4:
[PMID:22935904]
Wang Y et al. (2016) Frizzled Receptors in Development and Disease. Curr. Top. Dev. Biol. 117:
113-39 [PMID:26969975]
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Complement peptide receptors
G protein-coupled receptors → Complement peptide receptors
Overview: Complement peptide receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Complement peptide receptors [1114]) are activated by the endogenous 75
amino-acid anaphylatoxin polypeptides C3a (C3, P01024) and C5a (C5, P01031), generated upon stimulation of the complement cascade. C3a and C5a exert their functions through binding to their
receptors (C3aR and C5aR), causing cell activation and triggering cellular degranulation that contributes to the local inﬂammation.
Nomenclature C3a receptor C5a1 receptor C5a2 receptor
HGNC, UniProt C3AR1, Q16581 C5AR1, P21730 C5AR2, Q9P296
Potency order of endogenous ligands C3a (C3, P01024) > C5a (C5, P01031) [45] C5a (C5, P01031), C5a des-Arg (C5) > C3a (C3,
P01024) [45]
–
Endogenous agonists – ribosomal protein S19 (RPS19, P39019) [2363] –
Agonists compound 17 [1786], compound 21 [1785], casoxin C
[2082, 2402], albutensin A [2086, 2402], oryzatensin
[1003, 2083, 2402]
NDT9513727 (Inverse agonist) [244],
N-methyl-Phe-Lys-Pro-D-Cha-Cha-D-Arg-CO2H [1054,
1136], lactomedin 1 [2276, 2402]
–
Selective agonists – – P59 (Biased agonist) [434], P32 (Biased agonist) [434]
Antagonists SB290157 (pIC50 7.6) [44], compound 4 (pIC50 5.9)
[1785]
avacopan (pIC50 9.7) [134], W54011 (pKi 8.7) [2056],
DF2593A (pIC50 8.3) [1499],
AcPhe-Orn-Pro-D-Cha-Trp-Arg (pIC50 7.9) [2323],
N-methyl-Phe-Lys-Pro-D-Cha-Trp-D-Arg-CO2H (pIC50
7.2) [1136]
–
Labelled ligands [125I]C3a (human) (Agonist) [342] [125I]C5a (human) (Agonist) [929] [125I]C5a (human) (Agonist)
Comments C3a-C3aR signalling plays a crucial role in inhibiting
neural progenitor cell proliferation during
neurodevelopment, playing a critical role in the normal
development of the mammalian brain [426].
– –
Comments: SB290157 has also been reported to have agonist
properties at the C3a receptor [1396]. The putative chemoattrac-
tant receptor termed C5a2 (also known as GPR77, C5L2) binds
[125I]C5a with no clear signalling function, but has a putative role
opposing inﬂammatory responses [291, 655, 673]. Binding to this
site may be displaced with the rank order C5a des-Arg (C5)> C5a
(C5, P01031) [291, 1631] while there is controversy over the abil-
ity of C3a (C3, P01024) and C3a des Arg (C3, P01024) to compete
[902, 1029, 1030, 1631]. C5a2 appears to lack G protein signalling
and has been termed a decoy receptor [1910]. However, C5a2 does
recruit arrestin after ligand binding, which might provide a signal-
ing pathway for this receptor [103, 2192], and forms heteromers
with C5a1. C5a, but not C5a-des Arg, induces upregulation of het-
eromer formation between complement C5a receptors C5a1 and
C5a2 [433]. There are also reports of pro-inﬂammatory activity of
C5a2, mediated byHMGB1, but the signaling pathway that under-
lies this is currently unclear (reviewed in [1271]). More recently,
work in T cells has shown that C5a1 and C5a2 act in opposition
to each other and that altering the equilibrium between the two
receptors, by differential expression or production of C5a-des Arg
(which favours C5a2), can affect the ﬁnal cellular response [61].
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Further reading on Complement peptide receptors
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Corticotropin-releasing factor receptors
G protein-coupled receptors → Corticotropin-releasing factor receptors
Overview: Corticotropin-releasing factor (CRF, nomen-
clature as agreed by the NC-IUPHAR subcommit-
tee on Corticotropin-releasing Factor Receptors
[824]) receptors are activated by the endogenous peptides
corticotrophin-releasing hormone (CRH, P06850), a 41 amino-
acid peptide, urocortin 1 (UCN, P55089), 40 amino-acids,
urocortin 2 (UCN2, Q96RP3), 38 amino-acids and urocortin 3
(UCN3, Q969E3), 38 amino-acids. CRF1 and CRF2 receptors are
activated non-selectively by CRH and UCN. CRF2 receptors are
selectively activated by UCN2 and UCN3. Binding to CRF re-
ceptors can be conducted using radioligands [125I]Tyr0-CRF or
[125I]Tyr0-sauvagine with Kd values of 0.1-0.4 nM. CRF1 and
CRF2 receptors are non-selectively antagonized by α-helical CRF,
D-Phe-CRF-(12-41) and astressin. CRF1 receptors are selectively
antagonized by small molecules NBI27914, R121919, antalarmin,
CP 154,526, CP 376,395. CRF2 receptors are selectively antago-
nized by antisauvagine and astressin 2B.
Nomenclature CRF1 receptor CRF2 receptor
HGNC, UniProt CRHR1, P34998 CRHR2, Q13324
Endogenous agonists urocortin 1 (UCN, P55089) [451, 453, 508], corticotrophin-releasing hormone (CRH,
P06850) [353, 450, 453, 508, 1648, 2212]
urocortin 2 (UCN2, Q96RP3) [451], urocortin 3 (UCN3, Q969E3) [451]
Antagonists SSR125543A (pKi 8.7) [766], astressin (pKi 8.7) [1812] astressin (pIC50 9.2) [1810]
Selective antagonists CP 154,526 (pIC50 9.3–10.4) [1328] – Rat, DMP696 (pKi 8.3–9) [835], NBI27914 (pKi
8.3–9) [346], R121919 (pKi 8.3–9) [2442], antalarmin (pKi 8.3–9) [2278], CP 376,395
(pIC50 8.3) [355] – Rat, CRA1000 (pIC50 6.4–7.1) [330]
antisauvagine (pKd 8.8–9.6) [453], K41498 (pKi 9.2) [1211], astressin 2B (pIC50 8.9)
[1810], K31440 (pKi 8.7–8.8) [1846]
Comments: A CRF binding protein has been identiﬁed (CRHBP, P24387) to which both corticotrophin-releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089) bind with high afﬁnities, which
has been suggested to bind and inactivate circulating corticotrophin-releasing hormone (CRH, P06850) [1686].
Further reading on Corticotropin-releasing factor receptors
Deussing JM et al. (2018) The Corticotropin-Releasing Factor Family: Physiology of the Stress Re-
sponse. Physiol. Rev. 98: 2225-2286 [PMID:30109816]
Grammatopoulos DK. (2012) Insights into mechanisms of corticotropin-releasing hormone receptor
signal transduction. Br. J. Pharmacol. 166: 85-97 [PMID:21883143]
Hauger RL et al. (2003) International Union of Pharmacology. XXXVI. Current status of the nomen-
clature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 55: 21-26
[PMID:12615952]
Liapakis G et al. (2011) Members of CRF family and their receptors: from past to future. Curr. Med.
Chem. 18: 2583-600 [PMID:21568890]
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Slater PG et al. (2016) Corticotropin-Releasing Factor Receptors and Their Interacting Proteins: Func-
tional Consequences. Mol. Pharmacol. 90: 627-632 [PMID:27612874]
Zelenay V et al. (2017) Structures of the First Extracellular Domain of CRF Receptors. Curr Mol
Pharmacol 10: 318-324 [PMID:28103782]
Dopamine receptors
G protein-coupled receptors → Dopamine receptors
Overview: Dopamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Dopamine Receptors [1906]) are commonly divided into D1-like (D1 and D5) and D2-like
(D2, D3 and D4) families, where the endogenous agonist is dopamine.
Nomenclature D1 receptor D2 receptor
HGNC, UniProt DRD1, P21728 DRD2, P14416
Sub/family-selective labelled ligands [125I]SCH23982 (Antagonist) (pKd 9.5) [478], [
3H]SCH-23390 (Antagonist) (pKd
9.5) [2435]
[3H]spiperone (Antagonist) (pKd 10.2) [266, 888, 2433] – Rat
Endogenous agonists dopamine [2060, 2132] dopamine [272, 628, 1876]
Agonists fenoldopam [2132] rotigotine [497], cabergoline (Partial agonist) [1451], aripiprazole (Partial agonist)
[2410], bromocriptine [628, 1451, 1876], MLS1547 (Biased agonist) [627],
ropinirole [843], apomorphine (Partial agonist) [272, 628, 1451, 1876, 2006],
pramipexole [1446, 1876], benzquinamide [744]
Sub/family-selective agonists A68930 [1569], SKF-38393 (Partial agonist) [2060, 2132] quinpirole [272, 1446, 1665, 2006, 2008, 2196]
Selective agonists SKF-83959 (Biased agonist) [413], A77636 [1844], SKF-81297 [50] – Rat sumanirole [1415]
Antagonists ﬂupentixol (pKi 7–8.4) [2060, 2132] blonanserin (pKi 9.9) [1611], pipotiazine (pKi 9.7) [2007], perphenazine (pKi
8.9–9.6) [1156, 1920], risperidone (pKi 9.4) [70], perospirone (pKi 9.2) [1919],
triﬂuoperazine (pKi 8.9–9) [1156, 1920], quetiapine (pKi 7.2) [70]
Sub/family-selective antagonists SCH-23390 (pKi 7.4–9.5) [2060, 2132], SKF-83566 (pKi 9.5) [2060], ecopipam (pKi
8.3) [2133]
haloperidol (pKi 7.4–8.8) [628, 1341, 1446, 2006, 2133]
Selective antagonists – L-741,626 (pKi 7.9–8.5) [755, 1171], domperidone (pKi 7.9–8.4) [628, 2006],
raclopride (pKi 8) [1453], ML321 (pKi 7) [2347, 2348]
Labelled ligands – [3H]raclopride (Antagonist) (pKd 8.9) [1184] – Rat
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Nomenclature D3 receptor D4 receptor D5 receptor
HGNC, UniProt DRD3, P35462 DRD4, P21917 DRD5, P21918
Sub/family-selective labelled ligands – [3H]spiperone (Antagonist) (pKd 9.5) [866, 2196] [
3H]SCH-23390 (Antagonist) (pKd 9.2) [1797]
Endogenous agonists dopamine [272, 628, 1876, 2008] dopamine [2196] dopamine [2060]
Agonists pramipexole [1446, 1876], bromocriptine (Partial
agonist) [628, 1451, 1876], ropinirole [843],
apomorphine (Partial agonist) [272, 628, 1451, 1876,
2006]
apomorphine (Partial agonist) [1451] –
Sub/family-selective agonists quinpirole [272, 1446, 1453, 1665, 1876, 2006, 2008,
2196]
quinpirole [1451, 1665, 2196] A68930 [1569]
Selective agonists PD 128907 [1745, 1876] PD168,077 (Partial agonist) [1141] – Rat, A412997
[1491] – Rat, A412997 [1491]
–
Antagonists perospirone (pKi 9.6) [2006], sertindole (pKi 8–8.8)
[70, 1901, 1920], prochlorperazine (pKi 8.4) [79],
(-)-sulpiride (pKi 6.7–7.7) [628, 2006, 2102], loxapine
(pKi 7.7) [1920], domperidone (pKi 7.1–7.6) [628,
2006], promazine (pKi 6.8) [273]
perospirone (pKi 10.1) [1921], sertindole (pKi 7.8–9.1)
[273, 1920, 1920, 1921], sonepiprazole (pKi 8.9)
[1892], loxapine (pKi 8.1) [1920]
–
Sub/family-selective antagonists haloperidol (pKi 7.5–8.6) [628, 1939, 2006, 2133] haloperidol (pKi 8.7–8.8) [1191, 1939, 2133] SCH-23390 (pKi 7.5–9.5) [2060], SKF-83566 (pKi 9.4)
[2060], ecopipam (pKi 8.3) [2060]
Selective antagonists S33084 (pKi 9.6) [1450], nafadotride (pKi 9.5) [1877],
PG01037 (pKi 9.2) [756], NGB 2904 (pKi 8.8) [2343],
SB 277011-A (pKi 8) [1783], (+)-S-14297 (pKi 6.9–7.9)
[1448, 1453]
L745870 (pKi 9.4) [1171], A-381393 (pKi 8.8) [1543],
L741742 (pKi 8.5) [1831], ML398 (pKi 7.4) [154]
–
Selective allosteric modulators SB269652 (Negative) (pKi ∼9) [642] – –
Labelled ligands [3H]spiperone (Antagonist) (pKd 9.9) [888, 2433] – Rat,
[3H]7-OH-DPAT (Agonist) [1798], [3H]PD128907
(Agonist) [29]
[125I]L750667 (Antagonist) (pKd 9.8) [1665],
[3H]NGD941 (Antagonist) (pKd 8.3) [1736]
[125I]SCH23982 (Antagonist) (pKd 9.1)
Comments: The selectivity of many of these agents is less than
two orders of magnitude. [3H]raclopride exhibits similar high
afﬁnity for D2 and D3 receptors (low afﬁnity for D4), but has been
used to label D2 receptors in the presence of a D3-selective antago-
nist. [3H]7-OH-DPAT has similar afﬁnity for D2 and D3 receptors,
but labels only D3 receptors in the absence of divalent cations.
The pharmacological proﬁle of the D5 receptor is similar to, yet
distinct from, that of the D1 receptor. The splice variants of the
D2 receptor are commonly termed D2S and D2L (short and long).
The DRD4 gene encoding the D4 receptor is highly polymorphic
in humans, with allelic variations of the protein from amino acid
387 to 515.
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Further reading on Dopamine receptors
Beaulieu JM et al. (2015) Dopamine receptors - IUPHAR Review 13. Br. J. Pharmacol. 172: 1-23
[PMID:25671228]
Beaulieu JM et al. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Phar-
macol. Rev. 63: 182-217 [PMID:21303898]
Cumming P. (2011) Absolute abundances and afﬁnity states of dopamine receptors in mammalian
brain: A review. Synapse 65: 892-909 [PMID:21308799]
Maggio R et al. (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and ther-
apeutic signiﬁcance. Curr Opin Pharmacol 10: 100-7 [PMID:19896900]
Ptácek R et al. (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disor-
ders. Med. Sci. Monit. 17: RA215-20 [PMID:21873960]
Schwartz J-C et al.. (1998) Dopamine Receptors. In The IUPHAR Compendium of Receptor Characteri-
zation and Classiﬁcation Edited by Girdlestone D: IUPHAR Media: 141-151
Undieh AS. (2010) Pharmacology of signaling induced by dopamine D(1)-like receptor activation.
Pharmacol. Ther. 128: 37-60 [PMID:20547182]
Endothelin receptors
G protein-coupled receptors → Endothelin receptors
Overview: Endothelin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Endothelin Receptors [454]) are activated by the endogenous 21 amino-acid peptides
endothelins 1-3 (endothelin-1 (EDN1, P05305), endothelin-2 (EDN2, P20800) and endothelin-3 (EDN3, P14138)).
Nomenclature ETA receptor ETB receptor
HGNC, UniProt EDNRA, P25101 EDNRB, P24530
Potency order of endogenous ligands endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800) > endothelin-3
(EDN3, P14138) [1353]
endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800), endothelin-3 (EDN3,
P14138) [1854]
Selective agonists – sarafotoxin S6c [1163, 1838], BQ 3020 [1793], [Ala1,3,11,15]ET-1 [1471], IRL 1620
[2268]
Antagonists SB209670 (pKB 9.4) [553] – Rat, TAK 044 (pA2 8.4) [2271] – Rat, bosentan (pA2
7.2) [403] – Rat
SB209670 (pKB 9.4) [553] – Rat, TAK 044 (pA2 8.4) [2271] – Rat, bosentan (pKi
7.1) [1527]
Selective antagonists macitentan (pIC50 9.3) [192], sitaxsentan (pA2 8) [2334], FR139317 (Inverse
agonist) (pIC50 7.3–7.9) [1353], BQ123 (pA2 6.9–7.4) [1353], ambrisentan (pA2
7.1) [193]
K-8794 (pIC50 8.2) [1951], A192621 (pKd 8.1) [2226], BQ788 (pKd 7.9–8) [1838],
IRL 2500 (pKd 7.2) [1838], Ro 46-8443 (pIC50 7.2) [232]
Labelled ligands [125I]PD164333 (Antagonist) (pKd 9.6–9.8) [457], [
3H]S0139 (Antagonist) (pKd
9.2), [125I]PD151242 (Antagonist) (pKd 9–9.1) [458], [
3H]BQ123 (Antagonist) (pKd
8.5) [944]
[125I]IRL1620 (Agonist) [1544], [125I]BQ3020 (Agonist) [810, 1471, 1693],
[125I][Ala1,3,11,15]ET-1 (Agonist) [1471]
Comments: Splice variants of the ETA receptor have been identiﬁed in rat pituitary cells; one of these, ETAR-C13, appeared to show loss of function with comparable plasma membrane expression to
wild type receptor [822]. Subtypes of the ETB receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists [1465]. Crystal structures of the ETB
receptor bound to the antagonist bosentan and ETB selective analogue K-8794 [1951] and selective ETB agonists endothelin-3 (EDN3, P14138) and IRL 1620 [1950] have been reported.
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Further reading on Endothelin receptors
Clozel M et al. (2013) Endothelin receptor antagonists. Handb Exp Pharmacol 218: 199-227
[PMID:24092342]
Davenport AP. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor
nomenclature. Pharmacol. Rev. 54: 219-26 [PMID:12037137]
Davenport AP et al. (2016) Endothelin. Pharmacol. Rev. 68: 357-418 [PMID:26956245]
Davenport AP et al. (2018) New drugs and emerging therapeutic targets in the endothelin sig-
naling pathway and prospects for personalized precision medicine. Physiol Res 67: S37-S54
[PMID:29947527]
Maguire JJ et al. (2014) Endothelin@25 - new agonists, antagonists, inhibitors and emerging research
frontiers: IUPHAR Review 12. Br. J. Pharmacol. 171: 5555-72 [PMID:25131455]
G protein-coupled estrogen receptor
G protein-coupled receptors → G protein-coupled estrogen receptor
Overview: The G protein-coupled estrogen receptor (GPER,
nomenclature as agreed by the NC-IUPHAR Subcom-
mittee on the G protein-coupled estrogen receptor
[1740]) was identiﬁed following observations of estrogen-evoked
cyclic AMP signalling in breast cancer cells [71], which mirrored
the differential expression of an orphan 7-transmembrane recep-
tor GPR30 [304]. There are observations of both cell-surface and
intracellular expression of the GPER receptor [1789, 2123]. Selec-
tive agonist/ antagonists for GPER have been characterized [1740].
Antagonists of the nuclear estrogen receptor, such as fulvestrant
[596], tamoxifen [1789, 2123] and raloxifene [1700], as well as
the ﬂavonoid ’phytoestrogens’ genistein and quercetin [1352], are
agonists of GPER. A complete review of GPER pharmacology has
been recently published [1740]. The roles of GPER in physiolog-
ical systems throughout the body (cardiovascular, metabolic, en-
docrine, immune, reproductive) and in cancer have also been re-
viewed [595, 1203, 1437, 1740, 1741].
Nomenclature GPER
HGNC, UniProt GPER1, Q99527
Agonists fulvestrant [2123], raloxifene [1700], 4-hydroxytamoxifen [1789]
Selective agonists G-1 [195]
Selective antagonists G36 (pIC50 6.8–6.9) [485], G15 (pIC50 6.7) [484]
Labelled ligands [3H]17β-estradiol (Agonist) [2123]
Comments: Antagonists at the nuclear estrogen receptor, such as fulvestrant, tamoxifen [596] and raloxifene [1700], as well as the ﬂavonoid ‘phytoestrogens’ genistein and quercetin [1352], are agonists
at GPER receptors. A complete review of GPER pharmacology has been recently published [1740].
Further reading on G protein-coupled estrogen receptor
Barton M et al. (2018) Twenty years of the G protein-coupled estrogen receptor GPER: Historical and
personal perspectives. J. Steroid Biochem. Mol. Biol. 176: 4-15 [PMID:28347854]
Gaudet HM et al. (2015) The G-protein coupled estrogen receptor, GPER: The inside and inside-out
story. Mol. Cell. Endocrinol. 418 Pt 3: 207-19 [PMID:26190834]
Prossnitz ER et al. (2015) International Union of Basic and Clinical Pharmacology. XCVII. G Protein-
Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev. 67: 505-40
[PMID:26023144]
Prossnitz ER et al. (2015)What have we learned about GPER function in physiology and disease from
knockout mice? J. Steroid Biochem. Mol. Biol. 153: 114-26 [PMID:26189910]
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Formylpeptide receptors
G protein-coupled receptors → Formylpeptide receptors
Overview: The formylpeptide receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on the formylpeptide receptor family [2387]) respond to exogenous ligands such as
the bacterial product fMet-Leu-Phe (fMLP) and endogenous ligands such as annexin I (ANXA1, P04083) , cathepsin G (CTSG, P08311), amyloid β42, serum amyloid A and spinorphin, derived from
β-haemoglobin (HBB, P68871).
Nomenclature FPR1 FPR2/ALX FPR3
HGNC, UniProt FPR1, P21462 FPR2, P25090 FPR3, P25089
Potency order of endogenous ligands fMet-Leu-Phe > cathepsin G (CTSG, P08311) > annexin I (ANXA1,
P04083) [1224, 2058]
LXA4 = aspirin triggered lipoxin A4 = ATLa2 = resolvin D1 > LTC4 =
LTD4  15-deoxy-LXA4  fMet-Leu-Phe [401, 600, 602, 750, 2086]
–
Endogenous agonists – LXA4 [1153], resolvin D1 [1153], aspirin-triggered resolvin D1
[1152], aspirin triggered lipoxin A4
F2L (HEBP1, Q9NRV9) [1447]
Agonists fMet-Leu-Phe [630, 1963] – –
Selective agonists – ATLa2 [765] –
Endogenous antagonists spinorphin (pIC50 4.3) [1275, 1526] – –
Antagonists t-Boc-FLFLF (pKi 6–6.5) [2288] – –
Selective antagonists cyclosporin H (pKi 6.1–7.1) [2288, 2370] WRWWWW (pIC50 6.6) [92], t-Boc-FLFLF (pIC50 4.3–6) [629, 2030,
2245]
–
Labelled ligands [3H]fMet-Leu-Phe (Agonist) [1137] [3H]LXA4 (Agonist) [600, 601] –
Comments A FITC-conjugated fMLP analogue has been used for binding to the
mouse recombinant receptor [833].
– –
Comments: Note that the data for FPR2/ALX are also reproduced on the leukotriene receptor page.
Further reading on Formylpeptide receptors
Dorward DA et al. (2015) The Role of Formylated Peptides and Formyl Peptide Receptor 1 in
Governing Neutrophil Function during Acute Inﬂammation. Am. J. Pathol. 185: 1172-1184
[PMID:25791526]
Dufton N et al. (2010) Therapeutic anti-inﬂammatory potential of formyl-peptide receptor agonists.
Pharmacol. Ther. 127: 175-88 [PMID:20546777]
Liu M et al. (2012) G protein-coupled receptor FPR1 as a pharmacologic target in inﬂammation and
human glioblastoma. Int. Immunopharmacol. 14: 283-8 [PMID:22863814]
Rabiet MJ et al. (2011) N-formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX
receptor with regard to the major processes governing chemoattractant receptor regulation, ex-
pression at the cell surface, and phosphorylation. J. Biol. Chem. 286: 26718-31 [PMID:21543323]
Yazid S et al. (2012) Anti-inﬂammatory drugs, eicosanoids and the annexin A1/FPR2 anti-
inﬂammatory system. Prostaglandins Other Lipid Mediat. 98: 94-100 [PMID:22123264]
Ye RD et al. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature
for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-61 [PMID:19498085]
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Free fatty acid receptors
G protein-coupled receptors → Free fatty acid receptors
Overview: Free fatty acid receptors (FFA, nomenclature as
agreed by the NC-IUPHAR Subcommittee on free fatty
acid receptors [455, 2039]) are activated by free fatty acids.
Long-chain saturated and unsaturated fatty acids (including C14.0
(myristic acid), C16:0 (palmitic acid), C18:1 (oleic acid), C18:2
(linoleic acid), C18:3, (α-linolenic acid), C20:4 (arachidonic acid),
C20:5,n-3 (EPA) and C22:6,n-3 (docosahexaenoic acid)) activate
FFA1 [239, 958, 1144] and FFA4 receptors [876, 938, 1617], while
short chain fatty acids (C2 (acetic acid), C3 (propanoic acid), C4
(butyric acid) and C5 (pentanoic acid)) activate FFA2 [249, 1223,
1591] and FFA3 [249, 1223] receptors. The crystal structure for
agonist bound FFA1 has been described [2023].
Nomenclature FFA1 receptor FFA2 receptor
HGNC, UniProt FFAR1, O14842 FFAR2, O15552
Endogenous agonists docosahexaenoic acid [239, 958], α-linolenic acid [239, 958, 1144], oleic acid [239, 958,
1144], myristic acid [239, 958, 1144]
propanoic acid [249, 1223, 1591, 1894], acetic acid [249, 1223, 1591, 1894], butyric acid
[249, 1223, 1591, 1894], trans-2-methylcrotonic acid [1894],
1-methylcyclopropanecarboxylic acid [1894]
Selective agonists AMG-837 [1286], compound 4 [381], TUG-770 [380], TUG-905 [379], GW9508 (Partial
agonist) [238], fasiglifam [1028, 1558, 2023, 2157]
TUG-1375 [801]
Selective antagonists GW1100 (pIC50 6) [238, 2038] GLPG0974 (pIC50 8.1) [1546, 1715], CATPB (pIC50 6.5) [927]
Comments A wide range of both saturated and unsaturated fatty acids containing from 6 to 22 carbons
have been shown to act as agonists at FFA1 [239, 958, 1144]. Antagonist GW1100 is also an
oxytocin receptor antagonist [238]. Fasiglifam, TUG-770 and GW9508 are approximately
100 fold selective for FFA1 over FFA4 [238, 380, 1558]. AMG-837 and the related analogue
AM6331 have been suggested to have an allosteric mechanism of action at FFA1, with
respect to the orthosteric fatty acid binding site [1286, 2353].
–
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Nomenclature FFA3 receptor FFA4 receptor GPR42
HGNC, UniProt FFAR3, O14843 FFAR4, Q5NUL3 GPR42, O15529
Endogenous agonists propanoic acid [249, 1223, 1894, 2352], butyric acid [249, 1223, 1894, 2352],
1-methylcyclopropanecarboxylic acid [1894]
α-linolenic acid [1955], myristic acid [2275], α-linolenic acid [2100] – Rat,
oleic acid [2275]
–
Agonists acetic acid [249, 1223, 1894, 2352] – –
Selective agonists – compound A [1616], TUG-891 [1955], NCG21 [2065] –
Comments Beta-hydroxybutyrate has been reported to antagonise FFA3 responses to short
chain fatty acids [1095]. A range of FFA3 selective molecules with agonist and
antagonist properties, but which bind at sites distinct from the short chain fatty
acid binding site (i.e. allosteric modulators), have been described [196, 926, 1337].
A wide range of both saturated and unsaturated fatty acids containing from 6 to 22
carbons have been shown to act as agonists at FFA4 [382] with a small subset listed
above. Compound A [PMID 24997608] exhibits more than 1000 fold selectivity
[1616], and TUG-891 50-1000 fold selectivity for FFA4 over FFA1 [1955],
dependent on the assay. NGC21 exhibits approximately 15 fold selectivity for FFA4
over FFA1 [2057].
–
Comments: Short (361 amino acids) and long (377 amino acids)
splice variants of human FFA4 have been reported [1490], which
differ by a 16 amino acid insertion in intracellular loop 3, and
exhibit differences in intracellular signalling properties in recom-
binant systems [2275]. The long FFA4 splice variant has not been
identiﬁed in other primates or rodents to date [876, 1490].
GPR42 was originally described as a pseudogene within the family
(ENSFM00250000002583), but the discovery of several polymor-
phisms suggests that some versions of GPR42 may be functional
[1276]. GPR84 is a structurally-unrelated G protein-coupled recep-
tor which has been found to respond to medium chain fatty acids
[2254].
Further reading on Free fatty acid receptors
Bolognini D et al. (2016) The Pharmacology and Function of Receptors for Short-Chain Fatty Acids.
Mol. Pharmacol. 89: 388-98 [PMID:26719580]
Mancini AD et al. (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?
Trends Endocrinol. Metab. 24: 398-407 [PMID:23631851]
Milligan G et al. (2017) Complex Pharmacology of Free Fatty Acid Receptors. Chem. Rev. 117: 67-110
[PMID:27299848]
Moniri NH. (2016) Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role
in metabolic disorders. Biochem. Pharmacol. 110-111: 1-15 [PMID:26827942]
Stoddart LA et al. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors
FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60: 405-17
[PMID:19047536]
Watterson KR et al. (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front
Endocrinol (Lausanne) 5: 137 [PMID:25221541]
Searchable database: http://www.guidetopharmacology.org/index.jsp Free fatty acid receptors S75
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
GABAB receptors
G protein-coupled receptors → GABAB receptors
Overview: Functional GABAB receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on GABAB re-
ceptors [215, 1710]) are formed from the heterodimerization
of two similar 7TM subunits termed GABAB1 and GABAB2 [215,
557, 1709, 1710, 2173]. GABAB receptors are widespread in
the CNS and regulate both pre- and postsynaptic activity. The
GABAB1 subunit, when expressed alone, binds both antagonists
and agonists, but the afﬁnity of the latter is generally 10-100-
fold less than for the native receptor. Co-expression of GABAB1
and GABAB2 subunits allows transport of GABAB1 to the cell sur-
face and generates a functional receptor that can couple to signal
transduction pathways such as high-voltage-activated Ca2+ chan-
nels (Cav2.1, Cav2.2), or inwardly rectifying potassium channels
(Kir3) [159, 215, 216]. The GABAB1 subunit harbours the GABA
(orthosteric)-binding site within an extracellular domain (ECD)
venus ﬂytrap module (VTM), whereas the GABAB2 subunit medi-
ates G protein-coupled signalling [215, 681, 683, 1709]. The two
subunits interact by direct allosteric coupling [1485], such that
GABAB2 increases the afﬁnity of GABAB1 for agonists and recip-
rocally GABAB1 facilitates the coupling of GABAB2 to G proteins
[681, 1161, 1709]. GABAB1 and GABAB2 subunits assemble in a
1:1 stoichiometry by means of a coiled-coil interaction between
α-helices within their carboxy-termini that masks an endoplas-
mic reticulum retention motif (RXRR) within the GABAB1 subunit
but other domains of the proteins also contribute to their het-
eromerization [159, 270, 1709]. Recent evidence indicates that
higher order assemblies of GABAB receptor comprising dimers of
heterodimers occur in recombinant expression systems and in vivo
and that such complexes exhibit negative functional cooperativ-
ity between heterodimers [409, 1708]. Adding further complex-
ity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b
and 16 associate as tetramers with the carboxy terminus of the
GABAB2 subunit to impart altered signalling kinetics and agonist
potency to the receptor complex [116, 1907, 2160] and are re-
viewed by [1711]. The molecular complexity of GABAB receptors
is further increased through association with trafﬁcking and ef-
fector proteins [Schwenk et al., 2016, Nature Neuroscience 19(2):
233-42] and reviewed by [1707]. Four isoforms of the human
GABAB1 subunit have been cloned. The predominant GABAB1a
and GABAB1b isoforms, which are most prevalent in neonatal
and adult brain tissue respectively, differ in their ECD sequences
as a result of the use of alternative transcription initiation sites.
GABAB1a-containing heterodimers localise to distal axons andme-
diate inhibition of glutamate release in the CA3-CA1 terminals,
and GABA release onto the layer 5 pyramidal neurons, whereas
GABAB1b-containing receptors occur within dendritic spines and
mediate slow postsynaptic inhibition [1749, 2216]. Only the 1a
and 1b variants are identiﬁed as components of native receptors
[215]. Additional GABAB1 subunit isoforms have been described
in rodents and humans [1236] and reviewed by [159].
Nomenclature GABAB receptor
Subunits kctd12b (Accessory protein), KCTD16 (Accessory protein), KCTD12 (Accessory protein),GABAB1, GABAB2, KCTD8 (Accessory protein)
Agonists CGP 44532 [635] – Rat, (-)-baclofen [635] – Rat, 3-APPA [881], baclofen [881, 2327], 3-APMPA [2327]
Antagonists CGP 62349 (pKi 8.5–8.9) [881, 2327], CGP 55845 (pKi 7.8) [2327], SCH 50911 (pKi 5.5–6) [881, 2327], CGP 35348 (pKi 4.4) [2327], 2-hydroxy-saclofen (pIC50 4.1) [1052] – Rat
Allosteric modulators rac-BHFF (Positive) (pEC50 6.6) [1366], GS39783 (Positive) (pKB 4.7) [849, 2182], compound 14 (Negative) (pIC50 4.4) [351], CGP7930 (Positive) [2181]
Labelled ligands [3H]CGP 54626 (Antagonist) (pKi 9.1) [1015] – Rat, [
3H]CGP 62349 (Antagonist) (pKd 9.1) [1060] – Rat, [
125I]CGP 64213 (Antagonist) (pKd 9) [650] – Rat, [
125I]CGP 71872
(Antagonist) (pKd 9) [1052] – Rat, [
3H](R)-(-)-baclofen (Agonist)
Subunits
Nomenclature GABAB1 GABAB2
HGNC, UniProt GABBR1, Q9UBS5 GABBR2, O75899
Searchable database: http://www.guidetopharmacology.org/index.jsp GABA receptors S76B
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
Comments: Potencies of agonists and antagonists listed in the ta-
ble, quantiﬁed as IC50 values for the inhibition of [
3H]CGP27492
binding to rat cerebral cortex membranes, are from [215, 634,
635]. Radioligand KD values relate to binding to rat brain mem-
branes. CGP 71872 is a photoafﬁnity ligand for the GABAB1
subunit [137]. CGP27492 (3-APPA), CGP35024 (3-APMPA) and
CGP 44532 act as antagonists at human GABAA ρ1 receptors, with
potencies in the low micromolar range [634]. In addition to the
ligands listed in the table, Ca2+ binds to the VTM of the GABAB1
subunit to act as a positive allosteric modulator of GABA [650].
Synthetic positive allosteric modulators with low, or no, intrinsic
activity include CGP7930, GS39783, BHF-177 [2223] and (+)-BHFF
[9, 159, 166, 634]. The site of action of CGP7930 and GS39783
appears to be on the heptahelical domain of the GABAB2 subunit
[534, 1709]. In the presence of CGP7930 or GS39783, CGP 35348
and 2-hydroxy-saclofen behave as partial agonists [634]. A neg-
ative allosteric modulator of GABAB activity has been reported
[351]. Knock-out of the GABAB1 subunit in C57B mice causes
the development of severe tonic-clonic convulsions that prove fa-
tal within a month of birth, whereas GABAB1
-/- BALB/c mice, al-
though also displaying spontaneous epileptiform activity, are vi-
able. The phenotype of the latter animals additionally includes
hyperalgesia, hyperlocomotion (in a novel, but not familiar, en-
vironment), hyperdopaminergia, memory impairment and be-
haviours indicative of anxiety [563, 2184]. A similar phenotype
has been found for GABAB2
-/- BALB/c mice [669].
Further reading on GABAB receptors
Bowery NG et al. (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-
aminobutyricacid(B) receptors: structure and function. Pharmacol Rev. 54: 247-264
[PMID:12037141]
Froestl W. (2011) An historical perspective on GABAergic drugs. Future Med Chem 3: 163-75
[PMID:21428811]
Gassmann M et al. (2012) Regulation of neuronal GABA(B) receptor functions by subunit composi-
tion. Nat. Rev. Neurosci. 13: 380-94 [PMID:22595784]
Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature
540: 60-68 [PMID:27905440]
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Galanin receptors
G protein-coupled receptors → Galanin receptors
Overview: Galanin receptors (provisional nomencla-
ture as recommended by NC-IUPHAR [612]) are acti-
vated by the endogenous peptides galanin (GAL, P22466) and
galanin-like peptide (GALP, Q9UBC7). Human galanin (GAL,
P22466) is a 30 amino-acid non-amidated peptide [579]; in other
species, it is 29 amino acids long and C-terminally amidated.
Amino acids 1–14 of galanin are highly conserved in mammals,
birds, reptiles, amphibia and ﬁsh. Shorter peptide species (e.g.
human galanin-1–19 [155] and porcine galanin-5–29 [1970]) and
N-terminally extended forms (e.g. N-terminally seven and nine
residue elongated forms of porcine galanin [156, 1970]) have been
reported.
Nomenclature GAL1 receptor GAL2 receptor GAL3 receptor
HGNC, UniProt GALR1, P47211 GALR2, O43603 GALR3, O60755
Potency order of endogenous ligands galanin (GAL, P22466) > galanin-like peptide (GALP,
Q9UBC7) [1623]
galanin-like peptide (GALP, Q9UBC7) ≥ galanin (GAL,
P22466) [1623]
galanin-like peptide (GALP, Q9UBC7) > galanin (GAL,
P22466) [1197]
Agonists – galanin(2-29) (rat/mouse) [1651, 2257, 2258, 2259] –
Rat
–
Selective agonists – [D-Trp2]galanin-(1-29) [1996] – Rat –
Selective antagonists 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide (pIC50 5.6)
[1914]
M871 (pKi 7.9) [2010] SNAP 398299 (pKi 8.3) [1132, 1133, 2069],
SNAP 37889 (pKi 7.8–7.8) [1132, 1133, 2069]
Selective allosteric modulators – CYM2503 (Positive) (pEC50 9.2) [1322] – Rat –
Labelled ligands [125I][Tyr26]galanin (human) (Agonist) [608],
[125I][Tyr26]galanin (human) (Agonist) [608]
[125I][Tyr26]galanin (human) (Agonist) [2258] – Rat [125I][Tyr26]galanin (pig) (Agonist) [207, 1997]
Comments – The CYM2503 PAM potentiates the anticonvulsant
activity of endogenous galanin in mouse seizure models
[1322].
–
Comments: Galanin-(1-11) is a high-afﬁnity agonist at
GAL1/GAL2 (pKi 9), and galanin(2-11) is selective for GAL2 and
GAL3 compared with GAL1 [1321]. [125I]-[Tyr26]galanin binds to
all three subtypes with Kd values generally reported to range from
0.05 to 1 nM, depending on the assay conditions used [608, 1982,
1996, 1997, 2258]. Porcine galanin-(3-29) does not bind to cloned
GAL1, GAL2 or GAL3 receptors, but a receptor that is functionally
activated by porcine galanin-(3–29) has been reported in pituitary
and gastric smooth muscle cells [758, 2342]. Additional galanin
receptor subtypes are also suggested from studies with chimeric
peptides (e.g. M15, M35 and M40), which act as antagonists in
functional assays in the cardiovascular system [2171], spinal cord
[2307], locus coeruleus, hippocampus [114] and hypothalamus
[115, 1249], but exhibit agonist activity at some peripheral sites
[115, 758]. The chimeric peptides M15, M32, M35, M40 and C7
are agonists at GAL1 receptors expressed endogenously in Bowes
human melanoma cells [1623], and at heterologously expressed
recombinant GAL1, GAL2 and GAL3 receptors [608, 1996, 1997].
Recent studies have described the synthesis of a series of novel,
systemically-active, galanin analogues, with modest preferential
binding at the GAL2 receptor. Speciﬁc chemical modiﬁcations to
the galanin backbone increased brain levels of these peptides af-
ter i.v. injection and several of these peptides exerted a potent
antidepressant-like effect in mouse models of depression [1847].
Further reading on Galanin receptors
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Lang R et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors:
three decades of emerging diversity. Pharmacol. Rev. 67: 118-75 [PMID:25428932]
Lang R et al. (2011) The galanin peptide family in inﬂammation. Neuropeptides 45: 1-8
[PMID:21087790]
Lawrence C et al. (2011) Galanin-like peptide (GALP) is a hypothalamic regulator of energy home-
ostasis and reproduction. Front Neuroendocrinol 32: 1-9 [PMID:20558195]
Webling KE et al. (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne) 3: 146
[PMID:23233848]
Searchable database: http://www.guidetopharmacology.org/index.jsp Galanin receptors S78
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
Ghrelin receptor
G protein-coupled receptors → Ghrelin receptor
Overview: The ghrelin receptor (nomenclature as agreed
by the NC-IUPHAR Subcommittee for the Ghrelin recep-
tor [456]) is activated by a 28 amino-acid peptide originally iso-
lated from rat stomach, where it is cleaved from a 117 amino-
acid precursor (GHRL, Q9UBU3). The human gene encoding the
precursor peptide has 83% sequence homology to rat prepro-
ghrelin, although the mature peptides from rat and human dif-
fer by only two amino acids [1399]. Alternative splicing results
in the formation of a second peptide, [des-Gln14]ghrelin (GHRL,
Q9UBU3) with equipotent biological activity [907]. A unique
post-translational modiﬁcation (octanoylation of Ser3, catalysed
by ghrelin O-acyltransferase (MBOAT4, Q96T53) [2374] occurs in
both peptides, essential for full activity in binding to ghrelin re-
ceptors in the hypothalamus and pituitary, and for the release
of growth hormone from the pituitary [1128]. Structure activ-
ity studies showed the ﬁrst ﬁve N-terminal amino acids to be
the minimum required for binding [131], and receptor mutage-
nesis has indicated overlap of the ghrelin binding site with those
for small molecule agonists and allosteric modulators of ghrelin
(GHRL, Q9UBU3) function [899]. In cell systems, the ghrelin re-
ceptor is constitutively active [900], but this is abolished by a nat-
urally occurring mutation (A204E) that results in decreased cell
surface receptor expression and is associated with familial short
stature [1652].
Nomenclature ghrelin receptor
HGNC, UniProt GHSR, Q92847
Potency order of endogenous ligands ghrelin (GHRL, Q9UBU3) = [des-Gln14]ghrelin (GHRL, Q9UBU3) [130, 1399]
Antagonists liver enriched antimicrobial peptide 2 (LEAP2, Q969E1) (pIC50 8.2) [675]
Selective antagonists GSK1614343 (pIC50 8.4) [1848], GSK1614343 (pKB 8) [1684] – Rat
Labelled ligands [125I][His9]ghrelin (human) (Agonist) [1051], [125I][Tyr4]ghrelin (human) (Agonist) [1515]
Comments: [des-octanoyl]ghrelin (GHRL, Q9UBU3) has been
shown to bind (as [125I]Tyr4-des-octanoyl-ghrelin) and have ef-
fects in the cardiovascular system [130], which raises the possible
existence of different receptor subtypes in peripheral tissues and
the central nervous system. A potent inverse agonist has been
identiﬁed ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, pD2 8.3;
[897]). Ulimorelin, described as a ghrelin receptor agonist (pKi 7.8
and pD2 7.5 at human recombinant ghrelin receptors), has been
shown to stimulate ghrelin receptormediated food intake and gas-
tric emptying but not elicit release of growth hormone, or modify
ghrelin stimulated growth hormone release, thus pharmacolog-
ically discriminating the orexigenic and gastrointestinal actions
of ghrelin (GHRL, Q9UBU3) from the release of growth hormone
[622]. A number of selective antagonists have been reported, in-
cluding peptidomimetic [1514] and non-peptide small molecules
including GSK1614343 [1684, 1848].
Further reading on Ghrelin receptor
Andrews ZB. (2011) The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neu-
rosci. 34: 31-40 [PMID:21035199]
Angelidis G et al. (2010) Current and potential roles of ghrelin in clinical practice. J. Endocrinol.
Invest. 33: 823-38 [PMID:21293171]
Briggs DI et al. (2011) Metabolic status regulates ghrelin function on energy homeostasis. Neuroen-
docrinology 93: 48-57 [PMID:21124019]
Callaghan B et al. (2014) Novel and conventional receptors for ghrelin, desacyl-ghrelin, and phar-
macologically related compounds. Pharmacol. Rev. 66: 984-1001 [PMID:25107984]
Davenport AP et al. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomencla-
ture, distribution, and function. Pharmacol. Rev. 57: 541-6 [PMID:16382107]
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Glucagon receptor family
G protein-coupled receptors → Glucagon receptor family
Overview: The glucagon family of receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on the
Glucagon receptor family [1410]) are activated by the en-
dogenous peptide (27-44 aa) hormones glucagon (GCG, P01275),
glucagon-like peptide 1 (GCG, P01275), glucagon-like peptide 2
(GCG, P01275), glucose-dependent insulinotropic polypep-
tide (also known as gastric inhibitory polypeptide (GIP,
P09681)), GHRH (GHRH, P01286) and secretin (SCT,
P09683). One common precursor (GCG) generates glucagon
(GCG, P01275), glucagon-like peptide 1 (GCG, P01275) and
glucagon-like peptide 2 (GCG, P01275) peptides [952]. For a re-
cent review on review the current understanding of the structures
of GLP-1 and GLP-1R, the molecular basis of their interaction,
and the signaling events associated with it, see de Graaf et al.,
2016 [736].
Nomenclature GHRH receptor GIP receptor GLP-1 receptor
HGNC, UniProt GHRHR, Q02643 GIPR, P48546 GLP1R, P43220
Endogenous agonists GHRH (GHRH, P01286) gastric inhibitory polypeptide (GIP, P09681) [2225] glucagon-like peptide 1-(7-36) amide (GCG, P01275)
[1020], glucagon-like peptide 1-(7-37) (GCG, P01275) [498]
Agonists JI-38 [289], sermorelin – liraglutide [11199], lixisenatide [2290], WB4-24 [583]
Selective agonists BIM28011 [431], tesamorelin – semaglutide [1206], exendin-4 [1460], exendin-4 [1020],
exendin-3 (P20394) [1776]
Selective antagonists JV-1-36 (pKi 10.1–10.4) [1886, 2205, 2206] – Rat, JV-1-38
(pKi 10.1) [1886, 2205, 2206] – Rat
[Pro3]GIP [672] – Mouse exendin-(9-39) (pKi 8.1) [1020], GLP-1-(9-36) (pIC50 6.9)
[1486] – Rat, T-0632 (pIC50 4.7) [2131]
Labelled ligands [125I]GHRH (human) (Agonist) [212] – Rat [125I]GIP (human) (Agonist) [648] – Rat [125I]GLP-1-(7-36)-amide (Agonist) [1020],
[125I]exendin-(9-39) (Antagonist) (pKd 8.3) [1020],
[125I]GLP-1-(7-37) (human) (Agonist)
Nomenclature GLP-2 receptor glucagon receptor secretin receptor
HGNC, UniProt GLP2R, O95838 GCGR, P47871 SCTR, P47872
Endogenous agonists glucagon-like peptide 2 (GCG, P01275) [2128] glucagon (GCG, P01275) [1718] secretin (SCT, P09683) [376]
Agonists teduglutide [1423] NNC1702 [2418] –
Selective antagonists – L-168,049 (pIC50 8.4) [312], adomeglivant (pKi 8.2) [1059,
1063], des-His1-[Glu9]glucagon-NH2 (pA2 7.2) [2176, 2177]
– Rat, NNC 92-1687 (pKi 5) [1345], BAY27-9955 [1695]
[(CH2NH)4,5]secretin (pKi 5.3) [776]
Labelled ligands – [125I]glucagon (human, mouse, rat) (Agonist) [125I](Tyr10)secretin-27 (rat) (Agonist) [2172] – Rat
Comments: The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), speciﬁcally RAMP2, in heterologous expression systems [384], although the physio-
logical signiﬁcance of this has yet to be established.
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Further reading on Glucagon receptor family
Ahrén B. (2019) Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug devel-
opment. J Diabetes Investig 10: 196-201 [PMID:30099845]
Andersen A et al. (2018) Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 14: 390-
403 [PMID:29728598]
Gentilella R et al. (2019) Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are
they all the same? Diabetes Metab. Res. Rev. 35: e3070 [PMID:30156747]
Graaf Cd et al. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long
March to Therapeutic Successes. Pharmacol. Rev. 68: 954-1013 [PMID:27630114]
Romera I et al. (2019) A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor
Agonists for the Management of Type 2 Diabetes. Diabetes Ther 10: 5-19 [PMID:30506340]
Trujillo JM et al. (2014) GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments
and emerging agents. Pharmacotherapy 34: 1174-86 [PMID:25382096]
Zhang Y et al. (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.
Nature 546: 248-253 [PMID:28538729]
Glycoprotein hormone receptors
G protein-coupled receptors → Glycoprotein hormone receptors
Overview: Glycoprotein hormone receptors (provisional
nomenclature [612]) are activated by a non-covalent het-
erodimeric glycoprotein made up of a common α chain
(glycoprotein hormone common alpha subunit (CGA, P01215)
CGA, P01215), with a unique β chain that confers the biologi-
cal speciﬁcity to FSH (CGA FSHB, P01215 P01225), LH (CGA LHB,
P01215 P01229), hCG (CGA CGB3, P01215 P01233) or TSH (CGA
TSHB, P01215 P01222). There is binding cross-reactivity across
the endogenous agonists for each of the glycoprotein hormone re-
ceptors. The deglycosylated hormones appear to exhibit reduced
efﬁcacy at these receptors [1850].
Nomenclature FSH receptor LH receptor TSH receptor
HGNC, UniProt FSHR, P23945 LHCGR, P22888 TSHR, P16473
Potency order of endogenous ligands FSH (CGA FSHB, P01215 P01225) LH (CGA LHB, P01215 P01229), hCG (CGA
CGB3, P01215 P01233) [997, 1534]
TSH (CGA TSHB, P01215 P01222)
Labelled ligands [125I]FSH (human) (Agonist) [125I]LH (Agonist),
[125I]chorionic gonadotropin (human) (Agonist)
[125I]TSH (human) (Agonist)
Further reading on Glycoprotein hormone receptors
Jiang X et al. (2012) Structure of follicle-stimulating hormone in complex with the entire ectodomain
of its receptor. Proc. Natl. Acad. Sci. U.S.A. 109: 12491-6 [PMID:22802634]
Kleinau G et al. TSH receptor mutations and disease. Thyroid Disease Manager. Accessed on 2017-
02-23.
Tao YX et al. (2009) Follicle stimulating hormone receptor mutations and reproductive disorders.
Prog Mol Biol Transl Sci 89: 115-31 [PMID:20374735]
Troppmann B et al. (2013) Structural and functional plasticity of the luteinizing hor-
mone/choriogonadotrophin receptor. Hum. Reprod. Update 19: 583-602 [PMID:23686864]
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Gonadotrophin-releasing hormone receptors
G protein-coupled receptors → Gonadotrophin-releasing hormone receptors
Overview: GnRH1 and GnRH2 receptors (provisonal nomen-
clature [612], also called Type I and Type II GnRH receptor, re-
spectively [1456]) have been cloned from numerous species, most
of which express two or three types of GnRH receptor [1455, 1456,
1971]. GnRH I (GNRH1, P01148) (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known as
luteinizing hormone-releasing hormone, gonadoliberin, luliberin,
gonadorelin or simply as GnRH. It is a member of a family of sim-
ilar peptides found in many species [1455, 1456, 1971] includ-
ing GnRH II (GNRH2, O43555) (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-
Pro-Gly-NH2 (which is also known as chicken GnRH-II). Recep-
tors for three forms of GnRH exist in some species but only GnRH
I and GnRH II and their cognate receptors have been found in
mammals [1455, 1456, 1971]. GnRH1 receptors are expressed by
pituitary gonadotrophs, where they mediate the effects of GnRH
on gonadotropin hormone synthesis and secretion that under-
pin central control of mammalian reproduction. GnRH analogues
are used in assisted reproduction and to treat steroid hormone-
dependent conditions [1079]. Notably, agonists cause desensiti-
zation of GnRH-stimulated gonadotropin secretion and the con-
sequent reduction in circulating sex steroids is exploited to treat
hormone-dependent cancers of the breast, ovary and prostate
[1079]. GnRH1 receptors are selectively activated by GnRH I and
all lack the COOH-terminal tails found in other GPCRs. GnRH2
receptors do have COOH-terminal tails and (where tested) are se-
lective for GnRH II over GnRH I. GnRH2 receptors are expressed by
some primates but not by humans [1496]. Phylogenetic classiﬁca-
tions divide GnRH receptors into three [1456] or ﬁve groups [2311]
and highlight examples of gene loss through evolution, with hu-
mans retaining only one ancient gene.
Nomenclature GnRH1 receptor GnRH2 receptor
HGNC, UniProt GNRHR, P30968 GNRHR2, Q96P88
Potency order of endogenous ligands GnRH I (GNRH1, P01148) > GnRH II (GNRH2, O43555) [1456] GnRH II (GNRH2, O43555) > GnRH I (GNRH1, P01148) (Monkey) [1454]
Endogenous agonists GnRH I (GNRH1, P01148) [1323], GnRH II (GNRH2, O43555) [606, 1323, 2032] GnRH II (GNRH2, O43555) [1454] – Monkey, GnRH I (GNRH1, P01148) [1454,
1456] – Monkey
Selective agonists buserelin [1555], buserelin [1554], buserelin [1554], triptorelin [127], leuprolide
[2045], goserelin, histrelin, nafarelin
–
Antagonists iturelix (pKi 9.5) [1811] –
Selective antagonists cetrorelix (pKi 9.3–10) [128, 129, 2045], abarelix (pKi 9.1–9.5) [2045], degarelix
(pKi 8.8) [2194], ganirelix
trptorelix-1 [1357] – Monkey
Labelled ligands [125I]cetrorelix (Antagonist) (pKd 9.7) [892], [
125I]triptorelin (Agonist) [480] – Rat,
[125I]buserelin (Agonist) [1178] – Rat, [125I]GnRH I (human, mouse, rat) (Agonist)
–
Comments: GnRH1 and GnRH2 receptors couple primarily to
Gq/11 [752] but coupling to Gs and Gi is evident in some sys-
tems [1157, 1178]. GnRH2 receptors may also mediate (het-
erotrimeric) G protein-independent signalling to protein kinases
[319]. There is increasing evidence for expression of GnRH recep-
tors on hormone-dependent cancer cells where they can exert an-
tiproliferative and/or proapoptotic effects and mediate effects of
cytotoxins conjugated to GnRH analogues [357, 814, 1284, 1885].
In some human cancer cell models GnRH II (GNRH2, O43555) is
more potent than GnRH I (GNRH1, P01148), implying mediation
by GnRH2 receptors [757], but GnRH2 receptors are not expressed
by humans because the human GNRHR2 gene contains a frame
shift and internal stop codon [1496]. The possibility remains
that this gene generates GnRH2 receptor-related proteins (other
than the full-length receptor) that mediate responses to GnRH II
(GNRH2, O43555) (see [1560]). Alternatively, evidence for mul-
tiple active GnRH receptor conformations [319, 320, 597, 1407,
1456] raises the possibility that GnRH1 receptor-mediated prolifer-
ation inhibition in hormone-dependent cancer cells is dependent
upon a conformation that couples toGi rather thanGq/11 proteins
as in pituitary cells [320, 1407]. Loss-of-function mutations in the
GnRH1 receptor and deﬁciency of GnRH I (GNRH1, P01148) are
associated with hypogonadotropic hypogonadism although some
’loss of function’ mutations may actually prevent trafﬁcking of
’functional’ GnRH1 receptors to the cell surface, as evidenced by
recovery of function by nonpeptide antagonists [1230]. Human
GnRH1 receptors are poorly expressed at the cell surface because
of failure to meet structural quality control criteria for endoplas-
mic reticulum exit [598, 1232], and this increases susceptibility
to point mutations that further impair trafﬁcking [598, 1230].
GnRH receptor signalling may require receptor oligomerisation
[412, 1155].
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Further reading on Gonadotrophin-releasing hormone receptors
Desaulniers AT et al. (2017) Expression and Role of Gonadotropin-Releasing Hormone 2 and Its
Receptor in Mammals. Front Endocrinol (Lausanne) 8: 269 [PMID:29312140]
Limonta P et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic
strategies. Endocr. Rev. 33: 784-811 [PMID:22778172]
McArdle CA and Roberson MS.. (2015) Gonadotropes and gonadotropin-releasing hormone signal-
ing. In Knobil and Neill’s Physiology of Reproduction (4th edition). Edited by Plant TM and Zeleznik
AJ.: Elsevier Inc.: [ISBN: 9780123971753]
Millar RP et al. (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235-275
[PMID:15082521]
Tao YX et al. (2014) Chaperoning G protein-coupled receptors: from cell biology to therapeutics.
Endocr. Rev. 35: 602-47 [PMID:24661201]
GPR18, GPR55 and GPR119
G protein-coupled receptors → GPR18, GPR55 and GPR119
Overview: GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1 and CB2 cannabinoid receptors, respond to endogenous agents analogous
to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [1692]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be
activated in vitro by N-arachidonoylglycine, lysophosphatidylinositol and N-oleoylethanolamide, respectively, there is a lack of evidence for activation by these lipid messengers in vivo. As such, therefore,
these receptors retain their orphan status.
Nomenclature GPR18 GPR55 GPR119
HGNC, UniProt GPR18, Q14330 GPR55, Q9Y2T6 GPR119, Q8TDV5
Potency order of endogenous ligands – – N-oleoylethanolamide, N-palmitoylethanolamine > SEA
(anandamide is ineffective) [1643]
Endogenous agonists N-arachidonoylglycine [1126] lysophosphatidylinositol [852, 1625, 2015],
2-arachidonoylglycerolphosphoinositol [1627]
N-oleoylethanolamide [389, 1643, 2015],
N-palmitoylethanolamine, SEA
Selective agonists – AM251 [852, 1042, 1843] AS1269574 [2400], PSN632408 [1643], PSN375963
[1643]
Selective antagonists – CID16020046 (apparent pA2) (pA2 7.3) [1044],
ML193 (pIC50 6.7) [865]
–
Comments The pairing of N-arachidonoylglycine with GPR18 was
not replicated in two studies based on arrestin assays
[2015, 2389]. See [455] for discussion.
See reviews [455] and [1961]. In addition to those shown above, further small
molecule agonists have been reported [793].
Comments: GPR18 failed to respond to a variety of lipid-
derived agents in an in vitro screen [2389], but has been re-
ported to be activated by9-tetrahydrocannabinol [1422]. GPR55
responds to AM251 and rimonabant at micromolar concentra-
tions, compared to their nanomolar afﬁnity as CB1 receptor
antagonists/inverse agonists [1692]. It has been reported that
lysophosphatidylinositol acts at other sites in addition to GPR55
[2367]. N-Arachidonoylserine has been suggested to act as a
low efﬁcacy agonist/antagonist at GPR18 in vitro [1420]. It has
also been suggested oleoyl-lysophosphatidylcholine acts, at least
in part, through GPR119 [1592]. Although PSN375963 and
PSN632408 produce GPR119-dependent responses in heterolo-
gous expression systems, comparison withN-oleoylethanolamide-
mediated responses suggests additional mechanisms of action
[1592].
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Further reading on GPR18, GPR55 and GPR119
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G
protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharma-
col. Rev. 65: 967-86 [PMID:23686350]
Hassing HA et al. (2016) Biased signaling of lipids and allosteric actions of synthetic molecules for
GPR119. Biochem. Pharmacol. 119: 66-75 [PMID:27569424]
Irving A et al. (2017) Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors. Adv Phar-
macol 80: 223-247 [PMID:28826536]
Liu B et al. (2015) GPR55: from orphan to metabolic regulator? Pharmacol. Ther. 145: 35-42
[PMID:24972076]
Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabi-
noid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev. 62: 588-631
[PMID:21079038]
Histamine receptors
G protein-coupled receptors → Histamine receptors
Overview: Histamine receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Histamine Receptors
[871, 1653]) are activated by the endogenous ligand histamine.
Marked species differences exist between histamine receptor or-
thologues [871]. The human and rat H3 receptor genes are sub-
ject to signiﬁcant splice variance [100]. The potency order of his-
tamine at histamine receptor subtypes is H3 = H4 > H2 > H1
[1653]. Some agonists at the human H3 receptor display signif-
icant ligand bias [1803]. Antagonists of all 4 histamine receptors
have clinical uses: H1 antagonists for allergies (e.g. cetirizine),
H2 antagonists for acid-reﬂux diseases (e.g. ranitidine), H3 an-
tagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and
H4 antagonists for atopic dermatitis (e.g. ZPL-3893787; Phase IIa)
[1653] and vestibular neuritis (AUV) (SENS-111 (Seliforant, previ-
ously UR-63325), entered and completed vestibular neuritis (AUV)
Phase IIa efﬁcacy and safety trials, respectively) [75, 2213].
Nomenclature H1 receptor H2 receptor
HGNC, UniProt HRH1, P35367 HRH2, P25021
Selective agonists methylhistaprodifen [1923], histaprodifen [1283] amthamine [1149]
Antagonists cyproheptadine (pKi 10.2) [1469], promethazine (pKi 9.6) [697], mepyramine (Inverse
agonist) (pKi 8.7–9) [204, 1775], cetirizine (Inverse agonist) (pKi 8.2) [1469],
diphenhydramine (pKi 7.9) [204]
–
Selective antagonists clemastine (pKi 10.3) [79], desloratadine (pKi 9) [1266], triprolidine (pKi 8.5–9) [204,
1469], azelastine (pKi 8.9) [1738], astemizole (pKi 8.5) [1673]
tiotidine (pKi 7.5) [161] – Rat, ranitidine (pKi 7.1) [1262], cimetidine (pKi 6.8) [299]
Labelled ligands [3H]pyrilamine (Antagonist, Inverse agonist) (pKd 8.4–9.1) [464, 1469, 1901, 1923],
[11C]doxepin (Antagonist) (pKd 9) [955], [
11C]pyrilamine (Antagonist, Inverse agonist)
[125I]iodoaminopotentidine (Antagonist) (pKd 8.7) [1185] – Rat, [
3H]tiotidine (Antagonist)
(pKd 7.7–8.7) [1480]
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Nomenclature H3 receptor H4 receptor
HGNC, UniProt HRH3, Q9Y5N1 HRH4, Q9H3N8
Selective agonists immethridine [1110], methimepip [1109], MK-0249 (Inverse agonist) [1536] clobenpropit (Partial agonist) [570, 1283, 1298, 1299, 1509], 4-methylhistamine [674,
1283], ST-1006 [1653], VUF 8430 [1282]
Antagonists iodophenpropit (pKi 8.2–8.7) [2305, 2338] –
Selective antagonists pitolisant (pKi 8.1–8.6) [1653, 2447], A331440 (pKi 8.5) [794], conessine (pKi 8.3) [1653],
MK-0249 (pKi 8.2) [1653], thioperamide (Selective for H3/H4 compared to H1 and H3.) (pKi
7.1–7.7) [404, 569, 570, 1280, 1320, 2305, 2338], ciproxifan (pKi 6.7–7.3) [404, 569, 570,
1280, 1653, 2338]
ZPL-3893787 (pKi 8.3) [1653], INCB-38579 (pKi 8.3) [1653], JNJ 7777120 (pKi 7.8–8.3)
[1283, 2001, 2129], JNJ-39758979 (pKi 7.9) [1653, 1878], thioperamide (Selective for
H3/H4 compared to H1 and H3.) (pKi 6.3–7.6) [569, 570, 1298, 1299, 1509, 2441]
Labelled ligands [123I]iodoproxyfan (Antagonist) (pKd 10.2) [1280], [
125I]iodophenpropit (Antagonist) (pKd
9.2) [980] – Rat, [3H](R)-α-methylhistamine (Agonist) [1298], N-[3H]α-methylhistamine
(Agonist) [349] – Mouse
[3H]JNJ 7777120 (Antagonist) (pKd 8.4) [2129]
Comments: Histaprodifen and methylhistaprodifen are reduced
efﬁcacy agonists. The H4 receptor appears to exhibit broadly simi-
lar pharmacology to the H3 receptor for imidazole-containing lig-
ands, although (R)-α-methylhistamine and N-α-methylhistamine
are less potent, while clobenpropit acts as a reduced efﬁcacy ago-
nist at the H4 receptor and an antagonist at the H3 receptor [1298,
1542, 1579, 1612, 2441]. Moreover, 4-methylhistamine is iden-
tiﬁed as a high afﬁnity, full agonist for the human H4 receptor
[1283]. [3H]histamine has been used to label the H4 receptor in
heterologous expression systems.
Further reading on Histamine receptors
Gbahou F et al. (2012) The histamine autoreceptor is a short isoform of the H_3 receptor. Br. J.
Pharmacol. 166: 1860-71 [PMID:22356432]
Nieto-Alamilla G et al. (2016) The Histamine H3 Receptor: Structure, Pharmacology, and Function.
Mol. Pharmacol. 90: 649-673 [PMID:27563055]
Panula P et al. (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine
Receptors. Pharmacol. Rev. 67: 601-55 [PMID:26084539]
van Rijn RM et al. (2008) Cloning and characterization of dominant negative splice variants of the
human histamine H4 receptor. Biochem. J. 414: 121-31 [PMID:18452403]
Searchable database: http://www.guidetopharmacology.org/index.jsp Histamine receptors S85
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
Hydroxycarboxylic acid receptors
G protein-coupled receptors → Hydroxycarboxylic acid receptors
Overview: The hydroxycarboxylic acid family of receptors
(ENSFM00500000271913, nomenclature as agreed by the
NC-IUPHAR Subcommittee on Hydroxycarboxylic acid
receptors [455, 1614]) respond to organic acids, including the
endogenous hydroxy carboxylic acids 3-hydroxy butyric acid and
L-lactic acid, as well as the lipid lowering agents nicotinic acid
(niacin), acipimox and acifran [2004, 2159, 2320]. These receptors
were provisionally described as nicotinic acid receptors, although
nicotinic acid shows submicromolar potency at HCA2 receptors
only and is unlikely to be the natural ligand [2159, 2320].
Nomenclature HCA1 receptor HCA2 receptor HCA3 receptor
HGNC, UniProt HCAR1, Q9BXC0 HCAR2, Q8TDS4 HCAR3, P49019
Potency order of endogenous ligands – β-D-hydroxybutyric acid > butyric acid –
Endogenous agonists L-lactic acid [18, 290, 1300, 2015] β-D-hydroxybutyric acid [2077], butyric acid 3-hydroxyoctanoic acid [17]
Agonists compound 2 [1853], 3,5-dihydroxybenzoic acid [1297] SCH 900271 [1646], GSK256073 [2022] –
Selective agonists – MK 6892 [1946], MK 1903 [180], nicotinic acid [2004, 2159,
2320], acipimox [2004, 2320], monomethyl fumarate [2101]
compound 6o [1981], IBC 293 [1925]
Labelled ligands – [3H]nicotinic acid (Agonist) [2004, 2159, 2320] –
Comments: Further closely-related GPCRs include the
5-oxoeicosanoid receptor (OXER1, Q8TDS5) andGPR31 (O00270).
Lactate activates HCA1 on adipocytes in an autocrine manner. It
inhibits lipolysis and thereby promotes anabolic effects. HCA2
and HCA3 regulate adipocyte lipolysis and immune functions un-
der conditions of increased FFA formation through lipolysis (e.g.,
during fasting). HCA2 agonists acting mainly through the recep-
tor on immune cells exert antiatherogenic and anti-inﬂammatory
effects. HCA2 is also a receptor for butyrate and mediates some
of the beneﬁcial effects of short-chain fatty acids produced by gut
microbiota. HCA3 has been shown to be activated by aromatic
D-amino acids.
Further reading on Hydroxycarboxylic acid receptors
Boatman PD et al. (2008) Nicotinic acid receptor agonists. J. Med. Chem. 51: 7653-62
[PMID:18983141]
Graff EC et al. (2016) Anti-inﬂammatory effects of the hydroxycarboxylic acid receptor 2. Metab.
Clin. Exp. 65: 102-13 [PMID:26773933]
Kamanna VS et al. (2013) Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol. 24:
239-45 [PMID:23619367]
Offermanns S. (2017) Hydroxy-Carboxylic Acid Receptor Actions in Metabolism. Trends Endocrinol.
Metab. 28: 227-236 [PMID:28087125]
Offermanns S et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXII:
Nomenclature and Classiﬁcation of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and
GPR109B). Pharmacol. Rev. 63: 269-90 [PMID:21454438]
Offermanns S et al. (2015) Nutritional or pharmacological activation of HCA(2) ameliorates neuroin-
ﬂammation. Trends Mol Med 21: 245-55 [PMID:25766751]
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Kisspeptin receptor
G protein-coupled receptors → Kisspeptin receptor
Overview: The kisspeptin receptor (nomenclature as agreed
by the NC-IUPHAR Subcommittee on the kisspeptin re-
ceptor [1102]), like neuropeptide FF (NPFF), prolactin-releasing
peptide (PrP) and QRFP receptors (provisional nomenclature) re-
sponds to endogenous peptides with an arginine-phenylalanine-
amide (RFamide) motif. Kisspeptin-54 (KISS1, Q15726) (KP54,
originally named metastin), kisspeptin-13 (KISS1, Q15726) (KP13)
and kisspeptin-10 (KISS1) (KP10) are biologically-active peptides
cleaved from the KISS1 (Q15726) gene product. Kisspeptins have
roles in, for example, cancer metastasis, fertility/puberty regula-
tion and glucose homeostasis.
Nomenclature kisspeptin receptor
HGNC, UniProt KISS1R, Q969F8
Endogenous agonists kisspeptin-10 (KISS1) [1142, 1624], kisspeptin-54 (KISS1, Q15726) [1142, 1624], kisspeptin-14 (KISS1, Q15726) [1142], kisspeptin-13 (KISS1, Q15726) [1142]
Selective agonists 4-ﬂuorobenzoyl-FGLRW-NH2 [2143], [dY]1KP-10 [439] – Mouse, TAK-448 [1593]
Selective antagonists peptide 234 [1822]
Labelled ligands [125I]Tyr45-kisspeptin-15 (Agonist) [1624], [125I]kisspeptin-13 (human) (Agonist) [1427], [125I]kisspeptin-10 (human) (Agonist) [1142], [125I]kisspeptin-14 (human) (Agonist)
[1427], [d-Tyr-14C]TAK-448 (Agonist) [1502]
Comments: 2-acylamino-4,6-diphenylpyridine derivatives have been described and are the ﬁrst small molecule kisspeptin receptor antagonists reported with potential for treatment of sex-hormone
dependent diseases such as prostate cancer and endometriosis [1120] .
Further reading on Kisspeptin receptor
Harter CJL et al. (2018) The role of kisspeptin neurons in reproduction andmetabolism. J. Endocrinol.
238: R173-R183 [PMID:30042117]
Kanda S et al. (2013) Structure, synthesis, and phylogeny of kisspeptin and its receptor. Adv. Exp.
Med. Biol. 784: 9-26 [PMID:23550000]
Kirby HR et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVII.
Kisspeptin receptor nomenclature, distribution, and function. Pharmacol. Rev. 62: 565-78
[PMID:21079036]
Oakley AE et al. (2009) Kisspeptin signaling in the brain. Endocr. Rev. 30: 713-43
[PMID:19770291]
Pasquier J et al. (2014) Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. J. Mol. En-
docrinol. 52: T101-17 [PMID:24577719]
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Leukotriene receptors
G protein-coupled receptors → Leukotriene receptors
Overview: The leukotriene receptors (nomenclature as
agreed by the NC-IUPHAR subcommittee on Leukotriene
Receptors [279, 280]) are activated by the endogenous
ligands leukotrienes (LT), synthesized from lipoxygenase
metabolism of arachidonic acid. The human BLT1 recep-
tor is the high afﬁnity LTB4 receptor whereas the BLT2 re-
ceptor in addition to being a low-afﬁnity LTB4 receptor also
binds several other lipoxygenase-products, such as 12S-HETE,
12S-HPETE, 15S-HETE, and the thromboxane synthase product
12-hydroxyheptadecatrienoic acid. The BLT receptors mediate
chemotaxis and immunomodulation in several leukocyte popu-
lations and are in addition expressed on non-myeloid cells, such
as vascular smooth muscle and endothelial cells. In addition to
BLT receptors, LTB4 has been reported to bind to the peroxisome
proliferator activated receptor (PPAR) α [1288] and the vanilloid
TRPV1 ligand-gated nonselective cation channel [1421]. The re-
ceptors for the cysteinyl-leukotrienes (i.e. LTC4, LTD4 and LTE4)
are termed CysLT1 andCysLT2 and exhibit distinct expression pat-
terns in human tissues, mediating for example smoothmuscle cell
contraction, regulation of vascular permeability, and leukocyte
activation. There is also evidence in the literature for additional
CysLT receptor subtypes, derived from functional in vitro studies,
radioligand binding and in mice lacking both CysLT1 and CysLT2
receptors [280]. Cysteinyl-leukotrienes have also been suggested
to signal through the P2Y12 receptor [625, 1600, 1659], GPR17
[395] and GPR99 [1036].
Nomenclature BLT1 receptor BLT2 receptor CysLT1 receptor CysLT2 receptor OXE receptor FPR2/ALX
HGNC, UniProt LTB4R, Q15722 LTB4R2, Q9NPC1 CYSLTR1, Q9Y271 CYSLTR2, Q9NS75 OXER1, Q8TDS5 FPR2, P25090
Potency order of
endogenous
ligands
LTB4 >20-hydroxy-LTB412R-HETE [2395]
12-hydroxyheptadecatrienoic
acid > LTB4 > 12S-HETE =
12S-HPETE > 15S-HETE >
12R-HETE > 20-hydroxy-LTB4
[1633, 2395]
LTD4 > LTC4 > LTE4 [1333,
1867]
LTC4 ≥ LTD4  LTE4 [844,
1604, 2087]
5-oxo-ETE, 5-oxo-C20:3,
5-oxo-ODE >
5-oxo-15-HETE > 5S-HPETE
> 5S-HETE [739, 908, 1013,
1607, 1664, 1729, 1908]
LXA4 = aspirin triggered lipoxin A4 =
ATLa2 = resolvin D1 > LTC4 = LTD4 
15-deoxy-LXA4  fMet-Leu-Phe [401,
600, 602, 750, 2086]
Endogenous
agonists
– – – – – LXA4 [1153], resolvin D1 [1153],
aspirin-triggered resolvin D1 [1152],
aspirin triggered lipoxin A4
Selective
agonists
– – – – – ATLa2 [765]
Endogenous
antagonists
– – – – 5-oxo-12-HETE (pIC50 6.3)
[1728]
–
Antagonists – – pranlukast (pKi 7.1–8.8)
[301, 1777], pobilukast (pKi
7.1) [303]
pranlukast (pA2 7.1) [302],
pobilukast (pA2 6.2) [302]
– –
Selective
antagonists
BIIL 260 (pKi 8.8) [168,
536], CP105696 (pIC50 8.1)
[1964], U75302 (pKi 6.4)
[189]
LY255283 (pIC50 6–7.1)
[859, 2395]
ICI198615 (pKi 9.7) [646] –
Guinea pig, zaﬁrlukast
(zaﬁrlukast is only about
100-fold selective for
CysLT1) (pKi 8.9) [301,
1777], montelukast (pKi
8.6) [1777], MK-571 (pIC50
8) [1333]
BayCysLT2 (pA2 8.4) [306],
BayCysLT2 (pA2 8.3) [306],
HAMI3379 (pIC50 7.4)
[2339]
– WRWWWW (pIC50 6.6) [92],
t-Boc-FLFLF (pIC50 4.3–6) [629, 2030,
2245]
Labelled ligands [3H]LTB4 (Agonist) [2394],
[3H]CGS23131 (Antagonist)
(pKd 7.9) [965]
[3H]LTB4 (pKd 7.6–9.7) [
3H]LTD4 (Agonist),
[3H]ICI-198615
(Antagonist) (pKd 10.6)
[1830]
[3H]LTD4 (Agonist) [844] [3H]5-oxo-ETE (Agonist)
[1607]
[3H]LXA4 (Agonist) [600, 601]
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Comments: The FPR2/ALX receptor (nomenclature as agreed
by the NC-IUPHAR subcommittee on Leukotriene and
Lipoxin Receptors [280]) is activated by the endogenous lipid-
derived, anti-inﬂammatory ligands lipoxin A4 (LXA4) and 15-epi-
LXA4 (aspirin triggered lipoxin A4, ATL). The FPR2/ALX recep-
tor also interacts with endogenous peptide and protein ligands,
such as MHC binding peptide [365] as well as annexin I (ANXA1,
P04083) (ANXA1) and its N-terminal peptides [415, 1688]. In
addition, a soluble hydrolytic product of protease action on the
urokinase-type plasminogen activator receptor has been reported
to activate the FPR2/ALX receptor [1788]. Furthermore, FPR2/ALX
has been suggested to act as a receptor mediating the proinﬂam-
matory actions of the acute-phase reactant, serum amyloid A
[2002, 2047]. The agonist activity of the lipid mediators described
has been questioned [804, 1716], which may derive from batch-
to-batch differences, partial agonism or biased agonism. Results
from Cooray et al. (2013) [415] have addressed this issue and the
role of homodimers and heterodimers in intracellular signaling.
A receptor selective for LXB4 has been suggested from functional
studies [64, 1343, 1818]. Note that the data for FPR2/ALX are also
reproduced on the Formylpeptide receptor pages.
Oxoeicosanoid receptors (OXE, nomenclature agreed by the
NC-IUPHAR subcommittee on Oxoeicosanoid Receptors
[236]) are activated by endogenous chemotactic eicosanoid lig-
ands oxidised at the C-5 position, with 5-oxo-ETE the most potent
agonist identiﬁed for this receptor. Initial characterization of the
heterologously expressed OXE receptor suggested that polyunsat-
urated fatty acids, such as docosahexaenoic acid and EPA, acted as
receptor antagonists [908].
Further reading on Leukotriene receptors
Brink C et al. (2004) International Union of Pharmacology XLIV. Nomenclature for the Oxoe-
icosanoid Receptor. Pharmacol. Rev. 56: 149-157 [PMID:15001665]
Brink C et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene
and lipoxin receptors. Pharmacol. Rev. 55: 195-227 [PMID:12615958]
Bäck M et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene
receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev. 63:
539-84 [PMID:21771892]
Bäck M et al. (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review
7. Br. J. Pharmacol. 171: 3551-74 [PMID:24588652]
Laidlaw TM et al. (2012) Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin.
Exp. Allergy 42: 1313-20 [PMID:22925317]
Lysophospholipid (LPA) receptors
G protein-coupled receptors → Lysophospholipid (LPA) receptors
Overview: Lysophosphatidic acid (LPA) receptors (nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Lysophospholipid Receptors [455, 1080]) are activated by
the endogenous phospholipid LPA. The ﬁrst receptor, LPA1, was
identiﬁed as ventricular zone gene-1 (vzg-1) [840], leading to deor-
phanisation of members of the endothelial differentiation gene
(edg) family as other LPA receptors along with sphingosine 1-
phosphate (S1P) receptors. Additional LPA receptor GPCRs were
later identiﬁed. Gene names have been codiﬁed as LPAR1, etc. to
reﬂect the receptor function of proteins. The crystal structure of
LPA1 was solved and demonstrates extracellular LPA access to the
binding pocket, consistent with proposed delivery via autotaxin
[378]. These studies have also implicated cross-talk with endo-
cannabinoids via phosphorylated intermediates that can also ac-
tivate these receptors. The identiﬁed receptors can account for
most, although not all, LPA-induced phenomena in the litera-
ture, indicating that a majority of LPA-dependent phenomena are
receptor-mediated. Binding afﬁnities of unlabeled, natural LPA
and AEAp to LPA1 weremeasured using backscattering interferom-
etry (pKd = 9) [1466]. Binding afﬁnities were 77-fold lower than
than values obtained using radioactivity [2371]. Targeted deletion
of LPA receptors has clariﬁed signalling pathways and identiﬁed
physiological and pathophysiological roles. Independent valida-
tion bymultiple groups has been reported in the peer-reviewed lit-
erature for all six LPA receptors described in the tables, including
further validation using a distinct read-out via a novel TGFα "shed-
ding" assay [949]. LPA has also been described as an agonist for
the transient receptor potential (Trp) ion channel TRPV1 [1586]
and TRPA1 [1111]. LPA was originally proposed to be a ligand for
GPCR35, but data show that in fact it is a receptor for CXCL17
(CXCL17, Q6UXB2) [1379]. All of these proposed non-GPCR re-
ceptor identities require conﬁrmation and are not currently rec-
ognized as bona ﬁde LPA receptors.
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Nomenclature LPA1 receptor LPA2 receptor LPA3 receptor LPA4 receptor LPA5 receptor LPA6 receptor
HGNC, UniProt LPAR1, Q92633 LPAR2, Q9HBW0 LPAR3, Q9UBY5 LPAR4, Q99677 LPAR5, Q9H1C0 LPAR6, P43657
Selective agonists – dodecylphosphate [2221],
decyl dihydrogen phosphate
[2221], GRI977143 [1106]
OMPT [818] – – –
Antagonists Ki16425 (pIC50 6.6–6.9)
[1622] – Mouse, VPC12249
(pKi 5.2–6.9) [846] – Mouse,
VPC32179 [839]
– VPC12249 (pKi 6.4) [846],
VPC32179 [839]
– – –
Sub/family-selective antagonists – – Ki16425 (pKi 6.4) [1622] – – –
Selective antagonists BMS-986020 (pIC50 8.9),
AM966 (pIC50 6.7–7.8)
[2068], ONO-7300243 (pIC50
6.8) [2108], AM095 (pIC50
6–6.1) [2068]
–
dioctanoylglycerol pyrophosphate
(pKi 5.5–7) [604, 1622]
– AS2717638 (pIC50 7.4)
[1521], TCLPA5 (pIC50 6.1)
[1148]
–
Comments: Ki16425 [1622], VPC12249 [846] and VPC32179
[839] have dual antagonist activity at LPA1 and LPA3 receptors.
There is growing evidence for in vivo efﬁcacy of these chemical
antagonists in several disorders, including fetal hydrocephalus
[2408], fetal hypoxia [857], lung ﬁbrosis [1618], systemic scle-
rosis [1618] and atherosclerosis progression [1154]. The LPA2
selective agonist, GRI977143, also shows efﬁcacy in an animal
model of multiple sclerosis [1896]. The LPA5 selective antagonist,
AS2717638, is effective in pain models [1058].
Further reading on Lysophospholipid (LPA) receptors
Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophos-
pholipid receptor nomenclature. Pharmacol. Rev. 62: 579-87 [PMID:21079037]
Kihara Y et al. (2014) Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J.
Pharmacol. 171: 3575-94 [PMID:24602016]
Yung YC et al. (2015) Lysophosphatidic Acid signaling in the nervous system. Neuron 85: 669-82
[PMID:25695267]
Lysophospholipid (S1P) receptors
G protein-coupled receptors → Lysophospholipid (S1P) receptors
Overview: Sphingosine 1-phosphate (S1P) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Lysophospholipid receptors [1080]) are activated by the en-
dogenous lipid sphingosine 1-phosphate (S1P). Originally cloned
as orphan members of the endothelial differentiation gene (edg)
family, current gene names have been designated as S1P1R
through S1P5R [884]. S1PRs, particularly S1P1, are expressed
throughout all mammalian organ systems. Ligand delivery oc-
curs via two known carriers (or "chaperones"): albumin and HDL-
bound apolipoprotein M (ApoM), the latter of which elicits biased
agonist signaling by S1P1 in multiple cell types [173, 649]. The
ﬁve S1PRs, two chaperones, and active cellular metabolism have
complicated analyses of receptor ligand binding in native systems.
Signaling pathways and physiological roles have been character-
ized through radioligand binding in heterologous expression sys-
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tems, targeted deletion of the different S1PRs, and most recently,
mouse models that report in vivo S1P1R activation [1134, 1135].
A crystal structure of an S1P1-T4 fusion protein conﬁrmed aspects
of ligand binding, speciﬁcity, and receptor activation determined
previously through biochemical and genetic studies [172, 805].
Fingolimod (FTY720), the ﬁrst drug to target any of the lysophos-
pholipid receptors, binds to four of the ﬁve S1PRs, and was the
ﬁrst oral therapy for multiple sclerosis [390]. The mechanisms of
action of ﬁngolimod and other S1PR modulating drugs in devel-
opment include binding S1PRs in multiple organ systems, e.g., im-
mune and nervous systems, although the precise nature of their
receptor interactions requires clariﬁcation [405, 753, 754, 1739].
Nomenclature S1P1 receptor S1P2 receptor S1P3 receptor S1P4 receptor S1P5 receptor
HGNC, UniProt S1PR1, P21453 S1PR2, O95136 S1PR3, Q99500 S1PR4, O95977 S1PR5, Q9H228
Potency order of endogenous
ligands
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate
[49, 1628]
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate
[49, 1628]
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate
[1628]
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate
[2189]
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate
[946]
Agonists ﬁngolimod-phosphate [237,
615], siponimod [709, 1649],
etrasimod [275]
– ﬁngolimod-phosphate [237,
615], ﬁngolimod-phosphate
[237, 615]
ﬁngolimod-phosphate [237, 615,
1650, 1864, 2362], etrasimod
[274, 275]
ﬁngolimod-phosphate [237, 615,
1650], siponimod [671, 694,
2178], etrasimod [275]
Selective agonists RP-001 [288], ponesimod [191],
cenerimod [1703], CYM5442
[721], SEW2871 [1864] – Mouse
– CYM-5541 [1004] CYM-50308 [2179] A-971432 [490, 889]
Antagonists VPC23019 (pKi 7.9) [460],
VPC03090-P (pKi 7.6–7.7)
[1069], VPC44116 (pIC50 7.6)
[616]
– VPC44116 (pKi 6.5) [616],
VPC23019 (pKi 5.9) [460]
– –
Selective antagonists NIBR-0213 (pIC50 8.6) [1751],
W146 (pKi 7.1) [1865]
JTE-013 (pIC50 7.8) [1638] TY-52156 (pKi 7) [1522] CYM-50358 (pIC50 7.6) [325,
761]
–
Comments: The FDA-approved immunomodulator ﬁngolimod
(FTY720) is phosphorylated in vivo [33] to generate an agonist with
activity at S1P1, S1P3, S1P4 and S1P5 receptors [237, 1371]. Many
of the physiological consequences of ﬁngolimod-phosphate ad-
ministration, as well as those of other currently described S1P1
agonists, may involve functional antagonism via ubiquitination
and subsequent degradation of S1P1 [1637]. Additionally, recep-
tor speciﬁcities of the different compounds may depend on the
functional assay system utilized and from which species the re-
ceptor sequence originated.
Further reading on Lysophospholipid (S1P) receptors
Chew WS et al. (2016) To ﬁngolimod and beyond: The rich pipeline of drug candidates that target
S1P signaling. Pharmacol. Res. 113: 521-532 [PMID:27663260]
Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophos-
pholipid receptor nomenclature. Pharmacol. Rev. 62: 579-87 [PMID:21079037]
Cyster JG et al. (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
Annu. Rev. Immunol. 30: 69-94 [PMID:22149932]
Pyne NJ et al. (2017) Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells. Molecules
22: [PMID:28241498]
Rosen H et al. (2013) Sphingosine-1-phosphate and its receptors: structure, signaling, and inﬂuence.
Annu. Rev. Biochem. 82: 637-62 [PMID:23527695]
Yanagida K et al. (2017) Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate
Gradient. Annu. Rev. Physiol. 79: 67-91 [PMID:27813829]
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Melanin-concentrating hormone receptors
G protein-coupled receptors → Melanin-concentrating hormone receptors
Overview: Melanin-concentrating hormone (MCH) receptors (provisional nomenclature as recommended by NC-IUPHAR [612]) are activated by an endogenous nonadecameric cyclic peptide
identical in humans and rats (DFDMLRCMLGRVYRPCWQV; mammalian MCH) generated from a precursor (PMCH, P20382), which also produces neuropeptide EI (PMCH, P20382) and neuropeptide GE
(PMCH, P20382).
Nomenclature MCH1 receptor MCH2 receptor
HGNC, UniProt MCHR1, Q99705 MCHR2, Q969V1
Selective antagonists GW803430 (pIC50 9.3) [860], SNAP-7941 (pA2 9.2) [206], T-226296 (pIC50 8.3) [2093], ATC0175 (pIC50 7.9–8.1) [329] –
Labelled ligands [125I]S36057 (Antagonist) (pKd 9.2–9.5) [77], [
125I][Phe13,Tyr19]MCH (Agonist) [269], [3H]MCH (human, mouse, rat) (Agonist) [269] –
Comments: The MCH2 receptor appears to be a non-functional pseudogene in rodents [2098].
Further reading on Melanin-concentrating hormone receptors
Chung S et al. (2011) Recent updates on the melanin-concentrating hormone (MCH) and its receptor
system: lessons from MCH1R antagonists. J. Mol. Neurosci. 43: 115-21 [PMID:20582487]
Eberle AN et al. (2010) Cellular models for the study of the pharmacology and signaling of melanin-
concentrating hormone receptors. J. Recept. Signal Transduct. Res. 30: 385-402 [PMID:21083507]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Takase K et al. (2014) Meta-analysis of melanin-concentrating hormone signaling-deﬁcient mice on
behavioral and metabolic phenotypes. PLoS ONE 9: e99961 [PMID:24924345]
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Melanocortin receptors
G protein-coupled receptors → Melanocortin receptors
Overview: Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [612]) are activated by members of the melanocortin family (α-MSH (POMC, P01189), β-MSH
(POMC, P01189) and γ-MSH (POMC, P01189) forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH (POMC, P01189)). Endogenous antagonists include agouti (ASIP, P42127) and
agouti-related protein (AGRP, O00253). ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test, whilst NDP-MSH was approved by EMA for the treatment of erythropoietic
protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.
Nomenclature MC1 receptor MC2 receptor MC3 receptor MC4 receptor MC5 receptor
HGNC, UniProt MC1R, Q01726 MC2R, Q01718 MC3R, P41968 MC4R, P32245 MC5R, P33032
Potency order of endogenous
agonists
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) > ACTH
(POMC, P01189), γ-MSH (POMC,
P01189)
ACTH (POMC, P01189) γ-MSH (POMC, P01189), β-MSH
(POMC, P01189) > ACTH
(POMC, P01189), α-MSH (POMC,
P01189)
β-MSH (POMC, P01189) >
α-MSH (POMC, P01189), ACTH
(POMC, P01189) > γ-MSH
(POMC, P01189)
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) > ACTH
(POMC, P01189) > γ-MSH
(POMC, P01189)
Selective agonists – corticotropin zinc hydroxide [D-Trp8]γ-MSH [745] THIQ [1916] –
Antagonists – – PG-106 (pIC50 6.7) [746] – –
Selective antagonists – – – MBP10 (pIC50 10) [132], HS014
(pKi 8.5) [1891]
–
Labelled ligands [125I]NDP-MSH (Agonist) [1138] [125I]ACTH-(1-24) (Agonist) [125I]NDP-MSH (Agonist) [1138],
[125I]SHU9119 (Antagonist)
[1581]
[125I]SHU9119 (Antagonist)
(pKd 9.2) [1581],
[125I]NDP-MSH (Agonist) [1138,
1889]
[125I]NDP-MSH (Agonist) [1138]
Comments: Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deﬁciency. Polymorphisms of the
MC4 receptor have been linked to obesity [328, 586].
Further reading on Melanocortin receptors
Caruso V et al. (2014) Synaptic changes induced by melanocortin signalling. Nat. Rev. Neurosci. 15:
98-110 [PMID:24588018]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Renquist BJ et al. (2011) Physiological roles of the melanocortin MC_3 receptor. Eur. J. Pharmacol.
660: 13-20 [PMID:21211527]
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Melatonin receptors
G protein-coupled receptors → Melatonin receptors
Overview: Melatonin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Melatonin Receptors [525]) are activated by the endogenous ligands melatonin and clinically
used drugs like ramelteon, agomelatine and tasimelteon.
Nomenclature MT1 receptor MT2 receptor
HGNC, UniProt MTNR1A, P48039 MTNR1B, P49286
Endogenous agonists melatonin [78, 524, 526] melatonin [78, 524, 526]
Agonists ramelteon [1049], agomelatine [78, 146], tasimelteon [1759] agomelatine [78, 146], ramelteon [1049, 1778], tasimelteon [1759]
Selective agonists – UCM1014 [2016], IIK7 [587, 2051], 5-methoxy-luzindole (Partial agonist) [526]
Selective antagonists – 4P-PDOT (pKi 8.8–9.4) [78, 526, 527], K185 (pKi 9.3) [587, 2051], DH97 (pKi 8) [2107]
Labelled ligands [125I]SD6 (Agonist) [1245], 2-[125I]melatonin (Agonist) [78, 526], [3H]melatonin (Agonist)
[254]
[125I]SD6 (Agonist) [1245], 2-[125I]melatonin (Agonist) [78, 526], [125I]DIV880 (Agonist,
Partial agonist) [1245], [3H]melatonin (Agonist) [254]
Comments: Melatonin, 2-iodo-melatonin, agomelatine,
GR 196429, LY 156735 and ramelteon [1049] are nonselective
agonists for MT1 and MT2 receptors. (-)-AMMTC displays an
˜400-fold greater agonist potency than (+)-AMMTC at rat MT1
receptors (see AMMTC for structure) [2136]. Luzindole is an
MT1/MT2 non-selective competitive melatonin receptor antago-
nist with about 15-25 fold selectivity for the MT2 receptor [527].
MT1/MT2 heterodimers present different pharmacological proﬁles
from MT1 and MT2 receptors [84].
TheMT3 binding site of hamster brain and peripheral tissues such
as kidney and testis, also termed the ML2 receptor, binds selec-
tively 2-iodo-[125I]5MCA-NAT [1473]. Pharmacological investiga-
tions ofMT3 binding sites have primarily been conducted in ham-
ster tissues. At this site, The endogenous ligand N-acetylserotonin
[546, 1324, 1473, 1719] and 5MCA-NAT [1719] appear to func-
tion as agonists, while prazosin [1324] functions as an antago-
nist. The MT3 binding site of hamster kidney was also iden-
tiﬁed as the hamster homologue of human quinone reductase
2 (NQO2, P16083 [1601, 1602]). The MT3 binding site acti-
vated by 5MCA-NAT in eye ciliary body is positively coupled to
adenylyl cyclase and regulates chloride secretion [928]. Xenopus
melanophores and chick brain express a distinct receptor (x420,
P49219; c346, P49288, initially termedMel1C) coupled to the Gi/o
family of G proteins, for which GPR50 has recently been suggested
to be a mammalian counterpart [530] although melatonin does
not bind to GPR50 receptors. Several variants of theMTNR1B gene
have been associated with increased type 2 diabetes risk [1043].
Further reading on Melatonin receptors
Cecon E et al. (2018) Melatonin receptors: molecular pharmacology and signalling in the context of
system bias. Br. J. Pharmacol. 175: 3263-3280 [PMID:28707298]
Dubocovich ML et al. (2010) International Union of Basic and Clinical Pharmacology. LXXV.
Nomenclature, classiﬁcation, and pharmacology of G protein-coupled melatonin receptors.
Pharmacol. Rev. 62: 343-80 [PMID:20605968]
Jockers R et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br. J. Pharmacol. 173:
2702-25 [PMID:27314810]
Karamitri A et al. (2019) Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol 15:
105-125 [PMID:30531911]
Liu J et al. (2016) MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu. Rev. Phar-
macol. Toxicol. 56: 361-83 [PMID:26514204]
Zlotos DP et al. (2014) MT1 and MT2 melatonin receptors: ligands, models, oligomers, and thera-
peutic potential. J. Med. Chem. 57: 3161-85 [PMID:24228714]
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Metabotropic glutamate receptors
G protein-coupled receptors → Metabotropic glutamate receptors
Overview: Metabotropic glutamate (mGlu) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Metabotropic Glutamate Receptors [1899]) are a family of G
protein-coupled receptors activated by the neurotransmitter glu-
tamate. The mGlu family is composed of eight members (named
mGlu1 to mGlu8) which are divided in three groups based on sim-
ilarities of agonist pharmacology, primary sequence and G pro-
tein coupling to effector: Group-I (mGlu1 and mGlu5), Group-II
(mGlu2 and mGlu3) and Group-III (mGlu4, mGlu6, mGlu7 and
mGlu8) (see Further reading).
Structurally, mGlu are composed of three juxtaposed domains:
a core G protein-activating seven-transmembrane domain (TM),
common to all GPCRs, is linked via a rigid cysteine-rich domain
(CRD) to the Venus Flytrap domain (VFTD), a large bi-lobed ex-
tracellular domain where glutamate binds. The structures of the
VFTD of mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 have been
solved [1177, 1482, 1530, 2156]. The structure of the 7 trans-
membrane (TM) domains of both mGlu1 and mGlu5 have been
solved, and conﬁrm a general helical organization similar to that
of other GPCRs, although the helices appear more compacted
[383, 515, 2335]. mGlu form constitutive dimers crosslinked by
a disulﬁde bridge. Recent studies revealed the possible formation
of heterodimers between either group-I receptors, or within and
between group-II and -III receptors [518]. Although well charac-
terized in transfected cells, co-localization and speciﬁc pharmaco-
logical properties also suggest the existence of such heterodimers
in the brain [1493, 2393].
The endogenous ligands of mGlu are L-glutamic acid,
L-serine-O-phosphate, N-acetylaspartylglutamate (NAAG) and
L-cysteine sulphinic acid. Group-I mGlu receptors may be ac-
tivated by 3,5-DHPG and (S)-3HPG [221] and antagonized by
(S)-hexylhomoibotenic acid [1346]. Group-II mGlu receptors may
be activated by LY389795 [1483], LY379268 [1483], eglumegad
[1898 2337], DCG-IV and (2R,3R)-APDC [1899, and antagonised
by eGlu [979] and LY307452 [571, 2289]. Group-III mGlu recep-
tors may be activated by L-AP4 and (R,S)-4-PPG [666]. An exam-
ple of an antagonist selective for mGlu receptors is LY341495,
which blocks mGlu2 and mGlu3 at low nanomolar concentra-
tions, mGlu8 at high nanomolar concentrations, and mGlu4,
mGlu5, and mGlu7 in the micromolar range [1099]. In addition
to orthosteric ligands that directly interact with the glutamate
recognition site, allosteric modulators that bind within the TM
domain have been described. Negative allosteric modulators are
listed separately. The positive allosteric modulators most often
act as ‘potentiators’ of an orthosteric agonist response, without
signiﬁcantly activating the receptor in the absence of agonist.
Nomenclature mGlu1 receptor mGlu2 receptor mGlu3 receptor mGlu4 receptor mGlu5 receptor
HGNC, UniProt GRM1, Q13255 GRM2, Q14416 GRM3, Q14832 GRM4, Q14833 GRM5, P41594
Endogenous
agonists
L-glutamic acid [1705] L-glutamic acid [1705] L-glutamic acid [1705],
NAAG [1906]
L-glutamic acid [1705] L-glutamic acid [1705]
Agonists – – – L-AP4 [2337], L-serine-O-phosphate [2337] –
Selective agonists – – – LSP4-2022 [731] (S)-(+)-CBPG (Partial agonist) [1373] – Rat,
CHPG [1529]
Antagonists LY367385 (pIC50 5.1) [400] – – MAP4 (pKi 4.6) [792] – Rat –
Selective
antagonists
3-MATIDA (pIC50 5.2) [1506] – Rat,
(S)-(+)-CBPG (pIC50 4.2) [1373] – Rat,
(S)-TBPG (pIC50 4.2) [417] – Rat, AIDA (pA2
4.2) [1507]
PCCG-4 (pIC50 5.1) [1677]
– Rat
– – ACDPP (pIC50 6.9) [202]
Allosteric
modulators
– CBiPES (Positive) (pEC50 7)
[1010], 4-MPPTS (Positive)
(pIC50 5.8) [108, 1009,
1010, 1884]
MNI-137 (Negative) (pIC50
7.7) [850] – Rat,
VU0650786 (Negative)
(pIC50 6.4) [560]
SIB-1893 (Positive) (pEC50 6.3–6.8) [1395],
MPEP (Positive) (pEC50 6.3–6.6) [1395],
PHCCC (Positive) (pEC50 4.5) [1358]
alloswitch-1 (Negative) (pIC50 8.1) [1714] –
Rat, CDPPB (Positive) (pEC50 7.6–8) [1100,
1290], MTEP (Negative) (pKi 7.8) [246], MPEP
(Negative) (pIC50 7.4–7.7) [665, 667],
fenobam (Negative) (pIC50 7.2) [1723]
Selective allosteric
modulators
BAY 367620 (Negative) (pKi 9.5) [309] – Rat,
JNJ16259685 (Negative) (pIC50 8.9) [1210],
Ro01-6128 (Positive) (pKi 7.5–7.7) [1118] –
Rat, LY456236 (Negative) (pIC50 6.9) [1270],
CPCCOEt (Negative) (pIC50 5.2–5.8) [1293]
Ro64-5229 (Negative)
(pIC50 7) [1130] – Rat,
biphenylindanone A
(Positive) (pEC50 7) [203]
ML337 (Negative) (pIC50
6.2) [2286] – Rat
VU0361737 (Positive) (pEC50 6.6) [559],
VU0155041 (Positive) (pEC50 6.1) [1595]
VU-1545 (Positive) (pEC50 8) [470]
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Nomenclature mGlu6 receptor mGlu7 receptor mGlu8 receptor
HGNC, UniProt GRM6, O15303 GRM7, Q14831 GRM8, O00222
Endogenous agonists L-glutamic acid [1705] L-glutamic acid [1705] L-serine-O-phosphate [1365, 2337], L-glutamic acid [1705]
Agonists – LSP4-2022 [731], L-serine-O-phosphate [2337], L-AP4 [2337] (S)-3,4-DCPG [2122], L-AP4 [1365]
Selective agonists 1-benzyl-APDC [2158] – Rat, homo-AMPA [264] – –
Antagonists MAP4 (pIC50 3.5) [1706] – Rat, THPG [2126] – MPPG (pIC50 4.3) [2337]
Allosteric modulators – MMPIP (Negative) (pIC50 6.1–7.6) [1594, 2063] – Rat,
ADX71743 (Negative) (pIC50 7.2) [1031], AMN082
(Positive) (pEC50 6.5–6.8) [1463], XAP044 (Negative) (pIC50
5.6) [676]
VU0422288 (Positive) (pKB 6.7) [978], VU0155094 (Positive)
(pKB 5) [978]
Comments: The activity of NAAG as an agonist at mGlu3 recep-
tors was questioned on the basis of contamination with glutamate
[374, 631], but this has been refuted [1553].
Radioligand binding using a variety of radioligands has been
conducted on recombinant receptors (for example, [3H]R214127
[1209] and [3H]YM298198 [1125] at mGlu1 receptors and
[3H]M-MPEP [665] and [3H]methoxymethyl-MTEP [51] at mGlu5
receptors; [3H]LY341495 and [3H]eglumegad for mGlu2 and
mGlu3 receptors [1008, 1906]). Although a number of radioli-
gands have been used to examine binding in native tissues, cor-
relation with individual subtypes is limited. Many pharmacolog-
ical agents have not been fully tested across all known subtypes
of mGlu receptors and may have unappreciated biased or neutral
activity at other subtypes [849]. Potential differences linked to the
species (e.g. human versus rat or mouse) of the receptors and the
receptor splice variants are generally not known. The inﬂuence of
receptor expression level on pharmacology and selectivity has not
been controlled for in most studies, particularly those involving
functional assays of receptor coupling.
(S)-(+)-CBPG is an antagonist at mGlu1, but is an agonist (albeit
of reduced efﬁcacy) at mGlu5 receptors. DCG-IV also exhibits ag-
onist activity at NMDA glutamate receptors [2183], and is an an-
tagonist at all Group-III mGluRs with an IC50 of 30μM. A poten-
tial novel metabotropic glutamate receptor coupled to phospho-
inositide turnover has been observed in rat brain; it is activated by
4-methylhomoibotenic acid (ineffective as an agonist at recombi-
nant Group Imetabotropic glutamate receptors), but is resistant to
LY341495 [392]. There are also reports of a distinct metabotropic
glutamate receptor coupled to phospholipase D in rat brain, which
does not readily ﬁt into the current classiﬁcation [1112, 1675]
A related class C receptor composed of two distinct subunits, T1R1
+ T1R3 is also activated by glutamate and is responsible for umami
taste detection.
All selective antagonists at metabotropic glutamate receptors are
competitive.
Further reading on Metabotropic glutamate receptors
Conn PJ et al. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev.
Pharmacol. Toxicol. 37: 205-237 [PMID:9131252]
Ferraguti F et al. (2006) Metabotropic glutamate receptors. Cell Tissue Res. 326: 483-504
[PMID:16847639]
Nicoletti F et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neu-
ropharmacology 60: 1017-41 [PMID:21036182]
Niswender CM et al. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and dis-
ease. Annu. Rev. Pharmacol. Toxicol. 50: 295-322 [PMID:20055706]
Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature 540:
60-68 [PMID:27905440]
Rondard P et al. (2011) The complexity of their activation mechanism opens new possibilities for
the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology
60: 82-92 [PMID:20713070]
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Motilin receptor
G protein-coupled receptors → Motilin receptor
Overview: Motilin receptors (provisional nomenclature) are activated by motilin (MLN, P12872), a 22 amino-acid peptide derived from a precursor (MLN, P12872), which may also generate a
motilin-associated peptide (MLN, P12872). These receptors promote gastrointestinal motility and are suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics
(often called motilides; e.g. erythromycin), although for many of these molecules the evidence is sparse.
Nomenclature motilin receptor
HGNC, UniProt MLNR, O43193
Endogenous agonists motilin (MLN, P12872) [422, 1400, 1401, 1402]
Agonists alemcinal [2117], erythromycin [588, 2117], azithromycin [241]
Selective agonists camicinal [113, 1863], mitemcinal [1123, 2085] – Rabbit
Selective antagonists MA-2029 (pA2 9.2) [2048], GM-109 (pIC50 8) [808] – Rabbit
Labelled ligands [125I]motilin (human) (Agonist) [588]
Comments: In terms of structure, the motilin receptor has clos-
est homology with the ghrelin receptor. Thus, the human motilin
receptor shares 52% overall amino acid identity with the ghre-
lin receptor and 86% in the transmembrane regions [834, 2085,
2117]. However, differences between the N-terminus regions of
these receptors means that their cognate peptide ligands do not
readily activate each other [448, 1863]. In laboratory rodents, the
gene encoding the motilin percursor appears to be absent, while
the receptor appears to be a pseudogene [834, 1861]. Functions
of motilin (MLN, P12872) are not usually detected in rodents, al-
though brain and other responses to motilin and the macrolide
alemcinal have been reported and the mechanism of these ac-
tions is obscure [1424, 1587]. Notably, in some non-laboratory
rodents (e.g. the North American kangaroo rat (Dipodomys) and
mouse (Microdipodops) a functional form of motilin may exist but
the motilin receptor is non-functional [1269]. Marked differences
in ligand afﬁnities for the motilin receptor in dogs and humans
may be explained by signiﬁcant differences in receptor structure
[1862]. Note that for the complex macrolide structures, selectivity
of action has often not been rigorously examined and other ac-
tions are possible (e.g. P2X inhibition by erythromycin; [2430]).
Small molecule motilin receptor agonists are now described [1269,
1863, 2293]. The motilin receptor does not appear to have consti-
tutive activity [897]. Although not proven, the existence of biased
agonism at the receptor has been suggested [1402, 1462, 1860]. A
truncated 5-transmembrane structure has been identiﬁed but this
is without activity when transfected into a host cell [588]. Recep-
tor dimerisation has not been reported.
Further reading on Motilin receptor
De Smet B et al. (2009) Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther. 123: 207-23
[PMID:19427331]
Marrinan SL et al. (2018) A randomized, double-blind, placebo-controlled trial of camicinal in Parkin-
son’s disease. Mov. Disord. 33: 329-332 [PMID:29278279]
Sanger GJ et al. (2016) Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
Nat Rev Gastroenterol Hepatol 13: 38-48 [PMID:26392067]
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Neuromedin U receptors
G protein-coupled receptors → Neuromedin U receptors
Overview: Neuromedin U receptors (provisional nomen-
clature as recommended by NC-IUPHAR [612]) are acti-
vated by the endogenous 25 amino acid peptide neuromedin U
(neuromedin U-25 (NMU, P48645), NmU-25), a peptide originally
isolated from pig spinal cord [1458]. In humans, NmU-25 appears
to be the sole product of a precursor gene (NMU, P48645) showing
a broad tissue distribution, but which is expressed at highest lev-
els in the upper gastrointestinal tract, CNS, bone marrow and fetal
liver. Much shorter versions of NmU are found in some species,
but not in human, and are derived at least in some instances from
the proteolytic cleavage of the longer NmU. Despite species differ-
ences in NmU structure, the C-terminal region (particularly the
C-terminal pentapeptide) is highly conserved and contains bio-
logical activity. Neuromedin S (neuromedin S-33 (NMS, Q5H8A3))
has also been identiﬁed as an endogenous agonist [1497]. NmS-
33 is, as its name suggests, a 33 amino-acid product of a precursor
protein derived from a single gene and contains an amidated C-
terminal heptapeptide identical to NmU. NmS-33 appears to acti-
vate NMU receptors with equivalent potency to NmU-25.
Nomenclature NMU1 receptor NMU2 receptor
HGNC, UniProt NMUR1, Q9HB89 NMUR2, Q9GZQ4
Antagonists – R-PSOP (pKB 7) [1303]
Comments: NMU1 and NMU2 couple predominantly to Gq/11 although there is evidence of good coupling to Gi/o [235, 910, 918]. NMU1 and NMU2 can be labelled with [125I]-NmU and [125I]-NmS
(of various species, e.g. [1432]), BODIPY TMR-NMU or Cy3B-NMU-8 [235]. A range of radiolabelled (125I-), ﬂuorescently labelled (e.g. Cy3, Cy5, rhodamine and FAM) and biotin labelled versions of
neuromedin U-25 (NMU, P48645) and neuromedin S-33 (NMS, Q5H8A3) are now commercially available.
Further reading on Neuromedin U receptors
Brighton PJ et al. (2004) Neuromedin U and its receptors: structure, function, and physiological
roles. Pharmacol. Rev. 56: 231-48 [PMID:15169928]
Budhiraja S et al. (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. Fun-
dam Clin Pharmacol 23: 149-57 [PMID:19645813]
Mitchell JD et al. (2009) Emerging pharmacology and physiology of neuromedin U and the struc-
turally related peptide neuromedin S. Br. J. Pharmacol. 158: 87-103 [PMID:19519756]
Novak CM. (2009) Neuromedin S and U. Endocrinology 150: 2985-7 [PMID:19549882]
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Neuropeptide FF/neuropeptide AF receptors
G protein-coupled receptors → Neuropeptide FF/neuropeptide AF receptors
Overview: The Neuropeptide FF receptor family contains
two subtypes, NPFF1 and NPFF2 (provisional nomenclature
[612]), which exhibit high afﬁnities for neuropeptide FF (NPFF,
O15130) and RFamide related peptides (RFRP: precursor gene sym-
bol NPVF, Q9HCQ7). NPFF1 is broadly distributed in the central
nervous system with the highest levels found in the limbic system
and the hypothalamus. NPFF2 is present in high density in the su-
perﬁcial layers of the mammalian spinal cord where it is involved
in nociception and modulation of opioid functions.
Nomenclature NPFF1 receptor NPFF2 receptor
HGNC, UniProt NPFFR1, Q9GZQ6 NPFFR2, Q9Y5X5
Potency order of endogenous ligands RFRP-1 (NPVF, Q9HCQ7) > RFRP-3 (NPVF, Q9HCQ7) > FMRFneuropeptide FF (NPFF,
O15130) > neuropeptide AF (NPFF, O15130) > neuropeptide SF (NPFF, O15130),
QRFP43 (QRFP, P83859), PrRP-31 (PRLH, P81277) [728]
neuropeptide AF (NPFF, O15130), neuropeptide FF (NPFF, O15130) > PrRP-31
(PRLH, P81277) > FMRF, QRFP43 (QRFP, P83859) > neuropeptide SF (NPFF,
O15130) [728]
Endogenous agonists neuropeptide FF (NPFF, O15130) [728, 729, 1476], RFRP-3 (NPVF, Q9HCQ7) [729,
730, 1476]
neuropeptide FF (NPFF, O15130) [729, 1475]
Selective agonists – dNPA [1829], AC263093 [1194]
Antagonists RF9 (pKi 7.2) [1974] –
Selective antagonists AC262620 (pKi 7.7–8.1) [1194], AC262970 (pKi 7.4–8.1) [1194] –
Labelled ligands [125I]Y-RFRP-3 (Agonist) [729], [3H]NPVF (Agonist) [2095], [125I]NPFF (Agonist)
[728]
[125I]EYF (Agonist) [1476], [3H]EYF (Agonist) [2095], [125I]NPFF (Agonist) [728]
Comments: An orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF receptors, but does not distinguish
between the NPFF1 and NPFF2 subtypes (pKi 7.1 and 7.2, respectively, [1974]).
Further reading on Neuropeptide FF/neuropeptide AF receptors
Moulédous L et al. (2010) Opioid-modulating properties of the neuropeptide FF system. Biofactors
36: 423-9 [PMID:20803521]
Vyas N et al. (2006) Structure-activity relationships of neuropeptide FF and related peptidic and
non-peptidic derivatives. Peptides 27: 990-6 [PMID:16490282]
Yang HY et al. (2008)Modulatory role of neuropeptide FF system in nociception and opiate analgesia.
Neuropeptides 42: 1-18 [PMID:17854890]
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Neuropeptide S receptor
G protein-coupled receptors → Neuropeptide S receptor
Overview: The neuropeptide S receptor (NPS, provisional nomenclature [612]) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6).
Nomenclature NPS receptor
HGNC, UniProt NPSR1, Q6W5P4
Endogenous agonists neuropeptide S (NPS, P0C0P6) [2360]
Selective agonists PWT1-NPS [1840] – Mouse
Selective antagonists NCGC 84 (pA2 9) [2127], SHA 68 (pA2 8.1) [1841] – Mouse, RTI-118 [2428]
Labelled ligands [125I]Tyr10NPS (human) (Agonist) [2360]
Comments: Multiple single-nucleotide polymorphisms (SNP)
and several splice variants have been identiﬁed in the human NPS
receptor. The most interesting of these is an Asn-Ile exchange at
position 107 (Asn107Ile). The human NPS receptor Asn107Ile dis-
played similar binding afﬁnity but higher NPS potency (by approx.
10-fold) than human NPS receptor Asn107 [1787]. Several epi-
demiological studies reported an association between Asn107Ile
receptor variant and susceptibility to panic disorders [507, 510,
1629, 1758]. The SNP Asn107Ile has also been linked to sleep
behavior [727], inﬂammatory bowel disease [440], schizophrenia
[1254], increased impulsivity and ADHD symptoms [1186]. Inter-
estingly, a carboxy-terminal splice variant of human NPS receptor
was found to be overexpressed in asthmatic patients [1193].
Further reading on Neuropeptide S receptor
Grund T et al. (2019) Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of
socio-emotional behaviors. Cell Tissue Res. 375: 123-132 [PMID:30112573]
Guerrini R et al. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S
and its receptor. Med Res Rev 30: 751-77 [PMID:19824051]
Ruzza C et al. (2017) Neuropeptide S receptor ligands: a patent review (2005-2016). Expert Opin Ther
Pat 27: 347-362 [PMID:27788040]
Xu YL et al. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.
Neuron 43: 487-497 [PMID:15312648]
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Neuropeptide W/neuropeptide B receptors
G protein-coupled receptors → Neuropeptide W/neuropeptide B receptors
Overview: The neuropeptide BW receptor 1 (NPBW1, pro-
visional nomenclature [612]) is activated by two 23-
amino-acid peptides, neuropeptide W (neuropeptide W-23
(NPW, Q8N729)) and neuropeptide B (neuropeptide B-23 (NPB,
Q8NG41)) [638, 1953]. C-terminally extended forms of the pep-
tides (neuropeptide W-30 (NPW, Q8N729) and neuropeptide B-29
(NPB, Q8NG41)) also activate NPBW1 [233]. Unique to both forms
of neuropeptide B is the N-terminal bromination of the ﬁrst tryp-
tophan residue, and it is from this post-translational modiﬁcation
that the nomenclature NPB is derived. These peptides were ﬁrst
identiﬁed from bovine hypothalamus and therefore are classed
as neuropeptides. Endogenous variants of the peptides with-
out the N-terminal bromination, des-Br-neuropeptide B-23 (NPB,
Q8NG41) and des-Br-neuropeptide B-29 (NPB, Q8NG41), were
not found to be major components of bovine hypothalamic tis-
sue extracts. The NPBW2 receptor is activated by the short and
C-terminal extended forms of neuropeptide W and neuropeptide
B [233].
Nomenclature NPBW1 receptor NPBW2 receptor
HGNC, UniProt NPBWR1, P48145 NPBWR2, P48146
Potency order of endogenous ligands neuropeptide B-29 (NPB, Q8NG41) > neuropeptide B-23 (NPB,
Q8NG41) > neuropeptide W-23 (NPW, Q8N729) >
neuropeptide W-30 (NPW, Q8N729) [233]
neuropeptide W-23 (NPW, Q8N729) > neuropeptide W-30 (NPW,
Q8N729) > neuropeptide B-29 (NPB, Q8NG41) >
neuropeptide B-23 (NPB, Q8NG41) [233]
Selective agonists Ava3 [1038], Ava5 [1038] –
Labelled ligands [125I]NPW-23 (human) (Agonist) [1976] [125I]NPW-23 (human) (Agonist) [1953]
Comments: Potency measurements were conducted with
heterologously-expressed receptors with a range of 0.14-0.57 nM
(NPBW1) and 0.98-21 nM (NPBW2).
NPBW1-/- mice show changes in social behavior, suggesting that
the NPBW1pathwaymay have an important role in the emotional
responses of social interaction [1537].
For a review of the contribution of neuropeptide B/W to social
dominance, see Watanabe and Yamamoto, 2015 [2270]. It has
been reported that neuropeptide W may have a key role in the
gating of stressful stimuli when mice are exposed to novel envi-
ronments [1512].
Two antagonists have been discovered and reported to have afﬁn-
ity for NPBW1, ML181 andML250, the latter exhibiting improved
selectivity (100 fold) for NPBW1 compared to MCH1 receptors
[762, 763]. Computational insights into the binding of antago-
nists to this receptor have also been described [1667].
Further reading on Neuropeptide W/neuropeptide B receptors
Sakurai T. (2013) NPBWR1 and NPBWR2: Implications in Energy Homeostasis, Pain, and Emotion.
Front Endocrinol (Lausanne) 4: 23 [PMID:23515889]
Singh G et al. (2006) Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled
receptor system. Br. J. Pharmacol. 148: 1033-41 [PMID:16847439]
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Neuropeptide Y receptors
G protein-coupled receptors → Neuropeptide Y receptors
Overview: Neuropeptide Y (NPY) receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Neuropep-
tide Y Receptors [1444]) are activated by the endogenous
peptides neuropeptide Y (NPY, P01303), neuropeptide Y-(3-36),
peptide YY (PYY, P10082), PYY-(3-36) and pancreatic polypeptide
(PPY, P01298) (PP). The receptor originally identiﬁed as the Y3
receptor has been identiﬁed as the CXCR4 chemokine recepter
(originally named LESTR, [1310]). The y6 receptor is a func-
tional gene product in mouse, absent in rat, but contains a frame-
shift mutation in primates producing a truncated non-functional
gene [743]. Many of the agonists exhibit differing degrees of se-
lectivity dependent on the species examined. For example, the
potency of PP is greater at the rat Y4 receptor than at the hu-
man receptor [566]. In addition, many agonists lack selectiv-
ity for individual subtypes, but can exhibit comparable potency
against pairs of NPY receptor subtypes, or have not been exam-
ined for activity at all subtypes. [125I]-PYY or [125I]-NPY can be
used to label Y1, Y2, Y5 and y6 subtypes non-selectively, while
[125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP may be used
to label Y5 receptors preferentially (note that cPP denotes chicken
peptide sequence and hPP is the human sequence).
Nomenclature Y1 receptor Y2 receptor Y4 receptor Y5 receptor y6 receptor
HGNC, UniProt NPY1R, P25929 NPY2R, P49146 NPY4R, P50391 NPY5R, Q15761 NPY6R, Q99463
Potency order of endogenous
ligands
neuropeptide Y = peptide YY 
pancreatic polypeptide
peptide YY = peptide YY(3-36) =
neuropeptide Y = neuropeptide
Y(3-36)  pancreatic
polypeptide
pancreatic polypeptide 
neuropeptide Y = peptide YY
neuropeptide Y > peptide YY >
pancreatic polypeptide
neuropeptide Y = peptide YY >
pancreatic polypeptide
Endogenous agonists neuropeptide Y (NPY, P01303),
peptide YY (PYY, P10082)
PYY-(3-36) (PYY, P10082) [677,
692], neuropeptide Y (NPY,
P01303), neuropeptide Y-(3-36)
(NPY, P01303), peptide YY (PYY,
P10082)
pancreatic polypeptide (PPY,
P01298) [106, 1327, 2149,
2368]
– –
Agonists [Leu31,Pro34]NPY [430],
[Leu31,Pro34]PYY (human),
[Pro34]NPY, [Pro34]PYY (human)
– – – –
Selective agonists – – – [Ala31,Aib32]NPY (pig) [287] –
Selective antagonists BIBO3304 (pIC50 9.5) [2303],
BIBP3226 (pKi 8.1–9.3) [513,
2304]
BIIE0246 (pIC50 8.5) [511],
JNJ-5207787 (pIC50 6.9–7.1)
[198]
– L-152,804 (pKi 7.6) [1037] –
Selective allosteric modulators – – niclosamide (Positive) [1988] – –
Labelled ligands [3H]BIBP3226 (Antagonist) (pKd
8.7), [125I][Leu31,Pro34]NPY
(Agonist)
[125I]PYY-(3-36) (human)
(Agonist)
[125I]PP (human) (Agonist) [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP
(Agonist) [532] – Rat
Comments Note that Pro34-containing NPY
and PYY can also bind Y4 and Y5
receptors, so strictly speaking are
not selective, but are the
’preferred’ agonists.
– – – –
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Comments: The Y1 agonists indicated are selective relative to Y2 receptors. BIBP3226 is selective relative to Y2, Y4 and Y5 receptors [691]. NPY-(13-36) is Y2 selective relative to Y1 and Y5 receptors.
PYY-(3-36) is Y2 selective relative to Y1 receptors. Note that Pro34-containing NPY and PYY can also bind Y4 and Y5, thus they are selective only relative to Y2. The y6 receptor is a pseudogene in humans,
but is functional in mouse, rabbit and some other mammals.
Further reading on Neuropeptide Y receptors
Bowers ME et al. (2012) Neuropeptide regulation of fear and anxiety: Implications of chole-
cystokinin, endogenous opioids, and neuropeptide Y. Physiol. Behav. 107: 699-710
[PMID:22429904]
Michel MC et al. (1998) XVI. International Union of Pharmacology recommendations for the
nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol.
Rev. 50: 143-150 [PMID:9549761]
Pedragosa-Badia X et al. (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front En-
docrinol (Lausanne) 4: 5 [PMID:23382728]
Zhang L et al. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications
in obesity and cancer. Pharmacol. Ther. 131: 91-113 [PMID:21439311]
Neurotensin receptors
G protein-coupled receptors → Neurotensin receptors
Overview: Neurotensin receptors (nomenclature as recommended by NC-IUPHAR [612]) are activated by the endogenous tridecapeptide neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-
Tyr-Ile-Leu) derived from a precursor (NTS, 30990), which also generates neuromedin N, an agonist at the NTS2 receptor. [
3H]neurotensin (human, mouse, rat) and [125I]neurotensin (human, mouse, rat)
may be used to label NTS1 and NTS2 receptors at 0.1-0.3 and 3-5 nM concentrations respectively.
Nomenclature NTS1 receptor NTS2 receptor
HGNC, UniProt NTSR1, P30989 NTSR2, O95665
Potency order of endogenous ligands neurotensin (NTS, P30990) > neuromedin N {Mouse, Rat} [855] neurotensin (NTS, P30990) = neuromedin N {Mouse, Rat} [1411]
Selective agonists JMV449 [1983] – Rat levocabastine [1411, 1801]
Selective antagonists meclinertant (pIC50 7.5–8.2) [767] –
Labelled ligands [3H]meclinertant (Antagonist) (pKd 8.5) [1188] – Rat –
Comments: Neurotensin (NTS, P30990) appears to be a low-
efﬁcacy agonist at the NTS2 receptor [2222], while the NTS1 recep-
tor antagonist meclinertant is an agonist at NTS2 receptors [2222].
An additional protein, provisionally termed NTS3 (also known as
NTR3, gp95 and sortilin; ENSG00000134243), has been suggested
to bind lipoprotein lipase and mediate its degradation [1585]. It
has been reported to interact with the NTS1 receptor [1388] and
the NTS2 receptor [283], and has been implicated in hormone traf-
ﬁcking and/or neurotensin uptake. A splice variant of the NTS2
receptor bearing 5 transmembrane domains has been identiﬁed
in mouse [211] and later in rat [1689].
Further reading on Neurotensin receptors
Boules M et al. (2013) Diverse roles of neurotensin agonists in the central nervous system. Front
Endocrinol (Lausanne) 4: 36 [PMID:23526754]
Mazella J et al. (2012) Neurotensin and its receptors in the control of glucose homeostasis. Front
Endocrinol (Lausanne) 3: 143 [PMID:23230428]
Myers RM et al. (2009) Cancer, chemistry, and the cell: molecules that interact with the neurotensin
receptors. ACS Chem. Biol. 4: 503-25 [PMID:19462983]
Ouyang Q et al. (2017) Oncogenic role of neurotensin and neurotensin receptors in various cancers.
Clin. Exp. Pharmacol. Physiol. 44: 841-846 [PMID:28556374]
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Opioid receptors
G protein-coupled receptors → Opioid receptors
Overview: Opioid and opioid-like receptors are activated by
a variety of endogenous peptides including [Met]enkephalin
(PENK, P01210) (met), [Leu]enkephalin (PENK, P01210) (leu),
β-endorphin (POMC, P01189) (β-end), α-neodynorphin (PDYN,
P01213), dynorphin A (PDYN, P01213) (dynA), dynorphin B
(PDYN, P01213) (dynB), big dynorphin (PDYN, P01213) (Big
dyn), nociceptin/orphanin FQ (PNOC, Q13519) (N/OFQ);
endomorphin-1 and endomorphin-2 are also potential endoge-
nous peptides. The Greek letter nomenclature for the opioid
receptors, μ, δ and κ, is well established, and NC-IUPHAR con-
siders this nomenclature appropriate, along with the symbols
spelled out (mu, delta, and kappa), and the acronyms, MOP,
DOP, and KOP. [428, 488, 612]. The human N/OFQ receptor,
NOP, is considered ’opioid-related’ rather than opioid because,
while it exhibits a high degree of structural homology with the
conventional opioid receptors [1478], it displays a distinct phar-
macology. Currently there are numerous clinically used drugs,
such as morphine and many other opioid analgesics, as well as
antagonists such as naloxone, however only for the μ receptor.
Nomenclature δ receptor κ receptor
HGNC, UniProt OPRD1, P41143 OPRK1, P41145
Principal endogenous agonists β-endorphin (POMC, P01189), [Leu]enkephalin (PENK, P01210), [Met]enkephalin
(PENK, P01210)
big dynorphin (PDYN, P01213), dynorphin A (PDYN, P01213)
Agonists DADLE [2142], etorphine [2142], ethylketocyclazocine [2142] –
Sub/family-selective agonists BU08028 (Partial agonist) [1076] BU08028 [1076]
Selective agonists UFP-512 [2215], BW373U86 [1220], ADL5859 [1220], DPDPE [1511, 2142],
[D-Ala2]deltorphin II [568], ADL5747 [1221], SNC80 [292, 1757]
U50488 [345, 1671, 1973, 2142, 2230, 2437, 2439], enadoline [934, 1571], U69593
[1192, 2142], salvinorin A [281, 1825]
Antagonists UFP-505 (pKi 9.8) [494, 495], naltrexone (pKi 8) [2142], naloxone (pKi 7.2) [2142] buprenorphine (pKi 9.1–10.2) [2142, 2439], nalmefene (pKi 9.5) [2142], naltrexone
(pKi 8.4–9.4) [1671, 1973, 2142], naloxone (pKi 7.6–8.6) [1671, 1973, 2142, 2437,
2439]
Sub/family-selective antagonists AT-076 (pKi 7.7) [2142, 2412] AT-076 (pKi 8.9) [2142, 2413]
Selective antagonists naltriben (pKi 10) [2003, 2142], naltrindole (pKi 9.7) [1725, 2142], TIPPψ (Inverse
agonist) (pKi 9) [1888, 2142]
nor-binaltorphimine (pKi 8.9–11) [1671, 1724, 1973, 2142, 2437, 2439],
5’-guanidinonaltrindole (pKi 9.7–9.9) [1017, 1671, 2031], JDTic (pKi 9–9.4) [1520,
2121, 2413]
Labelled ligands [3H]naltrindole (Antagonist) (pKd 10.4) [2364] – Rat, [
3H][D-Ala2]deltorphin I
(Selective Agonist) [2027], [3H]diprenorphine (Agonist) [56, 2142], [3H]DPDPE
(Agonist) [28], [3H]deltorphin II (Agonist) [284], [3H]naltriben (Antagonist) [1264]
[3H]diprenorphine (Antagonist) (pKd 9.1) [56, 1973], [
3H]U69593 (Agonist) [1192,
1671, 1973], [3H]enadoline (Agonist) [1975]
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Nomenclature μ receptor NOP receptor
HGNC, UniProt OPRM1, P35372 OPRL1, P41146
Potential endogenous agonists endomorphin-1, endomorphin-2 –
Principal endogenous agonists β-endorphin (POMC, P01189), [Met]enkephalin (PENK, P01210), [Leu]enkephalin
(PENK, P01210)
–
Endogenous agonists – nociceptin/orphanin FQ (PNOC, Q13519) [11, 165, 1630]
Agonists levorphanol [797], hydromorphone [2287], fentanyl [2142], buprenorphine (Partial
agonist) [2142], methadone [1727], UFP-505 [494, 495], codeine [2142], tapentadol
[2163], pethidine [1727]
–
Sub/family-selective agonists BU08028 (Partial agonist) [1076] cebranopadol [1292], BU08028 (Partial agonist) [1076]
Selective agonists sufentanil [2224], DAMGO [796, 2142], loperamide [356], morphine [717, 2142],
PL017 [336, 2142]
N/OFQ-(1-13)-NH2 [165, 764, 1418, 1630], Ac-RYYRWK-NH2 (Partial agonist) [514,
1418], SCH221510 [2208], Ro64-6198 [987, 2301], AT-403 [63]
Antagonists naltrexone (pKi 9.1–9.7) [1061, 2142], nalmefene (pKi 9.5) [2142], nalorphine (pKi
8.9) [2142], naloxone (pKi 8.9) [2142], methylnaltrexone (pKi 8.7) [2287]
–
Sub/family-selective antagonists AT-076 (pKi 8.8) [2142, 2413] AT-076 (pKi 8.8) [2413]
Selective antagonists alvimopan (pKi 9.3) [1219], levallorphan (pKi 8.8–9.3) [1361], CTAP (pKi 8.6) [336,
2142]
UFP-101 (pKi 10.2) [294], LY2940094 (pKi 10) [2141], compound 24 (pKi 9.6) [605],
SB 612111 (pKi 9.2–9.5) [2017, 2411], J-113397 (pIC50 8.3) [1057]
Allosteric modulators BMS-986123 (Neutral) (pKB 6) [267], BMS-986121 (Positive) (pKB 5.7) [267],
BMS-986124 (Neutral) (pKB 5.7) [267], BMS-986122 (Positive) (pKB 5.3) [267]
–
Labelled ligands [3H]diprenorphine (Antagonist) (pKd 10.1) [1780] – Mouse, [
3H]DAMGO (Agonist)
[1780] – Rat, [3H]PL017 (Agonist) [825] – Rat
[3H]N/OFQ (Agonist) [514, 1477]
Comments: Three naloxone-sensitive opioid receptor genes have
been identiﬁed in humans, and while the μ-receptor in particu-
lar may be subject to extensive alternative splicing [1660], these
putative isoforms have not been correlated with any of the sub-
types of receptor proposed in years past. Opioid receptorsmay het-
erodimerize with each other or with other 7TM receptors [1019],
and give rise to complexes with a unique pharmacology, how-
ever, evidence for such heterodimers in native cells is equivocal
and the consequences of this heterodimerization for signalling re-
mains largely unknown. For μ-opioid receptors at least, dimer-
ization does not seem to be required for signalling [1180]. A dis-
tinct met-enkephalin receptor lacking structural resemblance to
the opioid receptors listed has been identiﬁed (OGFR, 9NZT2) and
termed an opioid growth factor receptor [2409].
endomorphin-1 and endomorphin-2 have been identiﬁed as
highly selective, putative endogenous agonists for the μ-opioid
receptor. At present, however, the mechanisms for endomorphin
synthesis in vivo have not been established, and there is no gene
identiﬁed that encodes for either. Thus, the status of these pep-
tides as endogenous ligands remains unproven.
Two areas of increasing importance in deﬁning opioid recep-
tor function are the presence of functionally relevant single nu-
cleotide polymorphisms in human μ-receptors [1613] and the
identiﬁcation of biased signalling by opioid receptor ligands, in
particular, compounds previously characterized as antagonists
[255]. Pathway bias for agonists makes general rank orders of po-
tency and efﬁcacy somewhat obsolete, so these do not appear in
the table. As ever, the mechanisms underlying the acute and long
term regulation of opiod receptor function are the subject of in-
tense investigation and debate.
The richness of opioid receptor pharmacology has been enhanced
with the recent discovery of allosteric modulators of μ and δ recep-
tors, notably the positive allosteric modulators and silent allosteric
"antagonists" outlined in [267, 268]. Negative allosteric modu-
lation of opioid receptors has been previously suggested [1048],
whether all compounds are acting at a similar site remains to be
established.
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Further reading on Opioid receptors
Butelman ER et al. (2012) κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic
implications for addiction. Trends Neurosci. 35: 587-96 [PMID:22709632]
Cox BM et al. (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br. J. Pharma-
col. 172: 317-23 [PMID:24528283]
Pradhan AA et al. (2011) The delta opioid receptor: an evolving target for the treatment of brain
disorders. Trends Pharmacol. Sci. 32: 581-90 [PMID:21925742]
Williams JT et al. (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, inter-
nalization, and tolerance. Pharmacol. Rev. 65: 223-54 [PMID:23321159]
Orexin receptors
G protein-coupled receptors → Orexin receptors
Overview: Orexin receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Orexin receptors
[612]) are activated by the endogenous polypeptides orexin-A
(HCRT, O43612) and orexin-B (HCRT, O43612) (also known as
hypocretin-1 and -2; 33 and 28 aa) derived from a common pre-
cursor, preproorexin or orexin precursor, by proteolytic cleavage
and some typical peptidemodiﬁcations [1852]. Currently the only
orexin receptor ligand in clinical use is suvorexant, which is used
as a hypnotic. Orexin receptor crystal structures have been solved
[2390, 2392].
Nomenclature OX1 receptor OX2 receptor
HGNC, UniProt HCRTR1, O43613 HCRTR2, O43614
Potency order of endogenous ligands orexin-A (HCRT, O43612) > orexin-B (HCRT, O43612) orexin-A (HCRT, O43612) = orexin-B (HCRT, O43612)
Selective agonists – [Ala11, D-Leu15]orexin-B [73, 1748], Nag 26 [1535, 1807], YNT-185 [951, 1535]
Antagonists SB-649868 (pKi 9.3–9.6) [293, 429], suvorexant (pKi 8.7–9.3) [293, 429, 1513],
ﬁlorexant (pKi 8.4–9.1) [293, 429, 2319], TCS 1102 (pKi 8.5) [148], almorexant
(pKi 7.8–8.5) [293, 581, 1363, 1364, 1367], Cp-1 (pKi 7.6–8) [1363, 1364]
SB-649868 (pKi 8.9–9.8) [293, 429], TCS 1102 (pKi 9.7) [148], suvorexant (pKi
8.9–9.5) [293, 429, 1513], Cp-1 (pKi 8.5–9.3) [1363, 1364], ﬁlorexant (pKi
8.9–9.1) [293, 429, 2319]
Selective antagonists SB-674042 (70–300-fold selective) (pKi 8.7–9.3) [1200, 1363, 1364, 1367],
SB-334867 (50–150-fold selective) (pKi 7.2–7.9) [1200, 1363, 1364, 1722, 1746,
1991], SB-408124 (60–80-fold selective) (pKi 7.2–7.9) [1200, 1364, 1513]
EMPA (300–3000-fold selective) (pKi 8.4–9.2) [1363, 1364, 1367, 1513, 2152],
JNJ-10397049 (200–800-fold selective) (pKi 7.7–8.4) [429, 1414, 2152],
TCS-OX2-29 (pKi 6.9–7.5) [148, 879]
Labelled ligands [3H]SB-674042 (Antagonist) (pKd 8.3–9.1) [1200, 1364, 1367], [
3H]-almorexant
(Antagonist) (pKd 8.6–8.9) [1364, 1367], [
125I]-orexin-A (Agonist) [1168, 1747,
1852]
[3H]-almorexant (Selective Antagonist) (pKd 8.9–9.8) [1364, 1367], [
3H]Cp-1
(Selective Antagonist) (pKd 9.2–9.4) [1364], [
3H]EMPA (Selective Antagonist) (pKd
8.6–9) [1363, 1367], [125I]-orexin-A (Agonist) [1168, 1747, 1852]
Comments: The primary coupling of orexin receptors to Gq/11
proteins is rather speculative and based on the strong activation
of phospholipase C, though recent studies in recombinant cells
also stress the importance of Gq/11 [1167]. Coupling of both re-
ceptors to Gi/o and Gs has also been reported [1046, 1170, 1255,
1769]. For most native cellular responses observed, the G protein
pathway is unknown. The relative potency order of endogenous
ligands depends on the cellular signal transduction machinery
[1166]. Similarly, [Ala11, D-Leu15]orexin-B, Nag 26 and YNT-185
may show variable selectivity for OX2 receptors and are also likely
to activate OX1 receptors [1748, 1807]. Many antagonists and
radioligands are not well-characterized, and thus the afﬁnities
are uncertain. Among radioligands, [3H]SB-674042, [3H]EMPA
and [3H]-almorexant are commercially available. [3H]-TCS 1102
(pKd/OX1 8.2, pKd/OX2 9.0) [293] and Rhodamine Green-orexin-
A [445] are also useful radioligand tools. Orexin receptors have
been reported to be able to form complexes with each other and
some other GPCRs as well as σ1 receptors, which might affect the
signaling and pharmacology [1169, 1549]. Loss-of-function mu-
tations in the gene encoding the OX2 receptor underlie canine
hereditary narcolepsy [1287]. Antagonists of the orexin receptors
are the focus of major drug discovery efforts for their potential to
treat insomnia and other disorders of wakefulness [1816], while
agonists would likely be useful in human narcolepsy.
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Further reading on Orexin receptors
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Oxoglutarate receptor
G protein-coupled receptors → Oxoglutarate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [455].
Nomenclature oxoglutarate receptor
HGNC, UniProt OXGR1, Q96P68
Endogenous agonists α-ketoglutaric acid [838, 2015]
Further reading on Oxoglutarate receptor
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII.
G protein-coupled receptor list: recommendations for new pairings with cognate ligands.
Pharmacol. Rev. 65: 967-86 [PMID:23686350]
Grimm PR and Welling PA (2017) alpha-Ketoglutarate drives electroneutral NaCl reabsorption in in-
tercalated cells by activating a G-protein coupled receptor. Oxgr1. Curr. Opin. Nephrol. Hypertens.
26: 426-433 [PMID:28771454]
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P2Y receptors
G protein-coupled receptors → P2Y receptors
Overview: P2Y receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on P2Y Receptors [1,
2]) are activated by the endogenous ligands ATP, ADP,
uridine triphosphate, uridine diphosphate and UDP-glucose. The
relationship of many of the cloned receptors to endogenously ex-
pressed receptors is not yet established and so it might be appro-
priate to use wording such as ’uridine triphosphate-preferring (or
ATP-, etc.) P2Y receptor’ or ’P2Y1-like’, etc., until further, as yet
undeﬁned, corroborative criteria can be applied [271, 567, 966,
2227, 2281].
Clinically used drugs acting on these receptors include the dinu-
cleoside polyphosphate diquafosol, agonist of the P2Y2 receptor
subtype, approved in Japan for the management of dry eye disease
[1207], and the P2Y12 receptor antagonists prasugrel, ticagrelor
and cangrelor, all approved as antiplatelet drugs [298, 1734].
Nomenclature P2Y1 receptor P2Y2 receptor P2Y4 receptor P2Y6 receptor
HGNC, UniProt P2RY1, P47900 P2RY2, P41231 P2RY4, P51582 P2RY6, Q15077
Potency order of endogenous ligands ADP>ATP uridine triphosphate > ATP [1217] uridine triphosphate>ATP (at rat
recombinant receptors, UTP = ATP)
uridine diphosphate 
uridine triphosphate > ADP
Endogenous agonists – uridine triphosphate [1087, 1217] – –
Agonists ADPβS [2088], 2MeSADP [1882, 2238] – – –
Sub/family-selective agonists – diquafosol [1680], denufosol [1218,
1680, 2388], UTPγS [1217]
diquafosol [259], denufosol [2388],
UTPγS [1218]
–
Selective agonists MRS2365 [364], 2-Cl-ADP(α-BH3) [85] MRS2698 [960], 2-thioUTP [549],
PSB1114 (EC50 value determined using
an IP3 functional assay) [549, 550, 959]
MRS4062 [1390], MRS2927 [1390],
(N)methanocarba-UTP [1087]
Rp-5-OMe-UDPαB [706, 774], MRS2957
[1389], MRS2693 [158]
Antagonists suramin (pKi 5.3) [2238], PPADS (pKi
5.2) [2238]
– – –
Sub/family-selective antagonists – reactive blue-2 (pIC50 6) [981], suramin
(pIC50 4.3) [981, 1882]
PPADS (pEC50 2–5) [969],
reactive blue-2 (pIC50 4.7) [185] – Rat
reactive blue-2 (pKB 6) [2228], PPADS
(pKB 4) [2228], suramin (pKB 4) [2228]
Selective antagonists MRS2500 (pKi 8.8–9.1) [316, 1086],
MRS2279 (pKi 7.9) [2238], MRS2179
(pKi 7–7.1) [220, 2238]
AR-C118925XX (pIC50 ∼6) [1064],
AR-C126313 (pEC50 6) [960], PSB-416
(pIC50 4.7) [873]
ATP (pKd 6.2) [1067] MRS2578 (pIC50 7.4) [1369], MRS2567
(pIC50 6.9) [1369]
Selective allosteric modulators BMS compound 16 (Negative) (pKi 6.9)
[2417], 2,2’-pyridylisatogen tosylate
(Negative) (pIC50 6.8) [657]
– – –
Labelled ligands [3H]MRS2279 (Antagonist) (pKd 8.1)
[2238], [3H]2MeSADP (Agonist) [2088],
[35S]ADPβS (Agonist)
– – MRS4162 (Selective Antagonist) (pEC50
7.6) [986]
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Nomenclature P2Y11 receptor P2Y12 receptor P2Y13 receptor P2Y14 receptor
HGNC, UniProt P2RY11, Q96G91 P2RY12, Q9H244 P2RY13, Q9BPV8 P2RY14, Q15391
Potency order of endogenous ligands ATP>ADP ADP>ATP ADPATP uridine diphosphate= UDP-glucose
[311]
Endogenous agonists – ADP [854] – –
Sub/family-selective agonists – 2MeSADP [854], ADPβS [2088] 2MeSADP [1386], 2MeSATP [1386],
ADPβS [1386]
–
Selective agonists AR-C67085 [102, 408], NF546 [1430],
ATPγS [408]
– – α.β-methylene-2-thio-UDP [446],
MRS2905 [967], 2-thio-UDP [446]
Antagonists – cangrelor (pIC50 9.4) [970], Ap4A
(pIC50 6) [1386], 2MeSAMP (pIC50 5.4)
[2088]
cangrelor (pIC50 8.3) [1386], Ap4A
(pIC50 6.7) [1386], 2MeSAMP (pIC50
5.6) [1386]
–
Sub/family-selective antagonists suramin (pIC50 4.8–6) [408],
reactive blue-2 (pIC50 5) [408]
– – –
Selective antagonists NF157 (pKi 7.3) [2170], NF340 (pIC50
6.4–7.1) [1430]
AZD1283 (pKi 8) [88, 2419], ARL66096
(pIC50 7.9) [932, 933], ticagrelor (pKi
7.8) [2414]
MRS2603 (pIC50 6.2) [1094], MRS2211
(pIC50 6) [1094]
PPTN (pKi 10.1) [110]
Labelled ligands – [3H]2MeSADP (Agonist) [2088],
[3H]PSB-0413 (Antagonist) (pKd
8.3–8.5) [548, 1620]
[33P]2MeSADP (Agonist) [1386] MRS4174 (Selective Antagonist) (pKi
10.1) [1105], MRS4183 (Selective
Agonist) [1104]
Comments: A series of 4-alkyloxyimino derivatives of uridine-
5’-triphosphate which could be useful for derivatization as ﬂuores-
cent P2Y2/4/6 receptor probes has been recently synthesized [986].
Single nucleotide polymorphisms of the P2YR1 gene have been
associated to different platelet reactivity to ADP ADP [863]. Three
frequent nonsynonymous P2Y2 receptor polymorphisms have
been identiﬁed, one of which was signiﬁcantly more common in
cystic ﬁbrosis patients. This polymorphism is linked to increases
in Ca2+ inﬂux in transfected cells, and might therefore play a
role in disease development [286]. Although uridine triphosphate
(UTP) was also shown to be a biased agonist at P2Y11, this is still
under debate [1508, 2297]. A group of single nucleotide poly-
morphisms in the P2Y12 gene, forming the so called P2Y12 H2
haplotype, has been associated with increased platelet responsive-
ness to ADP, increased risk of peripheral arterial disease and with
coronary artery disease [321]. The platelet-type bleeding disorder
due to P2Y12 receptor defects is an autosomal recessive condition
characterized by mild to moderate mucocutaneous bleeding and
excessive bleeding after surgery or trauma. The defect is due to the
inability of ADP to induce platelet aggregation [317]. The P2Y13
receptor Met-158-Thr polymorphism, which is in linkage disequi-
librium with the P2Y12 locus, is not associated with acute my-
ocardial infarction, diabetes mellitus or related risk factors [47].
The P2Y14 receptor was previously considered to exclusively bind
sugar nucleotides such as UDP-glucose and UDP-galactose [331].
However, more recent evidence with several cell lines has demon-
strated that uridine diphosphate (UDP) is 5-foldmore potent than
UDP-glucose [311]. UDP was also shown to competitively antago-
nise the UDP-glucose response at the human recombinant P2Y14
receptor [632].
Further reading on P2Y receptors
Abbracchio MP et al. (2006) International Union of Pharmacology LVIII: update on the P2Y G
protein-coupled nucleotide receptors: frommolecular mechanisms and pathophysiology to ther-
apy. Pharmacol. Rev. 58: 281-341 [PMID:16968944]
Jacobson KA et al. (2015) Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.
Mol. Pharmacol. 88: 220-30 [PMID:25837834]
von Kügelgen I et al. (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:
50-61 [PMID:26519900]
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Parathyroid hormone receptors
G protein-coupled receptors → Parathyroid hormone receptors
Overview: The parathyroid hormone receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Parathyroid Hormone Receptors [662]) are family B G protein-coupled
receptors. The parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor-derived peptides: PTH (PTH, P01270) (84 amino acids), and
PTHrP (PTHLH, P12272) (141 amino-acids) and related peptides (PTH-(1-34), PTHrP-(1-36) (PTHLH, P12272)). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor-derived
peptide TIP39 (PTH2, Q96A98) (39 amino acids). [125I]PTH may be used to label both PTH1 and PTH2 receptors.
Nomenclature PTH1 receptor PTH2 receptor
HGNC, UniProt PTH1R, Q03431 PTH2R, P49190
Potency order of endogenous ligands PTH (PTH, P01270) = PTHrP (PTHLH, P12272) TIP39 (PTH2, Q96A98), PTH (PTH, P01270)  PTHrP (PTHLH, P12272)
Agonists teriparatide [660] TIP39 (PTH2, Q96A98) [725, 887]
Selective agonists PTHrP-(1-34) (human) [661] – Rat –
Comments: The parathyroid hormone type 1 receptor (PTHR) is the canonical GPCR for PTH and PTHrP. It is coupled to Gs and Gq and regulates the development of bone, heart, mammary glands and
other tissues in response to PTHrP, and blood concentrations of calcium and phosphate ions, as well as vitamin D, in response to PTH. Another important action of the PTH/PTHR system is to stimulate
bone formation when the hormone is intermittently administrated (daily injection).
Although PTH (PTH, P01270) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. TIP39 (PTH2, Q96A98) is a weak antagonist at PTH1 receptors [1018].
Further reading on Parathyroid hormone receptors
Cheloha RW et al. (2015) PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.
Nat Rev Endocrinol 11: 712-24 [PMID:26303600]
Gardella TJ et al. (2015) International Union of Basic and Clinical Pharmacology. XCIII. The Parathy-
roid Hormone Receptors-Family B G Protein-Coupled Receptors. Pharmacol. Rev. 67: 310-37
[PMID:25713287]
Vilardaga JP et al. (2014) Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 10:
700-6 [PMID:25271346]
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Platelet-activating factor receptor
G protein-coupled receptors → Platelet-activating factor receptor
Overview: Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inﬂammatory roles.
The PAF receptor (provisional nomenclature recommended by NC-IUPHAR [612]) is activated by PAF and other suggested endogenous ligands are oxidized phosphatidylcholine [1378] and
lysophosphatidylcholine [1615]. It may also be activated by bacterial lipopolysaccharide [1540].
Nomenclature PAF receptor
HGNC, UniProt PTAFR, P25105
Selective agonists methylcarbamyl PAF
Selective antagonists foropafant (pKi 10.3) [853], ABT-491 (pKi 9.2) [32], CV-6209 (pIC50 8.1–8.3) [716, 1539], L659989 (pKi 7.8) [937], apafant (pKi 5.2–7.5) [1654, 2067]
Labelled ligands [3H]PAF (Agonist) [640, 1539]
Comments: Note that a previously recommended radioligand ([3H]apafant; Kd 44.6 nM) is currently unavailable.
Further reading on Platelet-activating factor receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Ishii S et al. (2000) Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor
mutant mice. Prog. Lipid Res. 39: 41-82 [PMID:10729607]
Prescott SM et al. (2000) Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem.
69: 419-45 [PMID:10966465]
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Prokineticin receptors
G protein-coupled receptors → Prokineticin receptors
Overview: Prokineticin receptors, PKR1 and PKR2 (provi-
sional nomenclature as recommended by NC-IUPHAR
[612]) respond to the cysteine-rich 81-86 amino-acid peptides
prokineticin-1 (PROK1, Q9HC23) (also known as endocrine gland-
derived vascular endothelial growth factor, mambakine) and
prokineticin-2 (PROK2, Q9HC23) (protein Bv8 homologue). An
orthologue of PROK1 from black mamba (Dendroaspis polylepis)
venom, mamba intestinal toxin 1 (MIT1, [1905]) is a potent, non-
selective agonist at prokineticin receptors [1393], while Bv8, an
orthologue of PROK2 from amphibians (Bombina sp., [1474]), is
equipotent at recombinant PKR1 and PKR2 [1559], and has high
potency inmacrophage chemotaxis assays, which are lost in PKR1-
null mice.
Nomenclature PKR1 PKR2
HGNC, UniProt PROKR1, Q8TCW9 PROKR2, Q8NFJ6
Potency order of endogenous ligands prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [348, 1285, 1393, 2005]
prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [348, 1285, 1393, 2005]
Agonists MIT1 [1393] MIT1 [1393]
Selective agonists IS20 [668], IS1 [668] –
Labelled ligands [125I]BH-MIT1 (Agonist) [1393] [125I]BH-MIT1 (Agonist) [1393]
Comments: Genetic mutations in PROKR1 are associated with Hirschsprung’s disease [1836], while genetic mutations in PROKR2 are associated with hypogonadotropic hypogonadism with anosmia
[504], hypopituitarism with pituitary stalk interruption [1792] and Hirschsprung’s disease [1836]. PKR2 has been recently identiﬁed as a receptor for T. cruzi natural infection [1077].
Further reading on Prokineticin receptors
Boulberdaa M et al. (2011) Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney
functions. Cardiovasc. Res. 92: 191-8 [PMID:21856786]
Negri L et al. (2018) The Prokineticins: Neuromodulators and Mediators of Inﬂammation and
Myeloid Cell-Dependent Angiogenesis. Physiol. Rev. 98: 1055-1082 [PMID:29537336]
Negri L et al. (2012) Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr
Opin Pharmacol 12: 62-6 [PMID:22136937]
Negri L et al. (2007) Bv8/Prokineticin proteins and their receptors. Life Sci. 81: 1103-16
[PMID:17881008]
Ngan ES et al. (2008) Prokineticin-signaling pathway. Int. J. Biochem. Cell Biol. 40: 1679-84
[PMID:18440852]
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Prolactin-releasing peptide receptor
G protein-coupled receptors → Prolactin-releasing peptide receptor
Overview: The precursor (PRLH, P81277) for PrRP generates 31
and 20-amino-acid versions. QRFP43 (QRFP, P83859) (named
after a pyroglutamylated arginine-phenylalanine-amide peptide)
is a 43 amino acid peptide derived from QRFP (P83859) and is
also known as P518 or 26RFa. RFRP is an RF amide-related pep-
tide [875] derived from a FMRFamide-related peptide precursor
(NPVF, Q9HCQ7), which is cleaved to generate neuropeptide SF
(NPFF, O15130), neuropeptide RFRP-1 (NPVF, Q9HCQ7), neu-
ropeptide RFRP-2 (NPVF, Q9HCQ7) and neuropeptide RFRP-3
(NPVF, Q9HCQ7) (neuropeptide NPVF).
Nomenclature PrRP receptor
HGNC, UniProt PRLHR, P49683
Potency order of endogenous ligands PrRP-20 (PRLH, P81277) = PrRP-31 (PRLH, P81277) [1201]
Endogenous agonists PrRP-20 (PRLH, P81277) [561, 1201], PrRP-31 (PRLH, P81277) [561, 1201]
Endogenous antagonists neuropeptide Y (NPY, P01303) (pKi 5.4) [1190]
Labelled ligands [125I]PrRP-20 (human) (Agonist) [1201], [125I]PrRP31 (Agonist) [552]
Comments: The orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.
Further reading on Prolactin-releasing peptide receptor
Samson WK et al. (2006) Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth.
Peptides 27: 1099-103 [PMID:16500730]
Takayanagi Y et al. (2010) Roles of prolactin-releasing peptide and RFamide related peptides in the
control of stress and food intake. FEBS J. 277: 4998-5005 [PMID:21126313]
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Prostanoid receptors
G protein-coupled receptors → Prostanoid receptors
Overview: Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [2329]) are activated by the endogenous ligands prostaglandins PGD2,
PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are
often replaced by cicaprost and U46619, respectively, in receptor characterization studies.
Nomenclature DP1 receptor DP2 receptor
HGNC, UniProt PTGDR, Q13258 PTGDR2, Q9Y5Y4
Potency order of
endogenous ligands
PGD2 > PGE1  PGE2 > PGF2α > PGI2, thromboxane A2 PGD2  PGF2α, PGE2 > PGI2, thromboxane A2
Agonists treprostinil [2071, 2300] –
Selective agonists BW 245C [188, 2330, 2331], L-644,698 [2330, 2331] 15(R)-15-methyl-PGD2 [821, 1484, 2052]
Antagonists – fevipiprant (pKd 9) [2072, 2073], ramatroban (pKi 7.4) [2052]
Selective antagonists laropiprant (pKi 10.1) [2046], BWA868C (pKi 8.6–9.3) [188, 701, 2330],
ONO-AE3-237 (pKi 7.7) [877, 2144, 2146]
CAY 10471 (pIC50 8.9) [1832, 2174]
Labelled ligands [3H]PGD2 (Agonist) [2314, 2330] [3H]PGD2 (Agonist) [1394, 1949]
Nomenclature EP1 receptor EP2 receptor EP3 receptor EP4 receptor
HGNC, UniProt PTGER1, P34995 PTGER2, P43116 PTGER3, P43115 PTGER4, P35408
Potency order of
endogenous ligands
PGE2 > PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 = PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2, PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 = PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
Endogenous agonists – PGE2 [7, 2034, 2314] PGE2 (EP3-III isoform) [7] –
Agonists 17-phenyl-ω-trinor-PGE2 [1940] treprostinil [2071, 2300], PGE1 [119] misoprostol (methyl ester) (EP3-III isoform)
[7]
17-phenyl-ω-trinor-PGE2 [2113]
Selective agonists ONO-DI-004 [2062] – Mouse ONO-AE1-259 [2062] – Mouse,
omidenepag [1103],
butaprost (free acid form) [7, 2034]
sulprostone (EP3-III isoform) [7],
ONO-AE-248 [617, 1315]
L902688 [618, 1235], ONO-AE1-329 [617,
618]
Antagonists – – – EP A4 (pKi 7.6–8.5) [1340, 2406]
Selective antagonists ONO-8711 (pKi 9.2) [2269], SC-51322
(pKi 7.9) [7]
PF-04418948 (PF-04418948 has weaker
afﬁnity at the EP2-receptor in guinea-pigs)
(pKB 8.3) [14, 169], TG6-129 (pKB 8.1)
[654]
L-826266 (EP3-III isoform (pKi=8.04 in the
presence of HSA)) (pKi 9.1) [1026],
ONO-AE3-240 (pIC50 8.8) [42] – Mouse,
DG-041 (pKi 8.4) [1024]
ONO-AE3-208 (pKi 8.5), GW 627368 (pKi
7–7.1) [2314, 2315]
Labelled ligands [3H]PGE2 (Agonist) [7, 1940, 2314] [3H]PGE2 (Agonist) [7, 2314] [3H]PGE2 (Agonist) [7, 2314] [3H]PGE2 (Agonist) [7, 461, 2300, 2314]
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Nomenclature FP receptor IP receptor TP receptor
HGNC, UniProt PTGFR, P43088 PTGIR, P43119 TBXA2R, P21731
Potency order of endogenous ligands PGF2α > PGD2 > PGE2 > PGI2, thromboxane A2 PGI2  PGE1 > PGD2, PGF2α > thromboxane A2 thromboxane A2 = PGH2  PGD2, PGE2, PGF2α, PGI2
Endogenous agonists – PGI2 [1965], PGE1 [1391, 2036] –
Agonists ONO-9054 [2366] iloprost [7, 2314], treprostinil [2300] –
Selective agonists ﬂuprostenol [7], latanoprost (free acid form) [7] cicaprost [7], MRE-269 [145, 1181] U46619 [7]
Antagonists – – ramatroban (pKi 8) [2114]
Selective antagonists AS604872 (pKi 7.5) [397] RO1138452 (pKi 8.7) [176], RO3244794 (pA2 8.5)
[176]
vapiprost (pKi 8.3–9.4) [69, 1326], SQ-29548 (pKi
8.1–9.1) [7, 2070, 2314]
Labelled ligands [3H]PGF2α (Agonist) [7, 8, 2314], [3H](+)-ﬂuprostenol
(Agonist)
[3H]iloprost (Agonist) [7, 187, 2300, 2314] [125I]SAP (Antagonist) (pKd 7.7–9.3) [1538], [
125I]BOP
(Agonist) [1500], [3H]SQ-29548 (Antagonist) (pKd
7.4–8.2) [7, 2314]
Comments: Whilst cicaprost is selective for IP receptors, it does
exhibit moderate agonist potency at EP4 receptors [7]. Apart from
IP receptors, iloprost also binds to EP1 receptors.
The EP1 agonist 17-phenyl-ω-trinor-PGE2 also shows agonist ac-
tivity at EP3 and EP4 receptors [617, 2113]. Butaprost and
SC46275 may require de-esteriﬁcation within tissues to attain full
agonist potency. There is evidence for subtypes of FP [1281] and
TP receptors [1151, 1779]. mRNA for the EP3 receptor undergoes
alternative splicing to produce variants which can interfere with
signalling [1632] or generate complex patterns of G-protein (Gi/o,
Gq/11, Gs and G12,13) coupling (e.g. [1143, 1557]). The number of
EP3 receptor (protein) variants are variable depending on species,
with ﬁve in human, three in rat and three in mouse. Putative re-
ceptor(s) for prostamide F (which as yet lack molecular correlates)
and which preferentially recognize PGF2-1-ethanolamide and its
analogues (e.g. Bimatoprost) have been identiﬁed, together with
moderate-potency antagonists (e.g. AGN 211334) [2328].
The free acid form of AL-12182, AL12180, used in in vitro studies,
has a EC50 of 15nM which is the concentration of the compound
giving half-maximal stimulation of inositol phosphate turnover
in HEK-293 cells expressing the human FP receptor [1941].
References given alongside the TP receptor agonists I-BOP [1409]
and STA2 [69] use human platelets as the source of TP receptors
for competition radio-ligand binding assays to determine the in-
dicated activity values.
Pharmacological evidence for a second IP receptor, denoted IP2, in
the central nervous system [2091, 2272] and in the BEAS-2B hu-
man airway epithelial cell line [2317] is available. This receptor
is selectively activated by 15R-17,18,19,20-tetranor-16-m-tolyl-
isocarbacyclin (15R-TIC) and 15R-Deoxy 17,18,19,20-tetranor-16-
m-tolyl-isocarbacyclin (15-deoxy-TIC). However, molecular bio-
logical evidence for an IP2 subtype is currently lacking.
Further reading on Prostanoid receptors
Woodward DF et al. (2011) International union of basic and clinical pharmacology. LXXXIII: clas-
siﬁcation of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63: 471-538
[PMID:21752876]
Searchable database: http://www.guidetopharmacology.org/index.jsp Prostanoid receptors S115
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14748/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141
Proteinase-activated receptors
G protein-coupled receptors → Proteinase-activated receptors
Overview: Proteinase-activated receptors (PARs, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Proteinase-activated Receptors [894]) are unique members
of the GPCR superfamily activated by proteolytic cleavage of their
amino terminal exodomains. Agonist proteinase-induced hydrol-
ysis unmasks a tethered ligand (TL) at the exposed amino termi-
nus, which acts intramolecularly at the binding site in the body
of the receptor to effect transmembrane signalling. TL sequences
at human PAR1-4 are SFLLRN-NH2, SLIGKV-NH2, TFRGAP-NH2
and GYPGQV-NH2, respectively. With the exception of PAR3, syn-
thetic peptides with these sequences (as carboxyl terminal amides)
are able to act as agonists at their respective receptors. Several
proteinases, including neutrophil elastase, cathepsin G and chy-
motrypsin can have inhibitory effects at PAR1 and PAR2 such that
they cleave the exodomain of the receptor without inducing ac-
tivation of Gαq-coupled calcium signalling, thereby preventing
activation by activating proteinases but not by agonist peptides.
Neutrophil elastase (NE) cleavage of PAR1 and PAR2 can however
activate MAP kinase signaling by exposing a TL that is different
from the one revealed by trypsin [1764]. PAR2 ectivation by NE
regulates inﬂammation and pain responses [1518, 2431] and trig-
gers mucin secretion from airway epithelial cells [2434].
Nomenclature PAR1 PAR2 PAR3 PAR4
HGNC, UniProt F2R, P25116 F2RL1, P55085 F2RL2, O00254 F2RL3, Q96RI0
Agonist proteases thrombin (F2, P00734), activated protein C (PROC, P04070),
matrix metalloproteinase 1 (MMP1, P45452),
matrix metalloproteinase 13 (MMP13, P45452) [81]
Trypsin, tryptase, TF/VIIa, Xa; elastase, neutrophil expressed;
cathepsin S [1001, 1762]
thrombin (F2,
P00734)
thrombin (F2, P00734), trypsin,
cathepsin G (CTSG, P08311)
Agonists F16357 – – –
Selective agonists TFLLR-NH2 [391] AY77 [2385], GB110 [112], 2-furoyl-LIGRLO-amide [1419],
SLIGKV-NH2 [1241], SLIGRL-NH2 [1241]
– AYPGKF-NH2, GYPGKF-NH2,
GYPGQV-NH2
Selective antagonists vorapaxar (pKi 8.1) [327], atopaxar (pIC50 7.7) [1124],
RWJ-56110 (pIC50 6.4) [52]
I-191 (pIC50 7.1) [1000], AZ8838 (pKd 6.5) [360], GB88 (pIC50
5.7) [2050], P2pal18s [1933]
– BMS-986120 (pKd 10) [2325],
YD-3 (pIC50 6.9) [2283], ML354
(pIC50 6.8) [2283], P4pal-10
[427], RAG8 (Agonist) [1763]
Allosteric modulators – AZ3451 (Negative) (pIC50 7.6) [360] – –
Labelled ligands [3H]haTRAP (Agonist) [19] 2-furoyl-LIGRL[N-(Alexa Fluor 594)-O]-NH2 (Agonist) [895],
2-furoyl-LIGRL[N[3H]propionyl]-O-NH2 (Agonist) [895],
[3H]2-furoyl-LIGRL-NH2 (Selective Agonist) [1040],
trans-cinnamoyl-LIGRLO [N-[3H]propionyl]-NH2 (Agonist) [30]
– –
Comments TFLLR-NH2 is selective relative to the PAR2 receptor [171, 1053]. 2-Furoyl-LIGRLO-NH2 activity was measured via calcium
mobilisation in HEK 293 cells which constitutively coexpress
human PAR1 and PAR2.
– –
Comments: Endogenous serine proteases (EC 3.4.21.) ac-
tive at the proteinase-activated receptors include: thrombin (F2,
P00734), generated by the action of Factor X (F10, P00742) on
liver-derived prothrombin (F2, P00734); trypsin, generated by the
action of enterokinase (TMPRSS15, P98073) on pancreatic-derived
trypsinogen (PRSS1, P07477); tryptase, a family of enzymes (α/β1
TPSAB1, Q15661 ; γ1 TPSG1, Q9NRR2; δ1 TPSD1, Q9BZJ3) secreted
from mast cells; cathepsin G (CTSG, P08311) generated from
leukocytes; liver-derived protein C (PROC, P04070) generated in
plasma by thrombin (F2, P00734) and matrix metalloproteinase 1
(MMP1, P45452).
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Further reading on Proteinase-activated receptors
Adams MN et al. (2011) Structure, function and pathophysiology of protease activated receptors.
Pharmacol. Ther. 130: 248-82 [PMID:21277892]
Canto I et al. (2012) Allosteric modulation of protease-activated receptor signaling. Mini Rev Med
Chem 12: 804-11 [PMID:22681248]
García PS et al. (2010) The role of thrombin and protease-activated receptors in pain mechanisms.
Thromb. Haemost. 103: 1145-51 [PMID:20431855]
Hollenberg MD et al. (2002) International Union of Pharmacology. XXVIII. Proteinase-activated
receptors. Pharmacol. Rev. 54: 203-17 [PMID:12037136]
Ramachandran R et al. (2012) Targeting proteinase-activated receptors: therapeutic potential and
challenges. Nat Rev Drug Discov 11: 69-86 [PMID:22212680]
Soh UJ et al. (2010) Signal transduction by protease-activated receptors. Br. J. Pharmacol. 160: 191-
203 [PMID:20423334]
QRFP receptor
G protein-coupled receptors → QRFP receptor
Overview: The human gene encoding the QRFP receptor
(nomenclature as agreed by the NC-IUPHAR Subcommit-
tee on the QRFP receptor [1259]; QRFPR, formerly known as
the Peptide P518 receptor), previously designated as an orphan
GPCR receptor was identiﬁed in 2001 by Lee et al. from a hy-
pothalamus cDNA library [1237]. However, the reported cDNA
(AF411117) is a chimera with bases 1-127 derived from chromo-
some 1 and bases 155-1368 derived from chromosome 4. When
corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a
431 amino acid protein that shares sequence similarities in the
transmembrane spanning regions with other peptide receptors.
These include neuropeptide FF2 (38%), neuropeptide Y2 (37%)
and galanin Gal1 (35%) receptors.
Nomenclature QRFP receptor
HGNC, UniProt QRFPR, Q96P65
Endogenous agonists QRFP26 (QRFP) [343, 999]
Agonists LV-2186 [41], LV-2172 [1572]
Selective antagonists compound 25e (pIC50 7.3) [687, 688]
Labelled ligands [125I]QRFP43 (human) (Agonist) [641, 1164, 2090], [125I]26RFa (human) (Agonist) [260]
Comments: The orphan receptor GPR83 (9NYM4) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.
Further reading on QRFP receptor
Chartrel N et al. (2011) The RFamide neuropeptide 26RFa and its role in the control of neuroen-
docrine functions. Front Neuroendocrinol 32: 387-97 [PMID:21530572]
Fukusumi S et al. (2006) Recent advances in mammalian RFamide peptides: the discovery and func-
tional analyses of PrRP, RFRPs and QRFP. Peptides 27: 1073-86 [PMID:16500002]
Leprince J et al. (2017) The Arg-Phe-amide peptide 26RFa/glutamine RF-amide peptide and its recep-
tor: IUPHAR Review 24. Br. J. Pharmacol. 174: 3573-3607 [PMID:28613412]
Searchable database: http://www.guidetopharmacology.org/index.jsp QRFP receptor S117
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Relaxin family peptide receptors
G protein-coupled receptors → Relaxin family peptide receptors
Overview: Relaxin family peptide receptors (RXFP, nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Relaxin family peptide receptors [120, 785]) may be di-
vided into two pairs, RXFP1/2 and RXFP3/4. Endogenous ago-
nists at these receptors are heterodimeric peptide hormones struc-
turally related to insulin: relaxin-1 (RLN1, P04808), relaxin (RLN2,
P04090), relaxin-3 (RLN3, Q8WXF3) (also known as INSL7),
insulin-like peptide 3 (INSL3 (INSL3, P51460)) and INSL5 (INSL5,
Q9Y5Q6). Species homologues of relaxin have distinct pharma-
cology and relaxin (RLN2, P04090) interacts with RXFP1, RXFP2
and RXFP3, whereas mouse and rat relaxin selectively bind to and
activate RXFP1 [1912]. Relaxin-3 (RLN3, Q8WXF3) is the ligand
for RXFP3 but it also binds to RXFP1 and RXFP4 and has differ-
ential afﬁnity for RXFP2 between species [1911]. INSL5 (INSL5,
Q9Y5Q6) is the ligand for RXFP4 but is a weak antagonist of
RXFP3. Relaxin (RLN2, P04090) and INSL3 (INSL3, P51460) have
multiple complex binding interactions with RXFP1 [1930] and
RXFP2 [886] which direct the N-terminal LDLa modules of the
receptors together with a linker domain to act as a tethered lig-
and to direct receptor signaling [1913]. INSL5 (INSL5, Q9Y5Q6)
and relaxin-3 (RLN3, Q8WXF3) interact with their receptors us-
ing distinct residues in their B-chains for binding, and activation,
respectively [921, 2324].
Nomenclature RXFP1 RXFP2 RXFP3 RXFP4
HGNC, UniProt RXFP1, Q9HBX9 RXFP2, Q8WXD0 RXFP3, Q9NSD7 RXFP4, Q8TDU9
Potency order of
endogenous ligands
relaxin (RLN2, P04090) = relaxin-1 (RLN1,
P04808) > relaxin-3 (RLN3, Q8WXF3) [2049]
INSL3 (INSL3, P51460) > relaxin (RLN2,
P04090)  relaxin-3 (RLN3, Q8WXF3)
[1174, 2049]
relaxin-3 (RLN3, Q8WXF3) >
relaxin-3 (B chain) (RLN3, Q8WXF3) >
relaxin (RLN2, P04090) [1296]
INSL5 (INSL5, Q9Y5Q6) = relaxin-3 (RLN3,
Q8WXF3) > relaxin-3 (B chain) (RLN3,
Q8WXF3) [1294, 1295]
Endogenous
antagonists
– – INSL5 (INSL5, Q9Y5Q6) (pKi 7) [2438] –
Antagonists B-R13/17K H2 relaxin (pEC50 5.7–6.7) [913,
1570]
– R3(B23-27)R/I5 chimeric peptide (pIC50
9.2) [1165]
R3(B23-27)R/I5 chimeric peptide (pIC50
8–8.6) [823, 1165]
Selective antagonists – A(9-26)INSL3 (pKi 9.1) [912], A(10-24)INSL3
(pKi 8.7) [912], A(C10/15S)INSL3 (pKi 8.6)
[2422], INSL3 B chain dimer analogue 8 (pKi
8.5) [1938], A(10/15C)INSL3 (pKi 8.3)
[2422], cyclic INSL3 B-chain analogue 6 (pKi
6.7) [1936], INSL3 B-chain analogue (pKi
5.1) [479], (des 1-8) A-chain INSL3 analogue
[285]
minimised relaxin-3 analogue 3 (pKi 7.6)
[1934], R3-B1-22R (pKi 7.4) [823]
minimised relaxin-3 analogue 3 (pIC50 6.6)
[1934]
Allosteric modulators ML290 (Agonist) (pEC50 7) [2346, 2349] – – –
Labelled ligands [33P]relaxin (human) (Agonist) [786, 2049],
europium-labelled relaxin (Agonist) [1935],
[125I]relaxin (human) (Agonist)
[125I]INSL3 (human) (Agonist) [1516],
[33P]relaxin (human) (Agonist) [786, 2049]
[125I]relaxin-3 (human) (Agonist) [1296],
[125I]relaxin-3-B/INSL5 A chimera (Agonist)
[1294], europium-labelled relaxin-3-B/INSL5
A chimera (Agonist) [823]
[125I]relaxin-3 (human) (Agonist) [1295],
[125I]relaxin-3-B/INSL5 A chimera (Agonist)
[1294], europium-labelled mouse INSL5
(Agonist) [135],
europium-labelled relaxin-3-B/INSL5
A chimera (Agonist) [823],
europium-labelled INSL5 (pKd 8.3) [823]
Comments – Europium-labelled INSL3 is a ﬂuorescent
ligand for this receptor (Kd=1nM) [1937].
– –
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Comments: Relaxin (RLN2, P04090) is the cognate peptide lig-
and for RXFP1 and is in extended Phase III clinical trials for the
treatment of acute heart failure [1435]. Relaxin has vasodilatory,
anti-ﬁbrotic, angiogenic, anti-apoptotic and anti-inﬂammatory ef-
fects. A small molecule allosteric agonists ML290 has been devel-
oped [1944, 2349], and a relaxin B-chain mimetic peptide B7-33
has been developed which that has cell speciﬁc signaling proper-
ties [911]. The antiﬁbrotic actions of relaxin are dependent on the
angiotensin receptor AT2 [377]. INSL3 (INSL3, P51460) is the cog-
nate peptide for RXFP2 and is a circulating hormone that in males
is essential for testicular descent in utero [1556] and in females has
important roles in ovarian follicle function [961]. In adults, INSL3
has potential roles in testicular function [962] and the musculo-
skeletal system [472]. RXFP2 is also present in brain, associated
with cortico-thalamic motor circuits [1917]. cAMP elevation is the
major signalling pathway for both RXFP1 and RXFP2 [919, 920],
but RXFP1 also activates MAP kinases, nitric oxide signalling, and
tyrosine kinase phosphorylation; and relaxin can interact with
glucocorticoid receptors [787]. Receptor expression proﬁles sug-
gest that RXFP3 is a brain neuropeptide receptor and RXFP4 a gut
hormone receptor. The brain relaxin-3/RXFP3 system modulates
feeding [652, 653, 823, 1934, 1992] via effects in hypothalamus
[475, 652, 1039], anxiety [1842, 2415], reward and motivated,
goal-directed behaviours [906, 1842, 2239], and spatial and so-
cial memory [34, 780]. Of the other relaxin peptides, relaxin-3
(RLN3, Q8WXF3) is an agonist at RXFP3 and RXFP4 whereas INSL5
(INSL5, Q9Y5Q6) is an agonist at RXFP4 and a weak antagonist at
RXFP3. INSL5 (INSL5, Q9Y5Q6) is secreted from enteroendocrine
L cells and the INSL5/RXFP4 system affects food intake [751] and
glucose homeostasis [1331]. RXFP3 and RXFP4 couple to Gi/o
and inhibit adenylyl cyclase [1296, 2191], and also cause Erk1/2
phosphorylation [2191]. RXFP4 also causes phosphorylation of
p38MAPK, Akt and S6RP [55] and GLP-1 secretion in vitro [54].
There is evidence that at RXFP3, relaxin (RLN2, P04090) is a biased
ligand compared to the cognate ligand relaxin-3 (RLN3, Q8WXF3)
[2191].
Further reading on Relaxin family peptide receptors
Bathgate RA et al. (2013) Relaxin family peptides and their receptors. Physiol. Rev. 93: 405-80
[PMID:23303914]
Du XJ et al. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev
Cardiol 7: 48-58 [PMID:19935741]
HallsML et al. (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent advances
in the understanding of the pharmacology and biological roles of relaxin family peptide recep-
tors 1-4, the receptors for relaxin family peptides. Pharmacol. Rev. 67: 389-440 [PMID:25761609]
Ivell R et al. (2011) Relaxin family peptides in the male reproductive system–a critical appraisal. Mol.
Hum. Reprod. 17: 71-84 [PMID:20952422]
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Somatostatin receptors
G protein-coupled receptors → Somatostatin receptors
Overview: Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on ﬁve subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the
NC-IUPHAR Subcommittee on Somatostatin Receptors [773]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of
secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28 (SRIF-28 (SST, P61278)). Cortistatin-14 {Mouse, Rat} has also been
suggested to be an endogenous ligand for somatostatin receptors [468].
Nomenclature SST1 receptor SST2 receptor SST3 receptor SST4 receptor SST5 receptor
HGNC, UniProt SSTR1, P30872 SSTR2, P30874 SSTR3, P32745 SSTR4, P31391 SSTR5, P35346
Agonists pasireotide [1893] pasireotide [1893], veldoreotide
[15]
pasireotide [1893] NNC269100 [1306],
veldoreotide [15]
pasireotide [1893], veldoreotide
[15]
Selective agonists L-797,591 [1817],
Des-Ala1,2,5-[D-Trp8,IAmp9]SRIF
[565]
L-054,522 [2376], BIM 23027
[313], L-779,976 [1817],
octreotide [257, 1666, 1966,
1967, 1968, 2376], lanreotide
[257, 1666, 1966, 1967, 1968]
L-796,778 [1817] L-803,087 [1817], J-2156 [562] BIM 23052 [1439, 1966, 1967,
1968], L-817,818 [1817]
Selective antagonists SRA880 (pKd 8–8.1) [916] DOTA-JR11 [326] MK-4256 (pIC50 9.2) [837],
ACQ090 (pKi 7.9) [917]
– S5A1 (pKi 9.3) [585]
Comments: [125I]Tyr11-SRIF-14, [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr10-CST14may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype-selective agonists
have been synthesised [1817]. Octreotide and lanreotide are being used in the treatment of SST2-expressing neuroendocrine tumors and pasireotide for SST5-expressing neuroendocrine tumors. A novel
peptide somatostatin analogue, veldoreotide (COR-005), has afﬁnity for SST2, SST4 and SST5 receptors and is a potent inhibitor of GH secretion [1717, 1954].
Further reading on Somatostatin receptors
Colao A et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32: 247-71
[PMID:21123741]
Günther T et al. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin
Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev. 70: 763-835
[PMID:30232095]
Hoyer D et al. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization
and Classiﬁcation, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354-364
Schulz S et al. (2014) Fine-tuning somatostatin receptor signalling by agonist-selective phosphoryla-
tion and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol. 171: 1591-9 [PMID:24328848]
Weckbecker G et al. (2003) Opportunities in somatostatin research: biological, chemical and thera-
peutic aspects. Nat Rev Drug Discov 2: 999-1017 [PMID:14654798]
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Succinate receptor
G protein-coupled receptors → Succinate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [455]. The Succinate receptor has been identiﬁed as being activated by physiological levels of the Kreb’s cycle intermediate succinate
and other dicarboxylic acids such as maleate in 2004. Since its pairing with its endogenous ligand, the receptor has been the focus of intensive research and its role has been evidenced in various
(patho)physiological processes such as regulation of renin production, retinal angiogenesis, inﬂammation or immune response.
Nomenclature succinate receptor
HGNC, UniProt SUCNR1, Q9BXA5
Endogenous agonists succinic acid [838, 2015], maleic acid [696]
Agonists compound 31 (Partial agonist) [1791], cis-epoxysuccinic acid [2153], compound 130 (Partial agonist) [2153], cis-epoxysuccinic acid [696], maleic acid [703],
maleic acid [838]
Comments: In humans, there is the possibility of two open-reading frames (ORFs) for SUCNR1, one giving a protein of 330 amino acids (AA) and the other one 334-AA. Wittenberger et al. [2322] noted
that the 330-AA protein was more likely to be expressed given the Kozak sequence surrounding the second ATG. Some databases report SUCNR1 as being 334-AA long.
Further reading on Succinate receptor
Ariza AC et al. (2012) The succinate receptor as a novel therapeutic target for oxidative andmetabolic
stress-related conditions. Front Endocrinol (Lausanne) 3: 22 [PMID:22649411]
de Castro Fonseca M et al. (2016) GPR91: expanding the frontiers of Krebs cycle intermediates. Cell
Commun. Signal 14: 3 [PMID:26759054]
Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther. 159:
56-65 [PMID:26808164]
Grimolizzi F et al. (2018) Multiple faces of succinate beyond metabolism in blood. Haematologica
103: 1586-1592 [PMID:29954939]
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Tachykinin receptors
G protein-coupled receptors → Tachykinin receptors
Overview: Tachykinin receptors (provisional nomencla-
ture as recommended by NC-IUPHAR [612]) are activated
by the endogenous peptides substance P (TAC1, P20366) (SP),
neurokinin A (TAC1, P20366) (NKA; previously known as sub-
stance K, neurokinin α, neuromedin L), neurokinin B (TAC3,
Q9UHF0) (NKB; previously known as neurokinin β, neuromedin
K), neuropeptide K (TAC1, P20366) and neuropeptide γ (TAC1,
P20366) (N-terminally extended forms of neurokinin A). The neu-
rokinins (A and B) are mammalian members of the tachykinin
family, which includes peptides of mammalian and nonmam-
malian origin containing the consensus sequence: Phe-x-Gly-Leu-
Met. Marked species differences in in vitro pharmacology exist for
all three receptors, in the context of nonpeptide ligands. Antago-
nists such as aprepitant and fosaprepitant were approved by FDA
and EMA, in combination with other antiemetic agents, for the
prevention of nausea and vomiting associated with emetogenic
cancer chemotherapy.
Nomenclature NK1 receptor NK2 receptor NK3 receptor
HGNC, UniProt TACR1, P25103 TACR2, P21452 TACR3, P29371
Potency order of endogenous ligands substance P (TAC1, P20366) > neurokinin A (TAC1,
P20366) > neurokinin B (TAC3, Q9UHF0)
neurokinin A (TAC1, P20366) > neurokinin B (TAC3,
Q9UHF0)  substance P (TAC1, P20366)
neurokinin B (TAC3, Q9UHF0) > neurokinin A (TAC1,
P20366) > substance P (TAC1, P20366)
Agonists substance P-OMe [2130] – –
Selective agonists [Sar9,Met(O2)11]SP [2130], septide [139, 820],
[Pro9]SP [2145] – Rat
[Lys5,Me-Leu9,Nle10]NKA-(4-10) [1406] – Rat,
GR64349 [476] – Rat, [βAla8]neurokinin A-(4-10) [556]
[Phe(Me)7]neurokinin B [1868, 1869], senktide [1868,
1869, 2130]
Antagonists L760735 (pIC50 9.7) [815] – –
Selective antagonists aprepitant (pKi 10.1) [781, 782], CP 99994 (pKi
9.3–9.7) [57, 1869], RP67580 (pIC50 7.7) [610]
GR94800 (pKi 9.8) [223], saredutant (pKi 9.4–9.7) [57,
556, 1869], GR 159897 (pKd 7.8–9.5) [147, 556,
1999], MEN10627 (pKi 9.2) [699], nepadutant (pKi
8.5–8.7) [314, 394]
osanetant (pKi 8.4–9.7) [57, 125, 393, 555, 1034,
1641, 1868, 1869, 2130], talnetant (pKi 7.4–9) [142,
700, 1868, 1869], PD157672 (pIC50 7.8–7.9) [182,
2130]
Labelled ligands [125I]L703,606 (Antagonist) (pKd 9.5) [621],
[125I]BH-[Sar9,Met(O2)11]SP (Agonist) [2150] – Rat,
[3H]SP (human, mouse, rat) (Agonist) [93],
[125I]SP (human, mouse, rat) (Agonist), [18F]SPA-RQ
(Antagonist) [367]
[3H]saredutant (Antagonist) (pKd 9.7) [749] – Rat,
[125I]NKA (human, mouse, rat) (Agonist) [2267],
[3H]GR100679 (Antagonist) (pKd 9.2) [778]
[3H]osanetant (Antagonist) (pKd 9.9), [
3H]senktide
(Agonist) [760] – Guinea pig, [125I][MePhe7]NKB
(Agonist)
Comments: The NK1 receptor has also been described to cou-
ple to G proteins other than Gq/11 [1828]. The crystal struc-
ture of the human NK1 receptor in complex with antagonists
has been determined [1909, 2391]. The hexapeptide agonist sep-
tide appears to bind to an overlapping but non-identical site to
substance P (TAC1, P20366) on the NK1 receptor. There are addi-
tional subtypes of tachykinin receptor; an orphan receptor (Swis-
sProt P30098) with structural similarities to the NK3 receptor was
found to respond to NKB when expressed in Xenopus oocytes or
Chinese hamster ovary cells [509, 1150].
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Further reading on Tachykinin receptors
Douglas SD et al. (2011) Neurokinin-1 receptor: functional signiﬁcance in the immune system
in reference to selected infections and inﬂammation. Ann. N. Y. Acad. Sci. 1217: 83-95
[PMID:21091716]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Jones S et al. (2008) The neurokinin 1 receptor: a potential new target for anti-platelet therapy? Curr
Opin Pharmacol 8: 114-9 [PMID:18296119]
Steinhoff MS et al. (2014) Tachykinins and their receptors: contributions to physiological control
and the mechanisms of disease. Physiol. Rev. 94: 265-301 [PMID:24382888]
Yin J et al. (2018) Crystal structure of the human NK_1 tachykinin receptor. Proc. Natl. Acad. Sci.
U.S.A. 115: 13264-13269 [PMID:30538204]
Thyrotropin-releasing hormone receptors
G protein-coupled receptors → Thyrotropin-releasing hormone receptors
Overview: Thyrotropin-releasing hormone (TRH) receptors (provisional nomenclature as recommended by NC-IUPHAR [612]) are activated by the endogenous tripeptide TRH (TRH, P20396)
(pGlu-His-ProNH2). TRH (TRH, P20396) and TRH analogues fail to distinguish TRH1 and TRH2 receptors [2059]. [3H]TRH (human, mouse, rat) is able to label both TRH1 and TRH2 receptors with Kd
values of 13 and 9 nM respectively. Synthesis and biology of ring-modiﬁed L-Histidine containing TRH analogues has been reported [1429].
Nomenclature TRH1 receptor TRH2 receptor
HGNC, UniProt TRHR, P34981 –
Antagonists diazepam (pKi 5.2) [522] – Rat –
Selective antagonists midazolam (pKi 5.5) [522] – Rat, chlordiazepoxide (pKi 4.8) [522] – Rat, chlordiazepoxide (pKi 4.7) [2042] – Mouse –
Comments – A class A G protein-coupled receptor: not present in man
Further reading on Thyrotropin-releasing hormone receptors
Bílek R et al. (2011) TRH-like peptides. Physiol Res 60: 207-15 [PMID:21114375]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Nillni EA. (2010) Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by
neuronal and peripheral inputs. Front Neuroendocrinol 31: 134-56 [PMID:20074584]
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Trace amine receptor
G protein-coupled receptors → Trace amine receptor
Overview: Trace amine-associated receptors were discovered
from a search for novel 5-HT receptors [205], where 15 mam-
malian orthologues were identiﬁed and divided into two fam-
ilies. The TA1 receptor (nomenclature as agreed by the
NC-IUPHAR Subcommittee for the Trace amine receptor
[1355]) has afﬁnity for the endogenous trace amines tyramine,
β-phenylethylamine and octopamine in addition to the classi-
cal amine dopamine [205]. Emerging evidence suggests that TA1
is a modulator of monoaminergic activity in the brain [2351]
with TA1 and dopamine D2 receptors shown to form constitu-
tive heterodimers when co-expressed [572]. In addition to trace
amines, receptors can be activated by amphetamine-like psychos-
timulants, and endogenous thyronamines.
Nomenclature TA1 receptor
HGNC, UniProt TAAR1, Q96RJ0
Potency order of endogenous ligands tyramine > β-phenylethylamine > octopamine = dopamine [205]
Agonists RO5166017 [1790]
Antagonists EPPTB (Inverse agonist) (pIC50 5.1) [222]
Labelled ligands [3H]tyramine (Agonist) [205]
Comments: In addition to TA1, in man there are up to 5 func-
tional TAAR genes (TAAR2,5,6,8,9). See [205] for detailed discus-
sion. The product of the gene TAAR2 (also known as GPR58) ap-
pears to respond to β-phenylethylamine > tyramine and to couple
through Gs [205].
TAAR3, in some individuals, and TAAR4 are pseudogenes in man,
although functional in rodents. The signalling characteristics
and pharmacology of TAAR5 (PNR, Putative Neurotransmitter Re-
ceptor: TAAR5, O14804), TAAR6 (Trace amine receptor 4, TaR-4:
TAAR6, 96RI8), TAAR8 (Trace amine receptor 5, GPR102: TAAR8,
Q969N4 ) and TAAR9 (trace amine associated receptor 9: TAAR9,
96RI9) are lacking. The thyronamines, endogenous derivatives of
thyroid hormone, have afﬁnity for rodent cloned trace amine re-
ceptors, including TA1 [1881]. An antagonist EPPTB has recently
been described with a pKi of 9.1 at the mouse TA1 but >5.3 for
human TA1 [2025].
Further reading on Trace amine receptor
Maguire JJ et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace
amine receptor nomenclature. Pharmacol. Rev. 61: 1-8 [PMID:19325074]
Pei Y et al. (2016) Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neuro-
chemistry, and Clinical Implications. Front Neurosci 10: 148 [PMID:27092049]
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Urotensin receptor
G protein-coupled receptors → Urotensin receptor
Overview: The urotensin-II (U-II) receptor (UT, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on the
Urotensin receptor [516, 612, 2211]) is activated by the en-
dogenous dodecapeptide urotensin-II (UTS2, O95399), originally
isolated from the urophysis, the endocrine organ of the caudal
neurosecretory system of teleost ﬁsh [150, 2210]. Several struc-
tural forms of U-II exist in ﬁsh and amphibians. The goby ortho-
logue was used to identify U-II as the cognate ligand for the pre-
dicted receptor encoded by the rat gene gpr14 [425, 1304, 1498,
1603]. Human urotensin-II (UTS2, O95399), an 11-amino-acid
peptide [425], retains the cyclohexapeptide sequence of goby U-II
that is thought to be important in ligand binding [240, 1101]. This
sequence is also conserved in the deduced amino-acid sequence
of rat urotensin-II {Rat} (14 amino-acids) and mouse urotensin-II
{Mouse} (14 amino-acids), although the N-terminal is more di-
vergent from the human sequence [424]. A second endogenous
ligand for the UT has been discovered in rat [2053]. This is the
urotensin II-related peptide (UTS2B, Q765I0), an octapeptide that
is derived from a different gene, but shares the C-terminal se-
quence (CFWKYCV) common to U-II from other species. Identical
sequences to rat urotensin II-related peptide (UTS2B, Q765I0) are
predicted for the mature mouse and human peptides [523]. UT ex-
hibits relatively high sequence identity with somatostatin, opioid
and galanin receptors [2211].
Nomenclature UT receptor
HGNC, UniProt UTS2R, Q9UKP6
Endogenous agonists urotensin II-related peptide (UTS2B, Q765I0) [523, 1354], urotensin-II (UTS2, O95399) [517, 554, 747]
Selective agonists [Pen5]U-(4-11) (human) [747], U-II-(4-11) (human) [747], [3-iodo-Tyr6]U-II-(4-11) (human) [1187], Urolinin [104], FL104 [1246, 1248], AC-7954 [436, 1247]
Selective antagonists urantide (pKi 8.3) [1661], [Orn
5]URP (pKi 7.2) [492] – Rat, palosuran (pIC50 7.1) [402], SB-611812 (pKi 6.6) [1760], [Cha
6]U-II-(4-11) (pKi 6.4) [344] – Rat
Labelled ligands [125I]U-II (human) (Agonist) [46, 214, 344, 1354], [125I]N-biotin-[Ahx0, Bpa3]U-II (human) [503]
Comments: In the human vasculature, human urotensin-II (UTS2, O95399) elicits both vasoconstrictor (pD2 9.3-10.1, [1354]) and vasodilator (pIC50 10.3-10.4, [2035]) responses.
Further reading on Urotensin receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Hunt BD et al. (2010) A rat brain atlas of urotensin-II receptor expression and a review of central
urotensin-II effects. Naunyn Schmiedebergs Arch. Pharmacol. 382: 1-31 [PMID:20422157]
Maryanoff BE et al. (2010) Urotensin-II receptor modulators as potential drugs. J. Med. Chem. 53:
2695-708 [PMID:20043680]
Ross B et al. (2010) Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 298: R1156-72 [PMID:20421634]
Vaudry H et al. (2015) International Union of Basic and Clinical Pharmacology. XCII. Urotensin II,
urotensin II-related peptide, and their receptor: from structure to function. Pharmacol. Rev. 67:
214-58 [PMID:25535277]
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Vasopressin and oxytocin receptors
G protein-coupled receptors → Vasopressin and oxytocin receptors
Overview: Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC-IUPHAR [612]) are activated by the endogenous cyclic nonapeptides vasopressin (AVP, P01185)
and oxytocin (OXT, P01178). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin). Vasopressin and oxytocin differ
at only 2 amino acids (positions 3 and 8). There are metabolites of these neuropeptides that may be biologically active [474].
Nomenclature V1A receptor V1B receptor
HGNC, UniProt AVPR1A, P37288 AVPR1B, P47901
Potency order of endogenous ligands vasopressin (AVP, P01185) > oxytocin (OXT, P01178) [26, 359, 419, 1541, 1851,
2078, 2115]
vasopressin (AVP, P01185) > oxytocin (OXT, P01178) [26, 359, 486, 748, 1541,
1851, 2078, 2116]
Selective agonists F180 [53, 419] d[Leu4]LVP [1679], d[Cha4]AVP [486, 748]
Antagonists conivaptan (pKi 8.2–8.4) [2078, 2079] nelivaptan (pKi 8.4–9.3) [748, 1929]
Selective antagonists relcovaptan (pKi 8.1–9.3) [26, 419, 748, 2078, 2115], d(CH2)5[Tyr(Me)
2,Arg8]VP
(pKi 9)
–
Labelled ligands [125I]OH-LVA (Antagonist) (pKd 10.3–10.4) [369, 419],
[3H]AVP (human, mouse, rat) (Agonist) [231, 369, 2078, 2079, 2115],
[3H]d(CH2)5[Tyr(Me)2]AVP (Antagonist) (pKd 9)
[3H]AVP (human, mouse, rat) (Agonist) [486, 1851, 2078, 2079, 2116]
Nomenclature V2 receptor OT receptor
HGNC, UniProt AVPR2, P30518 OXTR, P30559
Potency order of endogenous ligands vasopressin (AVP, P01185) > oxytocin (OXT, P01178) [26, 359, 369, 1679, 1927,
2078, 2365]
oxytocin (OXT, P01178) > vasopressin (AVP, P01185) [26, 369, 370, 396, 748, 984,
1096]
Selective agonists VNA932 [582], OPC-51803 [1541], d[Val4,DArg8]VP [Thr4,Gly7]OT [370, 551, 984]
Antagonists – L-371,257 (pKi 8.8) [748]
Selective antagonists conivaptan (pKi 9.4) [435], tolvaptan (pKi 9.4) [2365], satavaptan (pKi 8.4–9.3)
[26, 420, 1926, 1927, 2078], lixivaptan (Inverse agonist) (pKi 8.9–9.2) [36, 1927],
d(CH2)5[D-Ile2,Ile4]AVP (pKi 6.9–8.4) [420, 1927], mozavaptan (Inverse agonist)
(pKi 7.4–8.1) [420, 1927, 2078, 2116, 2365]
SSR126768A (pKi 8.8–9.1) [1928], desGlyNH2-d(CH2)5[Tyr(Me)
2,Thr4,Orn8]OT
(pKi 8.5), L-372662 (pKi 8.4) [136]
Labelled ligands [3H]AVP (human, mouse, rat) (Agonist) [420, 1541, 2078, 2079, 2365], [3H]dDAVP
(Agonist) [1383], [3H]desGly-NH2[D-Ile2,Ile4]VP (pKd 8.6)
[125I]d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr-NH29]OVT (Antagonist) (pKd 10),
[3H]OT (human, mouse, rat) (Agonist) [369, 637, 984, 1098], [111In]DOTA-dLVT
(pKd 8.3) [368]
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Comments: Vasopressin and oxytocin receptors have a char-
acteristic and sometimes overlapping distribution in a num-
ber of tissues including brain. There are phylogenetic, onto-
genetic and sex-speciﬁc differences in the levels and distribu-
tion of these receptors, particularly in the brain. The V2 recep-
tor exhibits marked species differences, such that many ligands
(d(CH2)5[D-Ile
2,Ile4]AVP and [3H]desGly-NH2[D-Ile
2,Ile4]VP) ex-
hibit low afﬁnity at human V2 receptors [31]. Similarly, DAVP
is more V2 selective in the rat than in the human [1851]. The
gene encoding the V2 receptor is polymorphic in man, underly-
ing nephrogenic diabetes insipidus [164]. D[Cha4]AVP is selec-
tive only for the human and bovine V1B receptors [486], while
d[Leu4]LVP has high afﬁnity for the rat V1B receptor [1679].
Knockouts of vasopressin and oxytocin receptors have system-
speciﬁc defects (e.g., impaired ability to concentrate urine in V2 re-
ceptor knockouts) which include behavioural deﬁcits (principally
in V1A, V1B and OT receptor knockouts).
Further reading on Vasopressin and oxytocin receptors
Knepper MA. (2012) Systems biology in physiology: the vasopressin signaling network in kidney.
Am. J. Physiol., Cell Physiol. 303: C1115-24 [PMID:22932685]
Koshimizu TA et al. (2012) Vasopressin V1a and V1b receptors: from molecules to physiological
systems. Physiol. Rev. 92: 1813-64 [PMID:23073632]
Manning M et al. (2012) Oxytocin and vasopressin agonists and antagonists as research tools and
potential therapeutics. J. Neuroendocrinol. 24: 609-28 [PMID:22375852]
Meyer-Lindenberg A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropeptides
for translational medicine. Nat. Rev. Neurosci. 12: 524-38 [PMID:21852800]
Neumann ID et al. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, de-
pression, and social behaviors. Trends Neurosci. 35: 649-59 [PMID:22974560]
VIP and PACAP receptors
G protein-coupled receptors → VIP and PACAP receptors
Overview: Vasoactive intestinal peptide (VIP) and pituitary
adenylate cyclase-activating peptide (PACAP) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Vasoactive Intestinal Peptide Receptors [812, 813]) are ac-
tivated by the endogenous peptides VIP (VIP, P01282), PACAP-38
(ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509), peptide his-
tidine isoleucineamide (PHI {Mouse, Rat}), peptide histidine me-
thionineamide (PHM (VIP, P01282)) and peptide histidine va-
line (PHV (VIP, P01282)). VPAC1 and VPAC2 receptors dis-
play comparable afﬁnity for the PACAP peptides, PACAP-27
(ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509), and
VIP (VIP, P01282), whereas PACAP-27 (ADCYAP1, P18509) and
PACAP-38 (ADCYAP1, P18509) are >100 fold more potent than
VIP (VIP, P01282) as agonists of most isoforms of the PAC1 re-
ceptor. However, one splice variant of the human PAC1 receptor
has been reported to respond to PACAP-38 (ADCYAP1, P18509),
PACAP-27 (ADCYAP1, P18509) and VIP (VIP, P01282) with com-
parable afﬁnity [452]. PG 99-465 [1492] has been used as a selec-
tive VPAC2 receptor antagonist in a number of physiological stud-
ies, but has been reported to have signiﬁcant activity at VPAC1
and PAC1 receptors [493]. The selective PAC1 receptor agonist
maxadilan, was extracted from the salivary glands of sand ﬂies
(Lutzomyia longipalpis) and has no sequence homology to VIP (VIP,
P01282) or the PACAP peptides [1503]. Two deletion variants of
maxadilan, M65 [2165] and Max.d.4 [1504] have been reported to
be PAC1 receptor antagonists, but these peptides have not been
extensively characterised.
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Nomenclature PAC1 receptor VPAC1 receptor VPAC2 receptor
HGNC, UniProt ADCYAP1R1, P41586 VIPR1, P32241 VIPR2, P41587
Potency order of endogenous ligands PACAP-27 (ADCYAP1, P18509), PACAP-38 (ADCYAP1,
P18509)  VIP (VIP, P01282)
VIP (VIP, P01282), PACAP-27 (ADCYAP1, P18509),
PACAP-38 (ADCYAP1, P18509)  GHRH (GHRH,
P01286), PHI {Pig}, secretin (SCT, P09683)
VIP (VIP, P01282), PACAP-38 (ADCYAP1, P18509),
PACAP-27 (ADCYAP1, P18509) > PHI {Pig}  GHRH
(GHRH, P01286), secretin (SCT, P09683)
Selective agonists maxadilan [493], maxadilan [493] [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 [1487],
[Ala11,22,28]VIP [1582]
Ro 25-1553 [735, 1023, 1487], Ro 25-1392 [2344]
Selective antagonists – PG 97-269 (pIC50 8.7) [734, 1023] –
Labelled ligands [125I]PACAP-27 (Agonist) [1712] [125I]VIP (human, mouse, rat) (Agonist) [1582],
[125I]PACAP-27 (Agonist)
[125I]VIP (human, mouse, rat) (Agonist) [1582],
[125I]PACAP-27 (Agonist)
Comments: Subtypes of PAC1 receptors have been proposed based on tissue differences in the potencies of PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509); these might result from
differences in G protein coupling and second messenger mechanisms [2195], or from alternative splicing of PAC1 receptor mRNA [2020].
Further reading on VIP and PACAP receptors
Harmar AJ et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for
vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol
Rev 50: 265-270 [PMID:9647867]
Harmar AJ et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide
and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166:
4-17 [PMID:22289055]
Reglodi D et al. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary
system, with special emphasis on its protective effects in the kidney. Neuropeptides 46: 61-70
[PMID:21621841]
Smith CB et al. (2012) Is PACAP the major neurotransmitter for stress transduction at the
adrenomedullary synapse? J. Mol. Neurosci. 48: 403-12 [PMID:22610912]
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